ALLG Allego NV

---

---

---

---

---

---

---

---

Allego N.V. (“Allego” or the "Company”), a continuation of the former Allego Holding B.V. (“Allego Holding”) as detailed below, was incorporated as a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) on June 3, 2021 under the laws of the Netherlands, under the name of Athena Pubco B.V.

On March 16, 2022, Athena Pubco B.V. changed its legal form from a private limited liability company to a public limited liability company (naamloze venootschap), changed its name to Allego N.V. and entered into the Deed of Conversion containing the Articles of Association of Allego N.V. Allego N.V. consummated the previously announced business combination (“the SPAC Transaction”) with Spartan Acquisition Corp. III (“Spartan”) pursuant to the terms of the business combination agreement (“BCA”) and became a publicly traded company on the New York Stock Exchange (“NYSE”). The new public company — Allego N.V. — trades under the Allego name with the ticker “ALLG”. The Company’s registered seat and head office are in Arnhem, the Netherlands. Its head office is located at Westervoortsedijk 73 KB, 6827 AV in Arnhem, the Netherlands. The Company is registered with the Dutch Trade Register under number 82985537.

The Company’s main activity is enabling electrification through designing, building and the operation of charging solutions for electric vehicles in Europe. The Company services corporate customers with the long-term operation of comprehensive charging solutions. The Company’s goal is to offer the best EV charging experience with end-to-end charging solutions through different charging products (e.g. slow, fast, ultra-fast charging) in combination with our EV Cloud platform and additional service support. Upon completion of the BCA, Allego N.V. underwent a capital restructuring process which resulted in additional shares being issued to Madeleine Charging B.V. (“Madeleine”), an external consulting firm, the Private Investment in Public Entity (“PIPE”) Investors and former Spartan shareholders. The majority of the Allego N.V. shares are held by Madeleine, which is an indirectly controlled subsidiary of Meridiam SAS (“Meridiam”) – a global investor and asset manager based in Paris, France. Meridiam specializes in the development, financing and long-term management of sustainable public infrastructure in the mobility, energy transition and social infrastructure sectors.

These financial statements are the interim condensed consolidated financial statements for the group consisting of Allego N.V. and its subsidiaries (jointly referred to as the “Group” or “Allego Group”).

2.1. Basis of preparation

The interim condensed consolidated financial statements for the three months ended September 30, 2023 and the nine months ended September 30, 2023 have been prepared in accordance with IAS 34 Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”) and are unaudited.

The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended December 31, 2022 as well as the Group's interim condensed consolidated financial statements for the six months ended June 30, 2023.

The interim condensed consolidated financial statements have been prepared on a historical cost basis, unless otherwise stated. All amounts disclosed in the interim condensed consolidated financial statements are presented in thousands of euros (€), unless otherwise indicated.

2.2. Going concern assumption and financial position

The accompanying interim condensed consolidated financial statements of the Group have been prepared assuming the Group will continue as a going concern. The going concern basis of presentation assumes that the Group will continue in operation for a period of at least one year after the date these interim condensed consolidated financial statements are issued and contemplates the realization of assets and the settlement of liabilities in the normal course of business. See further discussion below.

The Group’s scale of operations

The Group’s strategy requires significant capital expenditures, as well as investments in building the Group’s organization aimed at increasing the scale of its operations. The Group incurred losses during the first years of its operations including

---

the three months ended September 30, 2023 and the nine months ended September 30, 2023 and expects to continue to incur losses in the next twelve months from the issuance date of these interim condensed consolidated financial statements. This is typical in the industry, as builders and operators of EV charging sites often incur losses in the early years of operation as the network grows and consumers begin adopting EVs. Therefore, the Group relies heavily on funding from bank financing and equity issuance. For example, during 2022, the Group expanded its old credit facility by an additional €50 million through an accordion feature with the group of lenders within the original old facility agreement. Additionally, during 2022, the Group entered into a new facility agreement (the "renewed facility") with a group of lenders led by Société Générale and Banco Santander, increasing the total available facility by €230 million to €400 million, to further support its growth. Further envisioned growth — in line with the Group’s strategy — will require additional significant investments from lenders or its existing shareholders.

Financial position of the Group

As of September 30, 2023, the Group had negative equity of €48,826 thousand due to the cumulative impact of losses incurred during its first years of operations (December 31, 2022: positive €27,758 thousand due to the losses incurred during its first years of operations being offset against proceeds from the SPAC Transaction) and cash and cash equivalents of €28,829 thousand (December 31, 2022: €83,022 thousand). The Group's operations to date have been funded by borrowings from the Company's shareholders and banks, as well as proceeds from the SPAC Transaction.

In the interim condensed consolidated statement of financial position as at September 30, 2023, the carrying value of the Group’s borrowings amounts to €312,160 thousand (December 31, 2022: €269,033 thousand). Additionally, the Group had €69,491 thousand in lease liabilities (December 31, 2022: €51,324 thousand) and €53,755 thousand in trade and other payables (December 31, 2022: €56,390 thousand).

Impact of increasing energy prices

The Group provides electricity directly through its own chargers and needs to procure this energy from the power markets in Europe. As a result of the war in Ukraine the price of gas has increased sharply, thereby increasing the demand on the European power markets with corresponding constraints in supply. This supply and demand imbalance has caused record increases in the price of electricity in Europe.

Allego obtains electricity through contracts with power suppliers or through direct sourcing on the power market. Allego utilizes an external, technology-enabled energy management platform to diversify its supply of power. Allego has entered into medium- and long-term power purchase agreements with renewable power to mitigate the future negative impact of increased energy costs. This has allowed the Group to fix the price of a portion of energy purchased, with plans to grow this percentage substantially over the next 6-18 months.

Additionally, the Group expects to be able to pass these costs onto EV customers. The Group increased prices several times during 2022, particularly in the second half of the year in response to rises in the price of electricity, whereas prices decreased during the first nine months of 2023 as a result of a reduction in the price of electricity. Despite the shifts in prices, the Group experienced improved utilization rates, indicating a relatively high degree of demand inelasticity by customers. If energy prices were to decline below the fixed price obtained through power purchase agreements, the Group would still expect to keep prices charged to customers constant, enabling predictable margins on charging revenues.

Financing

On December 19, 2022, the Group entered into the renewed facility with a group of lenders led by Société Générale and Banco Santander, increasing the total available facility by €230,000 thousand to €400,000 thousand, to further support its growth. The renewed facility expires in December 2027 and bears interest at Euribor plus a margin. Under the terms of the renewed facility, the Group is required to comply with financial covenants relating to interest and EBITDA at the consolidated level of Allego N.V. as detailed in Note 13.

Historically the Group met its covenants as per the old facility agreement. A covenant breach would negatively affect the Group’s financial position and cash flows, in a way that could reasonably be expected to influence the decisions of the primary users of these interim condensed consolidated financial statements. The Group considers the likelihood of a breach occurring as higher than remote as the Group incurred losses during the first years of its operations, even though the Group has complied with the covenants of the old facility throughout all reporting periods presented and expects to continue to meet financial covenants performance criteria of the renewed facility.

---

In parallel to the renewed facility, the Group entered into two interest rate caps derivatives to help offset the interest rate risk on between 65% and 74% (2022: between 65% and 85%) of the outstanding loan amounts under the renewed facility, with a notional of €237,458 thousand, which mature in December 2027. Interest rate risks on the remaining portion of the outstanding loan amounts, including the impact that higher interest rates would have on the Company’s going concern analysis, was included in the cash flow forecasts described below. Additional information on interest rate risk is described in Note 17.

As at September 30, 2023 the Group has not drawn on €77,390 thousand (December 31, 2022: €120,790 thousand) of this facility.

Liquidity forecasts

Management prepares detailed liquidity forecasts and monitors cash and liquidity forecasts on a continuous basis. In assessing the going concern basis of preparation of the interim condensed consolidated financial statements, management estimated the expected cash flows for the next 12 months, incorporating current cash levels, revenue projections and detailed capital expenditures, operating expenses budget, interest payment obligations, and working capital projections, as well as compliance with covenants, the potential exercise of warrants, potential future equity raises, and availability of other financial funding from banks, like those obtained in 2022. The Group invests in new stations, chargers and grid connections and potential business acquisitions only if the Group has secured financing for such investments. These forecasts reflect potential scenarios and management plans and are dependent on securing significant contracts and related revenues.

The Group has applied different scenarios ranging from a scenario that assumes regular capital expenditure levels based on the current available capex facility and a scenario that assumes a service-light model including revenues based only on existing contracts. All scenarios result in the Group having sufficient available cash and liquidity.

Based on these estimations, management has concluded that Allego will be able to fund the expected cash outflows in the next 12 months. Although the expectation for the coming year is that the Company will continue to make additional investments, its cash flows from operations and renewed credit facility is sufficient for at least the next 12 months from the issuance of these interim condensed consolidated financial statements. Therefore, the interim condensed consolidated financial statements have been prepared under the assumption that the Group operates on a going concern basis.

As described above, long-term investments, development activities, and operations more than 12 months out may require additional financing to be obtained. Currently, no commitments exist for further growth investments. The Group will be required to seek additional financing to continue to execute its growth strategy and business plan in the long-term. The realization of such financing is inherently uncertain. Securing additional funding — by raising additional equity or debt financing — is important for the Group’s ability to continue as a going concern in the long-term. However, there is no assurance that the Group will be able to raise additional equity or debt financing on acceptable terms, or at all.

2.3. Significant accounting policies

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s consolidated annual financial statements for the year ended December 31, 2022 as well as the Group's interim condensed consolidated financial statements for the six months ended June 30, 2023, except for the adoption of new standards effective as of January 1, 2023 (refer to Note 2.4), and the adoption of new accounting policies as indicated in this note.

2.3.1 Share-based payments

2.3.1.1 Other share-based payment plans

The share-based payment arrangements in place related to the Long-Term Incentive Plan ("LTIP") qualify as equity settled share-based payments in accordance with IFRS 2. As mentioned in Note 7.3, as part of Allego´s incentive plans, certain eligible members of the board of directors and employees were granted Restricted Stock Units ("RSUs"), performance based share options ("LTIP Performance Options") and Company ordinary shares ("IPO Grant Shares"), based on the Company's internal performance evaluation framework.

The grant date fair value is recognized as an operating expense with a corresponding increase in retained earnings. The fair value is determined at the grant date and the total expense is recognized over the vesting period. At the end of each reporting period, the Group revises the expense for the services received based on the vesting conditions. The impact is

---

recognized in the (interim condensed) consolidated statement of profit or loss with the corresponding increase in retained earnings.

The IPO Grant Shares, LTIP Performance Options and RSUs do not include any market conditions or non-vesting conditions that should be included in their fair value. The grant date fair value remains the same over time.

2.4. New accounting standards, interpretations and amendments adopted by the group

A number of amended standards became applicable for the current reporting period as disclosed in the Group’s consolidated annual financial statements for the year ended December 31, 2022. The Group did not have to change its accounting policies or make retrospective adjustments as these amended standards do not have a material effect on the Group's interim condensed consolidated financial statements:

Furthermore, the following amendments to standards have been published by the IASB. The amendments to IAS 12 are effective as of January 1, 2023. All other amendments will become effective on or after January 1, 2024. These have no material effect on the Group's interim condensed consolidated financial statements:

•Amendments to IAS 21 - Lack of Exchangeability

•Amendments to IAS 7 and IFRS 7 - Supplier Finance Arrangements

•Amendments to IAS 12 - International Tax Reform — Pillar Two Model Rules

•Amendment to IFRS 16 – Leases on sale and leaseback

The preparation of the Group’s interim condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent assets and liabilities. The reported amounts that result from making estimates and assumptions, by definition, will seldom equal the actual results. Management also needs to exercise judgment in applying the Group’s accounting policies.

The significant accounting estimates, assumptions and judgments applied in preparing these interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s consolidated annual financial statements for the year ended December 31, 2022, as well as the Group's interim condensed consolidated financial statements for the six months ended June 30, 2023.

3.1. Judgments

In the process of applying the Group’s accounting policies, no significant changes have occurred compared to the judgements disclosed in the Group’s consolidated annual financial statements for the year ended December 31, 2022, as well as the Group's interim condensed consolidated financial statements for the six months ended June 30, 2023.

3.2. Estimates and assumptions

In the process of applying the Group’s accounting policies, no significant changes have occurred compared to the estimates and assumptions disclosed in Group’s consolidated annual financial statements for the year ended December 31, 2022, as well as the Group's interim condensed consolidated financial statements for the six months ended June 30, 2023.

---

The CODM assesses the financial information of the business on a consolidated level. As the operating results of the business for the purpose of making decisions about resource allocation and performance assessment are monitored on a consolidated level, the Group has one operating segment which is also its only reporting segment.

As the Group only has one reporting segment, all relevant financial information is disclosed in the interim condensed consolidated financial statements.

Revenue from external customers

The Company is domiciled in the Netherlands. The amount of revenue from external customers, based on the locations of the customers, can be broken down by country as follows:

						For the three months ended September 30,												For the nine months ended September 30,
(in €‘000)						2023						2022						2023						2022
The Netherlands						12,492						9,925						46,475						29,901
Belgium						4,546						2,217						14,201						6,016
Germany						5,071						3,434						15,264						10,041
France						5,394						6,188						18,076						25,327
Other						1,104						556						2,801						1,727
Total						28,607						22,320						96,817						73,012

Disaggregation and timing of revenue from contracts with customers

Set out below is the disaggregation of the Group’s revenue from contracts with customers.

						For the three months ended September 30,												For the nine months ended September 30,
(in €‘000)						2023						2022						2023						2022
Type of goods or service
Charging sessions						22,036						14,405						73,174						38,399
Service revenue from the sale of charging equipment						523						889						2,009						19,331
Service revenue from installation services						3,451						5,181						13,734						11,145
Service revenue from operation and maintenance of charging equipment						1,073						556						3,329						2,378
Service revenue from consulting services						1,524						1,289						4,571						1,759
Total revenue from external customers						28,607						22,320						96,817						73,012
Timing of revenue recognition
Services transferred over time						6,048						7,026						21,634						15,282
Goods and services transferred at a point in time						22,559						15,294						75,183						57,730
Total revenue from external customers						28,607						22,320						96,817						73,012

---

						For the three months ended September 30,												For the nine months ended September 30,
(in €‘000)						2023						2022						2023						2022
Government grants						92						320						277						320
Income from sale of CO2 tickets						1,728						4,106						5,851						8,979
Net gain/(loss) on disposal of property, plant and equipment						(4,784)						1						(5,365)						1
Sublease rental income						50						46						150						150
Fair value gains/(losses) on derivatives (purchase options)						—						—						—						3,856
Fair value gains/(losses) on pref. shares derivatives						—						34						—						34
Other items						1,406						36						1,732						190
Total						(1,508)						4,543						2,645						13,530

Other items

Other items primarily consist of reimbursements that the Group has received from one of its suppliers for chargers.

During the year ended December 31, 2022, the Group purchased a number of chargers that malfunctioned and the Group has disposed of these chargers. As disclosed in the table above, the Group recognized a loss on disposal during the three and nine months ended September 30, 2023. In July 2023, a settlement has been reached with a supplier for damages caused. As a result, the Group has recognized a gain of €1,400 thousand for reimbursement received from suppliers (nine months ended September 30, 2022 and three months ended September 30, 2022: € nil).

7.1. Second Special Fees Agreement

On February 25, 2022, the then immediate parent entity of Allego Holding — Madeleine — entered into a second Special Fees Agreement (the “Second Agreement”) with the same external consulting firm as for the First Agreement described in Note 11.1 of the consolidated financial statements for the year ended December 31, 2022. The purpose of this Second Special Fees Agreement is to compensate the external consulting firm for their continuous strategic and operational advice, as well as support with regards to Allego’s fundraising efforts in the near future. The Agreement ultimately expires on the earlier of June 30, 2025, and the date on which Madeleine would no longer hold any equity security in Allego. As consideration for the Second Special Fees Agreement, the external consulting firm is entitled to receive cash compensation based on the value of the Group in connection with any new injection of equity, whether in cash or in kind, in any entity of the Group subsequent to the Business Combination (each an “Equity Injection”).

On March 10, 2022, the Second Special Fees Agreement was amended to modify the formula of the relevant percentage used in the determination of the fees payable (the “Relevant Percentage”) for equity injections subsequent to the first Equity Injection.

The Group accounts for the Second Special Fees Agreement as a share-based payment since the Group obtained services from the consulting firm in exchange for cash amounts based on the equity value of the Company. Madeleine, instead of the Group, had the obligation to settle the share-based payment arrangement with the consulting firm. The Second Agreement was therefore classified as an equity-settled share-based payment arrangement. On April 20, 2022, the Second Special Fees Agreement was novated from Madeleine to Allego (the “Novation”), with all the other terms of the Second Special Fees Agreement remaining the same. As a result of the Novation, Allego has now the obligation, instead of Madeleine, to settle the share-based payment arrangement with the consulting firm. The Second Special Fees Agreement’s classification therefore changed to a cash-settled share-based payment arrangement from the Novation date.

Certain directors of the Company are entitled to compensation from the external consulting firm in the form of a fixed percentage of the total benefits that the external consulting firm will generate under the Second Special Fees Agreement, including any amendments. The share-based payment expenses for the Second Special Fees Agreement therefore reflect both compensation for external consulting services and key management remuneration.

---

Measurement of fair value as an equity-settled plan

In accordance with IFRS 2 Share-based Payment, the fair value of key management remuneration under an equity-settled share-based payment arrangement is measured by reference to the fair value of the equity instruments granted, measured at the grant date. The fair value determined at the grant date is not subsequently adjusted.

As the value of the services provided by the consulting firm is not directly related to the time incurred by the consultants, management considers that the fair value of the services cannot be measured reliably. Therefore, the fair value of the services received under the Second Special Fees Agreement are measured by reference to the fair value of the share-based payment arrangement offered as consideration, as the Group obtains these services. The Group applies an approach where the average fair value over the reporting period is used to determine the fair value of the services received.

Since the Second Special Fees Agreement includes an implicit service condition, the services received under the Second Special Fees Agreement are recognized as expenses over the period in which the Company expects to have the Equity Injections, therefore between February 25, 2022 (the “grant date”) and the dates of the Equity Injections by reference to the fair value of the share-based payment arrangement measured at the grant date (for key management remuneration) or the average fair value over the reporting period (for external consulting services).

Measurement of fair value as a cash-settled plan

Following the Novation, the Second Special Fees Agreement was classified as a cash-settled plan as opposed to an equity-settled plan. Therefore, in accordance with IFRS 2 Share-based Payment, the fair value of both the key management remuneration and the services provided by the consulting firm under a cash-settled share-based payment arrangement is measured by reference to the fair value of the share-based payment arrangement offered as consideration, as the Group obtains these services. The fair value of the liability is recognized over the service period.

In effect, IFRS 2 Share-based Payment provides that the cumulative amount recognized as the expense over the life of the Second Special Fees Agreement is the grant-date fair value plus or minus any subsequent changes in fair value after the change in classification. Therefore, the cumulative amount may be less than the original grant-date fair value.

Fair value of equity instruments granted

The fees payable under the Second Special Fees Agreement will depend on the future value of the Allego Group following each future Equity Injection. Since there is no market price for the services, to measure the fair value of this instrument under IFRS 2 Share-based Payment, the future value of the Allego Group for the Equity Injections has been derived from a weighted average valuation model in which that value can be simulated based on various amounts and expected dates of Equity Injection events, and taking into account the likelihood of Equity Injections to happen, as well as the expected price per share upon Equity Injection.

The total fair value of the share-based payment arrangement as at September 30, 2023 is estimated at €49,958 thousand (grant date: €32,250 thousand). The increase in fair value of the share-based payment arrangement is mainly driven by an increase in the probability and expected amount of the Equity Injection events.

The Group assessed the impact to the fair value of the share-based payment arrangement as a result of the amendment to the Second Special Fees Agreement which was entered into in March 2022. The amendment modifies the formula of the Relevant Percentage applied to the future value of the Group for equity injections subsequent to the first Equity Injection, which is a component of the calculation of the fees payable. However, the Relevant Percentage used to calculate the fees remained the same following the amendment and therefore did not impact the fair value of the Second Special Fees Agreement as of the amendment date.

Additionally, the Group assessed the accounting impact of the Novation. The Group measured the liability using the Novation date fair value of the equity-settled shared-based payment arrangement based on the elapsed portion of the vesting period (period from Grant Date to each Equity Injection date). Therefore, as of the Novation, an amount of €4,440 thousand was recognized as a current liability, and an amount of €1,353 thousand was recognized as a non-current liability, with a corresponding decrease to equity of €5,793 thousand.

The Group recognized a share-based payment provision related to the Second Special Fees Agreement of €38,357 thousand as of September 30, 2023 (December 31, 2022: €16,806 thousand), included in the current liabilities in the interim condensed consolidated statement of financial position.

---

Share-based payment expenses

During the three months ended September 30, 2023, the Group recognized total share-based payment expenses with respect to the Second Special Fees Agreement of €15,028 thousand (three months ended September 30, 2022: gain of €421 thousand). As the share-based payment expenses for the Second Special Fees Agreement reflect both compensation for external consulting services and key management remuneration, the Group has recognized share-based payment expenses for an amount of €9,843 thousand (three months ended September 30, 2022: gain of €276 thousand) as legal, accounting and consulting fees and share-based payments expenses for an amount of €5,185 thousand (three months ended September 30, 2022: gain of €145 thousand) has been recognized as employee benefits expenses, both within general and administrative expenses.

During the nine months ended September 30, 2023, the Group recognized total share-based payment expenses with respect to the Second Special Fees Agreement of €21,551 thousand (nine months ended September 30, 2022: €2,187 thousand). As the share-based payment expenses for the Second Special Fees Agreement reflect both compensation for external consulting services and key management remuneration, the Group has recognized share-based payment expenses for an amount of €14,116 thousand (nine months ended September 30, 2022; €1,752 thousand) as legal, accounting and consulting fees and share-based payments expenses for an amount of €7,435 thousand (nine months ended September 30, 2022: €435 thousand) has been recognized as employee benefits expenses, both within general and administrative expenses.

During the nine months ended September 30, 2022, the Second Special Fees Agreement was modified from equity-settled plan to cash-settled plan as a result of the Novation. The Group recognized share-based payments expenses of €6,380 thousand for the period before the Novation, with a corresponding increase in retained earnings. This amount was split into legal, accounting and consulting fees of €4,498 thousand and employee benefits expenses of €1,882 thousand. For the period after the Novation, the Group recognized a gain on the share-based payments of €4,193 thousand with a corresponding decrease in liability. This amount consisted of a gain of €2,747 thousand recognized in legal, accounting and consulting fees and a gain of €1,446 thousand recognized in employee benefits expenses.

7.2. Management incentive plan

The establishment of the Company’s MIP was approved by the board of directors on April 20, 2022. The MIP is designed to provide long-term incentives for key management employees to deliver long-term shareholder returns, and includes two types of granted options: the right to acquire a percentage of the Company's issued share capital immediately following the listing, subject to the expiry of a blocking period of 18 months (the “MIP Grant Options”), and the right to acquire a percentage of the Company's issued share capital immediately following the listing, subject to predefined performance conditions and the expiry of the blocking period (the “MIP Performance Options”). The granted options carry no dividend or voting rights. The options do not include any market conditions or non-vesting conditions that should be included in the fair value at recognition.

Under the plan, the MIP Grant Options vest immediately, and the MIP Performance Options only vest if certain performance standards are met. Participation in the plan is at the board of directors’ discretion, and no individual has a contractual right to participate in the plan or to receive any guaranteed benefits.

The amount of MIP Performance Options that will vest depends on the group’s performance, including operational EBITDA, financing targets, compliance and reporting, engagement with investors, and the minimum service period of the employees. Once vested, the granted options remain exercisable for a period of ten years following the end of the blocking period, which ended on September 18, 2023 for the MIP Grant Options and ten years from the grant date (May 14, 2022) for the MIP Performance Options.

In April 2023, one non-market performance condition included in the original MIP agreement was modified, together with their respective service periods, to be applied to the group's performance over financial year 2023 instead of 2022. For the MIP performance options the blocking period was extended to April 30, 2024. The exercise period is ten years following the end of the blocking period. The exercise period and blocking period end date remain unchanged for the other MIP Performance Options. These changes result in an increased number of awards being expected to vest but do not have an impact on the fair value of the options.

The exercise price of the granted options under the plan is €0.12 per option. When exercisable, each option is convertible into one ordinary share of the Company.

---

Set out below are summaries of MIP Grant Options and MIP Performance Options granted under the plan:

						2023																		2022
						Average exercise price per share option (in €)						Number of MIP Grant Options						Number of MIP performance options						Average exercise price per share option (in €)						Number of MIP Grant Options						Number of MIP Performance Options
As at January 1						0.12						1,329,213						1,329,213						—						—						—
Granted during the period						—						—						—						0.12						1,329,213						1,329,213
Exercised during the period						—						—						—						—						—						—
Forfeited during the period						—						—						—						—						—						—
As at September 30						0.12						1,329,213						1,329,213						0.12						1,329,213						1,329,213
Vested and exercisable at September 30						0.12						1,329,213						996,910						—						—						—

As of September 30, 2023, 1,329,213 MIP Grant Options and 996,910 MIP Performance Options vested and became exercisable after the end of the blocking period, which ended on September 18, 2023. No options expired and no options were exercised during the period ended September 30, 2023.

Share options outstanding at the end of the reporting period have the following expiry dates and exercise prices:

Options

Grant date

Expiry date

Exercise price (in €)

Share options September  30, 2023

MIP Grant Options

May 14, 2022

September 17, 2033

0.12

1,329,213

MIP Performance Options

May 14, 2022

May 13, 2032

0.12

996,910

MIP Performance Options (modified)

May 14, 2022

April 29, 2034

0.12

332,303

Total

2,658,426

The weighted average remaining contractual life of options outstanding at the end of period is 9.54 years.

For the three months ended September 30, 2023, the total expenses arising from the MIP transactions recognized during the period as part of employee benefit expense was €1,612 thousand (three months ended September 30, 2022: €1,200 thousand). This includes an amount of €489 thousand (three months ended September 30, 2022: € nil) related to the additional expense recognized as a result of the modification of the MIP agreement.

For the nine months ended September 30, 2023 the total expenses arising from the MIP transactions recognized during the period as part of employee benefit expense was €5,110,682 (nine months ended September 30, 2022: €12,976,086). This includes an amount of €1,444 thousand (nine months ended September 30, 2022: € nil ) related to the additional expense recognized as a result of the modification of the MIP agreement.

Fair value of options granted

The assessed fair value of options was €7.75 per option (September 30, 2022: €7.75) for both the MIP Grant Options and MIP Performance Options.

The fair value was determined as the share price of the Company’s ordinary shares on grant date of $8.17 (€7.871), determined as the closing price on May 13, 2022 (the last working day preceding the grant date), less the exercise price of €0.12.

No specific option-pricing model (e.g., Black-Scholes) was applied for the valuation, as in the situation when the exercise price applicable to the options is negligible, the calculated fair value of an option is close (or equal) to the value of an ordinary share less the exercise price, regardless of the other input parameters applied in the option valuation.

---

7.3. Long-term Incentive Plan

The Allego board of directors and the compensation committee approved the general framework for the LTIP on 16 March 2022. The purpose of the LTIP is to provide eligible directors and employees the opportunity to receive stock-based incentive awards for employee motivation and retention and to align the economic interests of such persons with those of Allego’s shareholders. The delivery of certain shares or other instruments under the LTIP to directors and key management are agreed and approved in certain Allego board of directors meetings. On December 20, 2022, the Allego board of directors approved a detailed plan for the LTIP for future years.

Performance Based Share Options

As it relates to the LTIP for Allego executive officers, performance based share options may be granted annually and would be exercisable after a contractual vesting period of two to three years. The number of LTIP Performance Options issued under the LTIP in 2023 is based on four equally-weighted performance criteria: revenue, operational EBITDA, renewable GWh delivered, and appreciation at the discretion of the board of directors. The targets for the performance criteria are set annually.

During the nine months ended September 30, 2023, LTIP Performance Options were granted to executive officers based on 2022 and (expected) 2023 year-end company performance. The LTIP Performance Options related to performance in financial year 2022 have a contractual vesting period of two years, and the number of options awarded was determined in line with the level of completion of the performance criteria for that financial year. In addition, Allego granted LTIP Performance Options with a contractual vesting period of three years and subject to company performance in financial year 2023. This estimated number may be adjusted in the next reporting period depending on the completion of the performance criteria.

The exercise price of the LTIP Performance Options granted under the LTIP is €0.12 per option. When exercised, each LTIP Performance Option is convertible into one ordinary share of the Company.

Set out below is a summary of LTIP Performance Options granted under the plan:

						2023
						Average exercise price per LTIP Performance Option (in €)						Number of LTIP Performance Options
As at January 1						—						—
Granted during the period						0.12						3,059,955
Exercised during the period						—						—
Forfeited during the period						—						—
As at September 30						0.12						3,059,955
Vested and exercisable at September 30						—						—

During the nine months ended September 30, 2023, the Company granted two types of LTIP Performance Options: 1,039,222 options based on actual 2022 company performance and 2,020,733 options with vesting based on 2023 company performance. The number of options based on 2022 company performance is final, subject to meeting the service condition of two years. The number of options based on 2023 company performance is estimated and will be adjusted, if necessary, based on the actual performance.

LTIP Performance Options outstanding at the end of the reporting period have the following expiry dates and exercise prices:

---

Options

Grant date

Vesting date

Expiry date

Exercise price (in €)

Number of options September  30, 2023

LTIP Performance Options (2022)

April 12, 2023

April 12, 2025

April 12, 2032

0.12

1,039,222

LTIP Performance Options (2023)

January 1, 2023

April 12, 2026

April 12, 2033

0.12

2,020,733

The weighted average remaining contractual life of LTIP Performance Options outstanding at the end of period is 9.65 years.

The total expense arising from the LTIP Performance Options recognized during the three months ended September 30, 2023 as part of employee benefit expense was €1,644 thousand (three months ended September 30, 2022: € nil). For the nine months ended September 30, 2023, the total expense arising from the LTIP Performance Options recognized as part of employee benefit expense was €1,742 thousand (nine months ended September 30, 2022: €nil).

Fair value of LTIP Performance Options granted

The assessed fair value of LTIP Performance Options 2022 was €1.83 per option (September 30, 2022: no options granted). This fair value was determined as the share price of the Company’s ordinary shares on grant date of $2.13 (€1.952), determined as the closing price on April 12, 2023 (the grant date), less the exercise price of €0.12.

The assessed fair value of LTIP Performance Options 2023 was €2.82 per option (September 30, 2022: no options granted). This fair value was determined as the share price of the Company’s ordinary shares on grant date of $3.14 (€2.943), determined as the closing price on December 30, 2022 (the last working day preceding the grant date), less the exercise price of €0.12.

As the LTIP Performance Options do not include any market conditions or non-vesting conditions that have an impact on the fair value and there is no adjustment for dividends, the grant date fair value of LTIP Performance Options was determined using the same approach as used for the options granted under the MIP.

Restricted Stock Units

As it relates to the LTIP for other Allego employees, individuals may elect to receive up to 50% of their annual performance bonus to be paid in RSUs, which would vest on an annual basis. Additionally, certain Allego employees are eligible to receive additional RSUs based on the Company's existing internal performance evaluation framework. These RSUs would be granted annually and vest after three years. In May 2023, the Group awarded RSUs to eligible and selected employees based on the Company's internal performance evaluation framework. The RSUs have a vesting period of three years and are subject to the participant's continued employment until the vesting date.

Under the terms of the same plan, RSUs were awarded to eligible members of the board of directors in May 2023. These RSUs were not subject to any vesting conditions and vested fully on the grant date. The Company's ordinary shares were issued to the eligible members of the board of directors on August 10, 2023.

Set out below are summaries of the number of RSUs granted under the plan:

						2023
						Employees						Eligible directors
As at January 1						—						—
Granted during the period						189,201						666,968
Forfeited during the period						—						—
Vested and issued during the period						—						(666,968)
As at September 30						189,201						—
Vested and exercisable at September 30						—						—

---

Fair value of RSUs granted

The grant date fair value of the RSUs granted to the employees in 2023 is recognized as an expense on a straight-line basis over the three-year vesting period, with a corresponding entry in equity. Since the RSUs granted to certain members of the board of directors are not subject to any vesting conditions, the grant date fair value of these awards is recognized immediately, on the grant date, as an expense with a corresponding entry in equity.

The assessed fair value of RSUs granted during the period ended September 30, 2023, was €1.97 per option (September 30, 2022: no RSUs granted). The fair value of the RSUs has been determined with reference to the share price of the Company’s ordinary shares at the grant date. Since the Company does not expect to pay dividends during the vesting period, the weighted average fair value of the RSUs granted in the nine months ended September 30, 2023 of $2.13 (€1.974) is equal to share price at the grant date, May 24, 2023.

The share-based payment expense recognized for the three months ended September 30, 2023 for the equity-settled RSUs amounted to €31 thousand (three months ended September 30, 2022: € nil), and only represented the expense in relation to the RSUs issued to employees.

The share-based payment expense recognized for the nine months ended September 30, 2023 for the equity-settled RSUs amounted to €1,361 thousand (nine months ended September 30, 2022: € nil), consisting of €1,317 thousand related to the fully vested board of directors' RSUs recognized on grant date and €44 thousand representing the expense for the current period in relation to the RSUs issued to employees.

IPO Grant Shares

In May 2023, the Group awarded 100 ordinary shares per employee to a select group of individuals who were instrumental in the success of the IPO. The Company granted this one-off share award as of the IPO date to employees of the Company, who were still employed by the Company a year later. This award granted in 2023 was not subject to any vesting conditions. The Company awarded a total number of 9,600 ordinary shares in May 2023. The ordinary shares were issued to the employees on June 9, 2023.

The fair value of the share awards of $2.13 (€1.972) is equal to the share price of the Company's ordinary shares at the date of grant. The share-based payment expenses for the three months ended September 30, 2023 is € nil (three months ended September 30, 2022: € nil) and for the nine months ended September 30, 2023 is €19 thousand (nine months ended September 30, 2022: € nil).

---

Basic loss per share is calculated by dividing the loss for the period attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding during the period.

The following table reflects the loss and share data used in the basic and diluted loss per share calculations for the three months ended September 30, 2023 and 2022, and the nine months ended September 30, 2023 and 2022:

						For the three months ended September 30,												For the nine months ended September 30,
						2023						2022						2023						2022
Loss attributable to ordinary equity holders of the Company (in €‘000)						(43,015)						(21,356)						(81,829)						(268,269)
Weighted average number of ordinary shares for basic and diluted loss per share						267,564,249						267,177,592						267,308,676						246,129,260
Basic and diluted loss per share (in €'000)						(0.16)						(0.08)						(0.31)						(1.09)

The Company only has ordinary shares. Refer to Note 12 for details about the Company’s share capital.

There is no difference between basic and diluted loss per share as the effect of the potential ordinary shares that would be issued by the Company under the Management Incentive Plan, the Long Term Incentive Plan, or the Public Warrants is anti-dilutive for all periods presented. Refer to Note 7.2 and 7.3 for details on the Management Incentive Plan and the Long Term Incentive Plan, and refer to Note 27 of the consolidated financial statements for the year ended December 31, 2022 for details on the Public Warrants.

---

(in €‘000)						Property, plant and equipment						Intangible assets (excl. goodwill)						Goodwill
Carrying amount at December 31, 2022						134,718						13,924						10,724
Movements in the nine months ended September 30, 2023
Additions						43,070						—						—
Disposals						(9,691)						—						—
Depreciation and amortization						(15,444)						(3,244)						—
Accumulated depreciation and amortization of disposals						4,628						—						—
Impairments						(321)						—						—
Reversal of impairments						549						—						—
Carrying amount at September 30, 2023						157,509						10,680						10,724

Investments and disposals of property, plant and equipment

During the nine months ended September 30, 2023, investments in property, plant and equipment amounted to €43,070 thousand (September 30, 2022: €116,590 thousand) and disposals of property, plant and equipment amounted to €5,063 thousand (September 30, 2022: €196 thousand). The disposals during the nine months ended September 30, 2023 mainly relate to chargers purchased by the Group during the year ended December 31, 2022, that malfunctioned and were disposed, refer to Note 6 for further details.

---

Impairments and reversals of impairments of chargers

During the three months ended September 30, 2023, the Group recorded an impairment loss of €85 thousand (three months ended September 30, 2022: €133 thousand) and a reversal of impairment of €218 thousand (three months ended September 30, 2022: €270 thousand).

During the nine months ended September 30, 2023, the Group recorded an impairment loss of €321 thousand (nine months ended September 30, 2022: €678 thousand) and a reversal of impairment of €549 thousand (nine months ended September 30, 2022: €392 thousand).

Purchase commitments

The Group’s purchase commitments for chargers and charging infrastructure are disclosed in Note 18. At the end of each reporting period presented, the Group did not have purchase commitments for other asset classes of property, plant and equipment.

Share capital

As at September 30, 2023, the issued share capital of the Company amounts to €32,142 thousand (December 31, 2022: 32,061 thousand), divided into 267,854,160 ordinary shares of €0.12 per share (December 31, 2022: 267,177,592 ordinary shares of €0.12 per share). They entitle the holders to participate in dividends, and to share in the proceeds of winding up the Company in proportion to the number of shares held. The authorized share capital of the Company as at September 30, 2023 amounted to €108,000 thousand (December 31, 2022: €108,000 thousand), divided into 900,000,000 ordinary shares of € 0.12 per share (December 31, 2022: 900,000,000 ordinary shares of € 0.12 per share).

Issuance of ordinary shares related to the IPO Grant Shares award under the LTIP

On June 9, 2023, 9,600 ordinary shares, with a nominal value of €0.12 per share, were issued for no consideration to employees of the Company. These shares relate to the IPO Grant Shares award under LTIP as described in note 7.3.

Issuance of ordinary shares related to the RSUs award under the LTIP

On August 10, 2023, 666,968 ordinary shares, with a nominal value of €0.12 per share, were issued for no consideration to eligible members of the board of directors. These shares relate to the RSUs award under the LTIP as described in note 7.3.

Transaction costs for the future issuance of ordinary shares in exchange of Public Warrants

During the nine months ended September 30, 2023, the Group incurred transaction costs of €972 thousand (nine months ended September 30, 2022: € nil) that are directly attributable to the future issuance of ordinary shares in relation to the exchange of Public Warrants. These transaction costs have been recorded as a deduction to share premium. For further details on the exchange of Public Warrants, refer to Note 20.

Share capital and share premium movements

Movement of share capital and share premium are as follows:

---

This note provides a breakdown of borrowings in place as at September 30, 2023 and December 31, 2022.

(in €‘000)

Interest rate

Maturity

September 30, 2023

December 31, 2022

Renewed facility

Euribor* + 3.9%**

December 19, 2027

312,160

269,033

Total

312,160

269,033

*The Euribor rate (6M) is floored at 0%. This floor is closely related to the contract of the loan and is therefore not presented separately in the interim condensed consolidated statement of financial position.

**The margin of 3.9% will increase by 0.2% per year, for the first time in December 2025.

---

Refinancing of the old facility with the renewed facility

On December 19, 2022, the Group has entered into a new facility agreement (“the renewed facility”) with a group of lenders led by Société Générale and Banco Santander, increasing the total existing available facility ("the old facility") by €230,000 thousand to €400,000 thousand, to further support its growth. The renewed facility consists of:

i.€170,000 thousand used to settle the old facility;

ii.up to €200,000 thousand to be used for financing and refinancing certain capital expenditures and permitted acquisitions (and for other permitted debt servicing uses); and

iii.up to €30,000 thousand to be used for issuance of guarantees and letters of credit (and when utilized by way of letters of credit, for general corporate purposes).

The renewed facility expires in December 2027 and bears interest at EURIBOR plus a margin. The principal terms and conditions of the renewed facility are as follows:

•drawdown stop when conditions precedent are not met;

•repayment in full at maturity date;

•commitment fee per year equals to 35% of the applicable margin and is payable for each undrawn facility in the period from the agreement signing date to the date being 42 months following the signing date. For the nine months ended September 30, 2023, the commitment fee was 1.365% per year (equal to 35% of the margin of 3.9%).

In December 2022, the Group completed two drawdowns on the renewed facility for a total amount of €279,210 thousand, of which €170,000 thousand was used to repay the Group’s old facility by a way of netting with the drawdown on the renewed facility. In June 2023, the Group completed an additional drawdown on the renewed facility of €43,400 thousand bringing the total drawdowns of the facility to €322,610 thousand.

In parallel to the renewed facility, the Group entered into two interest rate caps to hedge the interest rate risk on between 65% and 74% (2022: between 65% and 85%) of the outstanding loan amounts under the renewed facility. Details about the Group’s interest rate caps are included Note 16.

The refinancing of the old facility was accounted for as extinguishment of the former financial liability and recognition of the new debt instrument. Details about the accounting treatment are included in Note 25 of the consolidated financial statements for the year ended December 31, 2022.

Assets pledged as security

The renewed facility is secured by pledges on the bank accounts (presented as part of cash and cash equivalents and non-current other financial assets), trade and other receivables and pledges on the shares in the capital of Allego Holding B.V., Allego B.V., Allego GmbH and Allego France SAS held by the Company.

During the nine months ended September 30, 2023, the Group has pledged additional assets in relation to the renewed facility as detailed in the table below.

---

The carrying amount of assets pledged as security for the renewed facility is as follows:

(in €‘000)						September 30, 2023						December 31, 2022
Current assets
Floating charge
Cash and cash equivalents						6,543						56,317
Trade receivables						8,480						—
Total current assets pledged as security						15,023						56,317
Non-current assets
Floating charge
Non-current other financial assets						10,500						10,500
Total non-current assets pledged as security						10,500						10,500
Total assets pledged as security						25,523						66,817

Transaction costs

During the period ended September 30, 2023, the Group incurred €1,689 thousand (September 30, 2022: €nil) of transaction costs that are directly attributable to the renewed facility. These costs are included in the measurement of the respective drawdowns and are amortized over the term of these drawdowns using the effective interest method. Interest expense on the Group’s renewed facility is recognized as part of finance income/(costs) in the interim condensed consolidated statement of profit or loss.

The Group expects that it will draw on the funds available under the renewed facility. Therefore, commitment fees paid on the unused portion of the renewed facility are deferred and treated as an adjustment to the loan’s effective interest rate and recognized as interest expense over the term of the facility.

Loan covenants

Under the terms of the renewed facility, the Group is required to comply with the following financial covenants related to interest and earnings before interest, taxes, depreciation and amortization (“EBITDA”) at the consolidated level of the Group:

1.Leverage ratio: calculated on a consolidated level as (total net debt / Group EBITDA).

2.Interest cover ratio: calculated on a consolidated basis as (Group EBITDA / interest paid).

The covenants shall be determined based on the IFRS financial statements of the Group, as required by the terms and conditions of the renewed facility. The compliance with these covenants shall be tested every six months, with the testing period being twelve months ending December 31 and June 30, with the first testing date being June 30, 2023.

The target covenant ratios are determined based on a twelve-month running basis and are as follows:

Testing period ending on

Leverage ratio

Interest cover ratio

June 30, 2023

Unconditional

-0.8x

December 31, 2023

Unconditional

-0.9x

June 30, 2024

33.9x

0.4x

December 31, 2024

5.4x

2.3x

June 30, 2025

3.2x

3.8x

December 31, 2025

2.2x

5.5x

June 30, 2026

2.2x

5.5x

December 31, 2026

2.2x

5.5x

June 30, 2027

2.2x

5.5x

---

The Group may within ten business days from the occurrence of a breach or the anticipated breach of the loan covenants remedy such default by providing evidence of receipt of new funding, sufficient to cure such breach (“equity cure right”). Such remediation is available for not more than two consecutive testing dates and four times over the duration of the renewed facility. In case if the covenants breach is not cured, such a breach is considered a default and could lead to the cancellation of the total undrawn commitments and the loan to become immediately due and payable.

Additionally, the following ratios are set as drawstop event conditions for the part of the renewed facility aimed at financing and refinancing certain capital expenditures and permitted acquisitions, which if breached prior to the anticipated utilization of the capex portion of the renewed facility – will result in the drawdown stop:

•Group EBITDA margin ratio: calculated on a consolidated level as (Group EBITDA / Real Period Revenue).

•Group EBITDA amount: calculated on a consolidated level

•Fast/ultra-fast charging equipment utilization rate: calculated on a consolidated level as (average number of sessions over the relevant Group charger base, divided by 50).

The target drawdown stop conditions are determined based on a twelve-month running basis and are as follows:

Testing period ending on						EBITDA margin (drawstop)						EBITDA (drawstop)						Fast/ultrafast charging equipment utilization rate (drawstop)
June 30, 2023						-4.3		%				€	(8.5)	million				10.4		%
December 31, 2023						-5.8		%				€	(11.6)	million				11.5		%
June 30, 2024						8.1		%				€	19.8	million				12.7		%
December 31, 2024						19.4		%				€	68.2	million				12.9		%
June 30, 2025						24.1		%				€	111.2	million				14.2		%
December 31, 2025						27.3		%				€	157.5	million				15.5		%
June 30, 2026						28.9		%				€	200.0	million				16.6		%
December 31, 2026						Unconditional						Unconditional						Unconditional
June 30, 2027						Unconditional						Unconditional						Unconditional

Breaching the requirements would cause a drawdown stop. Continuing breaches in the drawstop conditions would permit the bank to cancel the total undrawn commitments. The Group may within twenty business days from the occurrence of a drawstop event provide a remedial plan setting out the actions, steps and/or measures (which may include a proposal for adjustments of the financial covenants' or utilization rate's levels) which are proposed to be implemented in order to remedy such drawstop event.

In the preparation of its interim condensed consolidated financial statements, the Group assessed whether information about the existence of the covenant and its terms is material information, considering both the consequences and the likelihood of a breach occurring. The consequences of a covenant breach have been described in this note. A covenant breach would affect the Group’s financial position and cash flows in a way that could reasonably be expected to influence the decisions of the primary users of these interim condensed consolidated financial statements. Refer to Note 2.2 for additional information.

---

This note provides information about the Group’s financial instruments, including:

•an overview of all financial instruments held by the Group;

•the classification of the financial instruments;

•the line item on the interim condensed consolidated statement of financial position in which the financial instrument is included;

•the financial instrument’s book and fair value.

The Group holds the following financial instruments:

Financial assets

(in €‘000)						Notes						At amortized cost						Fair value through PL						Fair value through OCI						Total book value						Total fair value
As at December 31, 2022
Non-current other financial assets												21,900						9,198						31,389						62,487						62,487
Current other financial assets												601						—						—						601						601
Trade and other receivables												44,776						—						—						44,776						44,776
Cash and cash equivalents												83,022						—						—						83,022						83,022
Total												150,299						9,198						31,389						190,886						190,886
As at September 30, 2023
Non-current other financial assets												22,439						8,603						29,463						60,505						60,505
Current other financial assets												6,469						—						—						6,469						6,469
Trade and other receivables												36,639						—						—						36,639						36,639
Cash and cash equivalents												28,829						—						—						28,829						28,829
Total												94,376						8,603						29,463						132,442						132,442

Due to the highly liquid nature of cash and cash equivalents and the pledged bank balances classified within non-current other financial assets, their carrying amount is considered to be the same as their fair value. Due to the short-term nature of trade and other receivables as well as current other financial assets, their carrying amount is considered to be the same as their fair value.

---

Financial liabilities

(in €‘000)						Notes						At amortized cost						Fair value through PL						Total book value						Total fair value
As at December 31, 2022
Borrowings						13						269,033						—						269,033						272,641
Non-current lease liabilities												44,044						—						44,044						N/A
Current lease liabilities												7,280						—						7,280						N/A
Trade and other payables												51,263						—						51,263						51,263
Warrant Liabilities												—						1,296						1,296						1,296
Total												371,620						1,296						372,916						325,200
As at September 30, 2023
Borrowings						13						312,160						—						312,160						325,409
Non-current lease liabilities												60,212						—						60,212						N/A
Current lease liabilities												9,279						—						9,279						N/A
Trade and other payables												51,640						—						51,640						51,640
Warrant liabilities												—						5,471						5,471						5,471
Total												433,291						5,471						438,762						382,520

This note explains the judgments and estimates made in determining the fair values of the financial instruments that are recognized and measured at fair value and the financial instruments for which the fair value is disclosed in the interim condensed consolidated financial statements. To provide an indication about the reliability of the inputs used in determining fair value, the Group has classified its financial instruments into the three levels prescribed under the accounting standards.

An explanation of each level is included in Note 2.7.18 of the consolidated financial statements for the year ended December 31, 2022.

Assets and liabilities measured at fair value

As at September 30, 2023, the Group has recorded the following financial instruments at fair value in the interim condensed consolidated statement of financial position:

•interest rate cap derivatives;

•warrant liabilities;

•investment in equity securities.

Interest rate cap derivatives and the investment in equity securities are presented within non-current other financial assets. Warrant liabilities are presented as a separate line in the interim condensed consolidated statement of financial position as at September 30, 2023.

The interest rate caps qualify for the level 2 category in the fair value hierarchy due to the fact that they are not traded in an active market and the fair value is determined using valuation techniques which maximize the use of observable market data. Since all significant inputs required to fair value the instruments are observable, the instruments are included in level 2.

The investment in equity securities qualifies for the level 3 category in the fair value hierarchy due to the fact that the securities are not traded in an active market and there is no observable market data. Therefore, the fair value of these securities is determined using valuation techniques which use unobservable inputs that are significant to fair value.

The warrants qualify for the level 1 category in the fair value hierarchy due to the fact that their fair value is determined based on quoted market inputs.

---

For assets and liabilities that are recognized in the interim condensed consolidated financial statements at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period. During the nine months ended September 30, 2023, there were no transfers that occurred between levels.

The fair values of the Group’s assets and liabilities measured at fair value are disclosed in the table in Note 15.

Fair value of assets and liabilities not measured at fair value

The Group has determined the fair value of assets and liabilities not measured at fair value, but for which the fair value is required to be disclosed.

Borrowings:

For the renewed facility, the fair value differs from its carrying amount because the interest payable on the facility is (partially) fixed. The borrowings qualify for the level 3 category in the fair value category due to the use of unobservable inputs, including own credit risk.

The fair values of the Group’s assets and liabilities not measured at fair value are disclosed in the table in Note 15.

Specific valuation techniques to determine fair values

Specific valuation techniques used to value financial instruments include:

•interest rate cap derivatives: option pricing model;

•investment in equity securities: discounted cash flow analysis;

•borrowings: discounted cash flow analysis using a market interest rate;

Financial instruments measured at fair value (level 3)

The changes in level 3 items for the nine months ended September 30, 2023 have been as follows:

(in €‘000)						Investment in equity securities
Carrying amount at January 1, 2023						31,389
Movements in the nine months ended September 30, 2023
Fair value loss on investment in equity securities recognized in other comprehensive income						(1,926)
Carrying amount at September 30, 2023						29,463

The Group’s engages with third party valuation specialists to perform its fair value measurements for financial reporting purposes on a periodic basis. Involvement of external valuers is determined annually by the Group’s finance team after discussion with and approval by the Group’s Executive Board. Selection criteria for valuation specialist include market knowledge, reputation, independence and whether professional standards are maintained.

The Group works closely with the qualified external valuers to establish the appropriate valuation techniques and inputs to the model. At each reporting date, the Group analyses the movements in the values of assets and liabilities which are required to be remeasured or re-assessed as per the Group’s accounting policies.

Valuation inputs to the fair value of investments in equity securities

The Group updated the third party valuation report to determine the fair value of investments in equity securities. Inputs to the fair value of the investments in equity securities are the earnings growth factor and risk-adjusted discount rate. The following table summarizes the quantitative information about the significant unobservable input parameters used in the

---

level 3 fair value measurement of the investments in equity securities, using the DCF (“Discounted Cash Flows”) methodology.

In %						September 30, 2023
Growth factor						3.0		%
Discount rate						11.9		%

An increase or decrease of 100 basis point in the growth factor would change the fair value of the investment in equity by an increase of €3,741 thousand or a decrease of €2,984 thousand, respectively.

This note explains the Group’s exposure to financial risks and how these risks could affect the Group’s future financial performance.

Risk

Exposure arising from

Measurement

Management

Market risk – interest rate risk

Long-term borrowings at variable rates

Sensitivity analysis

Economic hedge with an interest rate caps

Market risk – price risk

Investments in equity securities

Sensitivity analysis

Monitoring quarterly valuation updates and forecasts of future cash flows

Liquidity risk

Borrowings and other liabilities

Cash flow forecasts

Availability of borrowing facilities.

The Group’s management oversees the management of these risks. The Group’s management is supported by the Finance department that advises on financial risks and the appropriate financial risk governance framework for the Group. The Group’s risk management is predominantly controlled by the Finance department under policies approved by the Executive Board. The Executive Board provides principles for overall risk management, as well as policies covering specific areas, such as foreign exchange risk, interest rate risk, credit risk, use of derivative financial instruments and non-derivative financial instruments. Since the largest part of the Group’s assets, liabilities, and transactions are denominated in euro, the market risk of foreign exchange is considered not to be significant. There are no changes compared to the previous period.

Market risk

Cash flow and fair value interest rate risk

The Group’s main interest rate risk arises from a long-term borrowing with a variable rate, which exposes the Group to cash flow interest rate risk. The cash flow risk is mitigated through the usage of interest rate caps. During the nine months ended September 30, 2023 and 2022, the Group’s borrowings at a variable rate were denominated in euro.

The Group’s borrowings are carried at amortized cost.

Instruments used by the Group

The Group has two interest rate caps in place with a notional of €237,458 thousand (December 31, 2022: two interest rate caps with a notional of €181,487 thousand) which mature in December 2027 (December 31, 2022: in December 2027). As at September 30, 2023, the interest rate caps cover approximately 74% (December 31, 2022: 65%) of the variable loan principal outstanding. The strike price changes over time and ranges between 1.50% and 3.43%. The interest rate caps mitigate between 65% and 74% (December 31, 2022: between 65% and 85%) of the variable debt outstanding, as the notional of the derivative instruments and the renewed facility changes over time. The remaining cash flow risk is accepted.

The interest rate caps require settlement of any interest receivable, if applicable, semiannually. The settlement dates coincide with the dates on which interest is payable on the renewed facility.

---

Sensitivity

The interim condensed consolidated statement of profit or loss is sensitive to higher/lower interest expenses from borrowings as a result of changes in interest rates as both the Group’s old and renewed facilities have a variable interest rate. Equity is not impacted as no hedge accounting is applied. Additionally, an increase or decrease of the Euribor has an impact on the fair value of the Group’s interest rate caps.

The impact on loss for the three and nine months ended September 30, 2023 and 2022 as a result of a change in interest rates is as follows:

(in €‘000)						Impact on pre-tax loss
						For the three months ended September 30,												For the nine months ended September 30,
						2023						2022						2023						2022
Interest rates – increase by 10 basis points*						5						31						463						258
Interest rates – decrease by 10 basis points*						(4)						(38)						(439)						(253)

*Keeping all other variables constant.

Global regulators and central banks have been driving international efforts to reform key benchmark interest rates. The market is therefore in transition to alternative risk-free reference rates. Although limited impact is expected on the Euribor, the Group is in the process of evaluating the implications of such a phase out. The Group has no interest rate hedging relationships which are affected by the reform and does not expect any significant impact on existing contracts due to a change in the interest rates. The Group will continue to monitor market developments.

Price risk

Exposure

The Group’s exposure to equity securities price risk arises from investments held by the group and classified in the interim condensed consolidated statement of financial position as at fair value through other comprehensive income ("FVOCI") as detailed in Note 19 of the consolidated financial statements for the year ended December 31, 2022. The price risk is mitigated by monitoring quarterly valuation updates and forecasts of future cash flows and aligning the business strategy accordingly.

Sensitivity

The table below summarizes the impact of increases/decreases of the price of equity securities on the group’s equity through OCI reserve for the period. The analysis is based on the assumption that the fair value of the equity securities held by the group has increased or decreased by 40%, with all other variables held constant.

(in €‘000)

Impact on Group's Equity

For the nine months ended September 30,

Fair Value – increase by 4,000 basis points

11,785

Fair Value – decrease by 4,000 basis points

(11,785)

Liquidity risk

Prudent liquidity risk management implies maintaining sufficient cash and the availability of funding through an adequate amount of committed credit facilities to meet obligations when due and to close out market positions. Due to the dynamic nature of the underlying businesses, the Group maintains flexibility in funding by maintaining availability under committed credit lines. The Group has been predominantly contracting customers of sound commercial standing and their payment behavior was generally good. Refer to Note 2.2 for details about the Group’s financial position and the going concern assumption applied in preparing the interim condensed consolidated financial statements.

As disclosed in Note 13, the Group has pledged bank balances to secure the payment of interest and commitment fees to the Group’s external lenders and pledged bank balances in relation to bank guarantees issued to suppliers of the Group.

The main risk for the Group is not meeting the debt covenants or drawdown requirements described in Note 13. In this case, funding via the renewed facility would not be available. The Group monitors the liquidity risk on a weekly basis.

---

Management monitors rolling forecasts of the Group’s cash and cash equivalents on the basis of expected cash flows. This is generally carried out at Group level, in accordance with practice and limits set by the Group. In addition, the Group’s liquidity management policy involves projecting cash flows and considering the level of liquid assets necessary to meet these, monitoring balance sheet liquidity ratios against internal and external regulatory requirements and maintaining debt financing plans. The Group assessed the concentration of risk with respect to refinancing its debt and concluded it to be low.

Financing arrangements

The Group had access to the following undrawn borrowing facilities for each reporting period presented:

(in €‘000)

September 30, 2023

December 31, 2022

Expiring beyond one year—renewed facility

77,390

120,790

Purchase commitments for chargers and charging infrastructure

Significant expenditures for chargers and charging infrastructure contracted for, but not recognized as liabilities, as at September 30, 2023 were €18,974 thousand (December 31, 2022: €2,452 thousand). The Group uses these assets either as own chargers (property, plant and equipment) or as charging equipment to fulfill its obligations under development contracts entered into with its customers (inventory). As a result of the additional liquidity obtained from the renewed facility in December 2022, and in line with the growth strategy and business plan of the Group, the company has been increasing its level of commitment towards capital expenditures and inventory purchases during the nine months ended September 30, 2023.

Purchase commitments for renewable electricity

As disclosed in Note 2.2, Allego has entered into medium- and long-term power purchase agreements with renewable power producers. Significant expenditures for renewable electricity and corresponding CO2 tickets contracted for, but not recognized as liabilities, as at September 30, 2023 were €233,149 thousand (December 31, 2022: €69,701 thousand).

Balances and transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note. Details of transactions between the Group and other related parties are disclosed below.

Terms and conditions of transactions with related parties

Management services were bought from the immediate parent entity for a fixed fee. All other transactions were made on normal commercial terms and conditions and at market rates. Outstanding balances are unsecured. Asset and liability positions can either be offset or can be settled in cash. No loss allowance is recognized on these balances.

---

19.1. Transactions with related parties

												For the three months ended September 30,												For the nine months ended September 30,
(in €‘000)						Relationship						2023						2022						2023						2022
Madeleine Charging B.V.						Immediate parent entity
Interest expenses on shareholder loans												—						—						—						1,755
Management fee												—						—						—						12
Reimbursement of advisory fees												—						—						—						280
Share-based payment expenses												—						—						—						74,001
Mega-E Group (Mega-E Charging B.V. and its subsidiaries)						Other related party
Revenue from contracts with related party												—						—						—						1,474
EV Cars						Other related party
Revenue from contracts with related party												3,205						4,482						12,311						22,826
Voltalis						Other related party
Revenue from contracts with related party												1,364						989						4,091						1,279

Madeleine Charging B.V

For the three months ended September 30, 2023, transactions with Madeleine amounted to € nil (three months ended September 30, 2022 : € nil). For the nine months ended September 30, 2023, transactions with Madeleine amounted to € nil (nine months ended September 30, 2022: €76,048 thousand). The change is largely driven by the SPAC Transaction, which occurred on March 16, 2022.

On March 16, 2022, immediately prior to the closing of the SPAC Transaction, the outstanding principal of the shareholder loans together with the accrued interest on these loans with Madeleine was converted into equity. As a result no further interest expenses related to these shareholder loans were incurred by the Group (Refer to Note 25 of the consolidated financial statements for the year ended December 31, 2022).

Prior to the SPAC Transaction, Allego was required to pay Madeleine management fees and reimburse advisory fees, which are no longer applicable From March 16, 2022 as a result of the SPAC Transaction.

Share-based payment expenses with Madeleine related to the First Special Fees Agreement and the Second Special Fees Agreement. The First Special Fees Agreement was terminated prior and in connection with the SPAC Transaction and no further share-based payment expenses with Madeleine were incurred in relation to it after March 16, 2022 (Refer to Note 11.1 of the consolidated financial statements for the year ended December 31, 2022). The Second Special Fees Agreement was novated from Madeleine to Allego on April 20, 2022 and no further share-based payment expenses were incurred from that date in relation to Madeleine (refer to note 7.1 for details on the Second Special Fees Agreement).

Mega-E Group

The transactions with Mega-E until March 16, 2022, are considered related-party transactions. The Group obtained control of Mega-E as of that date. All subsequent transactions are therefore considered to be intra-group transactions and have been eliminated in these interim condensed consolidated financial statements.

---

The following subsequent events occurred after September 30, 2023:

Public warrants exchange

As at September 30, 2023, the Group had 13,799,948 public warrants outstanding and no private placement warrants. On October 3, 2023, the Group announced the completion of its previously announced exchange offer (dated August 25, 2023) and consent solicitation relating to its outstanding public warrants. On October 3, 2023, the Company issued 2,996,918 ordinary shares in exchange for the 13,029,838 public warrants tendered in the exchange offer. The remaining 770,110 public warrants were exchanged for 159,712 ordinary shares, effective October 18, 2023. No consideration was received from the Company as part of the exchange. As a result of these transactions, no public warrants remain outstanding.

Guarantee facility

On December 19, 2022, the Group has entered into a renewed facility agreement with a group of lenders led by Société

Générale and Banco Santander, which included up to €30,000 thousand to be used for issuance of guarantees and letters of credit. The first letters of credit were issued on October 19, 2023 to Solarpark Lindenhof GmbH, as follows: one letter of credit from Banco Santander for the maximum original amount of €6,250 thousand and one letter of credit from Société

Générale for the maximum original amount of €6,250 thousand.

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

v3.23.3

Cover	9 Months Ended
	Sep. 30, 2023
Document Information [Line Items]
Document Type	6-K
Document Period End Date	Sep. 30, 2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-41329
Entity Registrant Name	Allego N.V.
Entity Central Index Key	0001874474
Amendment Flag	false

v3.23.3

Interim condensed consolidated statement of profit or loss - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue from contracts with customers
Total revenue from contracts with customers	€ 28,607	€ 22,320	€ 96,817	€ 73,012
Cost of sales	(23,204)	(26,886)	(70,956)	(75,302)
Gross profit	5,403	(4,566)	25,861	(2,290)
Other income/(expenses)	(1,508)	4,543	2,645	13,530
Selling and distribution expenses	(565)	(804)	(1,674)	(2,501)
General and administrative expenses	(36,653)	(15,431)	(83,847)	(287,084)
Operating loss	(33,323)	(16,258)	(57,015)	(278,345)
Finance income/(costs)	(9,907)	(4,438)	(24,656)	10,735
Loss before income tax	(43,230)	(20,696)	(81,671)	(267,610)
Income tax benefit (expense)	112	(802)	(393)	(963)
Loss for the period	(43,118)	(21,498)	(82,064)	(268,573)
Attributable to:
Equity holders of the Company	(43,015)	(21,356)	(81,829)	(268,269)
Non-controlling interests	€ (103)	€ (142)	€ (235)	€ (304)
Loss per share attributable to the equity holders of the Company:
Basic loss per share (in EUR per share)	€ (0.16)	€ (0.08)	€ (0.31)	€ (1.09)
Diluted (loss) per share (in EUR per share)	€ (0.16)	€ (0.08)	€ (0.31)	€ (1.09)
Charging sessions
Revenue from contracts with customers
Total revenue from contracts with customers	€ 22,036	€ 14,405	€ 73,174	€ 38,399
Cost of sales	(19,547)	(21,304)	(57,307)	(53,641)
Sale of charging equipment
Revenue from contracts with customers
Total revenue from contracts with customers	523	889	2,009	19,331
Cost of sales	(398)	(667)	(952)	(13,689)
installation services
Revenue from contracts with customers
Total revenue from contracts with customers	3,451	5,181	13,734	11,145
Cost of sales	(2,937)	(4,801)	(11,574)	(7,704)
Operation and maintenance of charging equipment
Revenue from contracts with customers
Total revenue from contracts with customers	1,073	556	3,329	2,378
Cost of sales	(322)	(114)	(1,123)	(268)
Service revenue from consulting services
Revenue from contracts with customers
Total revenue from contracts with customers	€ 1,524	€ 1,289	€ 4,571	€ 1,759

v3.23.3

Interim condensed consolidated statement of comprehensive income - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of comprehensive income [abstract]
Loss for the period	€ (43,118)	€ (21,498)	€ (82,064)	€ (268,573)
Items that may be reclassified to profit or loss in subsequent periods
Exchange differences on translation of foreign operations	(14)	(3)	(60)	(36)
Income tax related to these items	0	0	0	0
Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods, net of tax	(14)	(3)	(60)	(36)
Items that may not be reclassified to profit or loss in subsequent periods
Changes in the fair value of equity investments at fair value through other comprehensive income	4,649	(2,922)	(1,926)	(2,922)
Remeasurements of post-employment benefit obligations	0	9	0	9
Income tax related to these items	0	88	204	88
Other comprehensive income/(loss) that may not be reclassified to profit or loss in subsequent periods, net of tax	4,649	(2,825)	(1,722)	(2,825)
Other comprehensive income/(loss) for the period, net of tax	4,635	(2,828)	(1,782)	(2,861)
Total comprehensive income/(loss) for the nine months	(38,483)	(24,326)	(83,846)	(271,434)
Attributable to:
Equity holders of the Company	(38,380)	(24,184)	(83,611)	(271,130)
Non-controlling interests	€ (103)	€ (142)	€ (235)	€ (304)

v3.23.3

Interim condensed consolidated statement of financial position - EUR (€) € in Thousands	Sep. 30, 2023	Dec. 31, 2022
Non-current assets
Property, plant and equipment	€ 157,509	€ 134,718
Intangible assets	21,404	24,648
Right-of-use assets	63,371	47,817
Deferred tax assets	523	523
Other financial assets	60,505	62,487
Total non-current assets	303,312	270,193
Current assets
Inventories	41,125	26,017
Prepayments and other assets	16,903	9,079
Trade and other receivables	42,835	47,235
Contract assets	896	1,512
Other financial assets	6,469	601
Cash and cash equivalents	28,829	83,022
Total current assets	137,057	167,466
Total assets	440,369	437,659
Equity
Share capital	32,142	32,061
Share premium	364,928	365,900
Reserves	(10,075)	(6,860)
Accumulated deficit	(436,331)	(364,088)
Equity attributable to equity holders of the Company	(49,336)	27,013
Non-controlling interests	510	745
Total equity	(48,826)	27,758
Non-current liabilities
Borrowings	312,160	269,033
Lease liabilities	60,212	44,044
Provisions and other liabilities	768	520
Contract liabilities	925	2,442
Deferred tax liabilities	1,980	2,184
Total non-current liabilities	376,045	318,223
Current liabilities
Trade and other payables	53,755	56,390
Contract liabilities	4,776	7,917
Current tax liabilities	705	1,572
Lease liabilities	9,279	7,280
Provisions and other liabilities	39,164	17,223
Warrant liabilities	5,471	1,296
Total current liabilities	113,150	91,678
Total liabilities	489,195	409,901
Total equity and liabilities	€ 440,369	€ 437,659

v3.23.3

Interim condensed consolidated statement of changes in equity - EUR (€) € in Thousands	Total	IPO	RSUs	Allego Holding shareholders	PIPE financing	Total	Total IPO	Total RSUs	Total Allego Holding shareholders	Total PIPE financing	Share capital	Share capital IPO	Share capital RSUs	Share capital Allego Holding shareholders	Share capital PIPE financing	Share premium	Share premium Allego Holding shareholders	Share premium PIPE financing	Reserves	Accumulated deficit	Accumulated deficit RSUs	Non-controlling interests
Beginning balance at Dec. 31, 2021	€ (76,651)					€ (76,651)					€ 1					€ 61,888			€ 4,195	€ (142,735)		€ 0
Changes in Stock Holders Equity [Roll Forward]
Loss for the period	(268,573)					(268,269)														(268,269)		(304)
Other comprehensive income/(loss)	(2,861)					(2,861)													(2,861)
Total comprehensive income/(loss) for the nine months	(271,434)					(271,130)													(2,861)	(268,269)		(304)
Other changes in reserves	0					0													(503)	503
Equity contribution (Allego Holding shareholders)				€ 101,931					€ 101,931					€ 28,311			€ 73,620
Equity contribution (Spartan shareholders)	87,597					87,597					1,789					85,808
Equity contribution (PIPE financing)					€ 132,690					€ 132,690					€ 1,800			€ 130,890
Equity contribution (Private warrants exercise)	13,854					13,854					160					13,694
Share-based payment expenses	81,184					81,184														81,184
Non-controlling interests on acquisition of subsidiary	1,259																					1,259
Ending balance at Sep. 30, 2022	70,430					69,475					32,061					365,900			831	(329,317)		955
Beginning balance at Dec. 31, 2022	27,758					27,013					32,061					365,900			(6,860)	(364,088)		745
Changes in Stock Holders Equity [Roll Forward]
Loss for the period	(82,064)					(81,829)														(81,829)		(235)
Other comprehensive income/(loss)	(1,782)					(1,782)													(1,782)
Total comprehensive income/(loss) for the nine months	(83,846)					(83,611)													(1,782)	(81,829)		(235)
Other changes in reserves	0					0													(1,433)	1,433
Share-based payment expenses	8,233	€ 1	€ 0			8,233	€ 1	€ 0				€ 1	€ 80							8,233	€ (80)
Transaction costs related to issuance of ordinary shares in exchange of Public Warrants	(972)					(972)										(972)
Ending balance at Sep. 30, 2023	€ (48,826)					€ (49,336)					€ 32,142					€ 364,928			€ (10,075)	€ (436,331)		€ 510

v3.23.3

Interim condensed consolidated statement of cash flows - EUR (€) € in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities
Cash generated from/(used in) operations	€ (32,914)	€ (89,640)
Interest paid	(13,465)	(5,697)
Income taxes paid	(813)	(343)
Other cash flows from operating activities	228	0
Net cash flows from/(used in) operating activities	(46,964)	(95,680)
Cash flows from investing activities
Acquisition of Mega-E, net of cash acquired	0	(3,949)
Acquisition of MOMA, net of cash acquired	0	(58,643)
Purchase of property, plant and equipment	(48,007)	(24,971)
Proceeds from sale of property, plant and equipment	0	12
Purchase of intangible assets	0	(1,241)
Proceeds from investment grants	2,381	371
Other cash flows used in investing activities	(113)	0
Net cash flows from/(used in) investing activities	(45,739)	(88,421)
Cash flows from financing activities
Proceeds from borrowings	43,400	50,000
Repayment of borrowings	0	(11,936)
Payment of principal portion of lease liabilities	(3,322)	(4,067)
Payment of transaction costs on new equity instruments	0	(925)
Payment of transaction costs on borrowings	(1,576)	0
Net cash flows from/(used in) financing activities	38,502	175,841
Net increase/(decrease) in cash and cash equivalents	(54,201)	(8,260)
Cash and cash equivalents at the beginning of the nine months	83,022	24,652
Effect of exchange rate changes on cash and cash equivalents	8	6
Cash and cash equivalents at the end of the nine months	28,829	16,398
Spartan Shareholders
Cash flows from financing activities
Proceeds from issuing equity instruments	0	132,690
PIPE financing
Cash flows from financing activities
Proceeds from issuing equity instruments	€ 0	€ 10,079

v3.23.3

Reporting Entity	9 Months Ended
	Sep. 30, 2023
Reporting Entity [Abstract]
Reporting Entity	Reporting Entity Allego N.V. (“Allego” or the "Company”), a continuation of the former Allego Holding B.V. (“Allego Holding”) as detailed below, was incorporated as a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) on June 3, 2021 under the laws of the Netherlands, under the name of Athena Pubco B.V. On March 16, 2022, Athena Pubco B.V. changed its legal form from a private limited liability company to a public limited liability company (naamloze venootschap), changed its name to Allego N.V. and entered into the Deed of Conversion containing the Articles of Association of Allego N.V. Allego N.V. consummated the previously announced business combination (“the SPAC Transaction”) with Spartan Acquisition Corp. III (“Spartan”) pursuant to the terms of the business combination agreement (“BCA”) and became a publicly traded company on the New York Stock Exchange (“NYSE”). The new public company — Allego N.V. — trades under the Allego name with the ticker “ALLG”. The Company’s registered seat and head office are in Arnhem, the Netherlands. Its head office is located at Westervoortsedijk 73 KB, 6827 AV in Arnhem, the Netherlands. The Company is registered with the Dutch Trade Register under number 82985537. The Company’s main activity is enabling electrification through designing, building and the operation of charging solutions for electric vehicles in Europe. The Company services corporate customers with the long-term operation of comprehensive charging solutions. The Company’s goal is to offer the best EV charging experience with end-to-end charging solutions through different charging products (e.g. slow, fast, ultra-fast charging) in combination with our EV Cloud platform and additional service support. Upon completion of the BCA, Allego N.V. underwent a capital restructuring process which resulted in additional shares being issued to Madeleine Charging B.V. (“Madeleine”), an external consulting firm, the Private Investment in Public Entity (“PIPE”) Investors and former Spartan shareholders. The majority of the Allego N.V. shares are held by Madeleine, which is an indirectly controlled subsidiary of Meridiam SAS (“Meridiam”) – a global investor and asset manager based in Paris, France. Meridiam specializes in the development, financing and long-term management of sustainable public infrastructure in the mobility, energy transition and social infrastructure sectors. These financial statements are the interim condensed consolidated financial statements for the group consisting of Allego N.V. and its subsidiaries (jointly referred to as the “Group” or “Allego Group”).

v3.23.3

Basis of preparation and changes to the Group's accounting policies	9 Months Ended
	Sep. 30, 2023
Significant Accounting Policies [Abstract]
Basis of preparation and changes to the Group's accounting policies	Basis of preparation and changes to the Group's accounting policies 2.1. Basis of preparation The interim condensed consolidated financial statements for the three months ended September 30, 2023 and the nine months ended September 30, 2023 have been prepared in accordance with IAS 34 Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”) and are unaudited. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended December 31, 2022 as well as the Group's interim condensed consolidated financial statements for the six months ended June 30, 2023. The interim condensed consolidated financial statements have been prepared on a historical cost basis, unless otherwise stated. All amounts disclosed in the interim condensed consolidated financial statements are presented in thousands of euros (€), unless otherwise indicated. The interim condensed consolidated financial statements were prepared by the Executive Board and were authorized for issue in accordance with a resolution of the Executive Board on November 28, 2023. 2.2. Going concern assumption and financial position The accompanying interim condensed consolidated financial statements of the Group have been prepared assuming the Group will continue as a going concern. The going concern basis of presentation assumes that the Group will continue in operation for a period of at least one year after the date these interim condensed consolidated financial statements are issued and contemplates the realization of assets and the settlement of liabilities in the normal course of business. See further discussion below. The Group’s scale of operations The Group’s strategy requires significant capital expenditures, as well as investments in building the Group’s organization aimed at increasing the scale of its operations. The Group incurred losses during the first years of its operations including the three months ended September 30, 2023 and the nine months ended September 30, 2023 and expects to continue to incur losses in the next twelve months from the issuance date of these interim condensed consolidated financial statements. This is typical in the industry, as builders and operators of EV charging sites often incur losses in the early years of operation as the network grows and consumers begin adopting EVs. Therefore, the Group relies heavily on funding from bank financing and equity issuance. For example, during 2022, the Group expanded its old credit facility by an additional €50 million through an accordion feature with the group of lenders within the original old facility agreement. Additionally, during 2022, the Group entered into a new facility agreement (the "renewed facility") with a group of lenders led by Société Générale and Banco Santander, increasing the total available facility by €230 million to €400 million, to further support its growth. Further envisioned growth — in line with the Group’s strategy — will require additional significant investments from lenders or its existing shareholders. Financial position of the Group As of September 30, 2023, the Group had negative equity of €48,826 thousand due to the cumulative impact of losses incurred during its first years of operations (December 31, 2022: positive €27,758 thousand due to the losses incurred during its first years of operations being offset against proceeds from the SPAC Transaction) and cash and cash equivalents of €28,829 thousand (December 31, 2022: €83,022 thousand). The Group's operations to date have been funded by borrowings from the Company's shareholders and banks, as well as proceeds from the SPAC Transaction. In the interim condensed consolidated statement of financial position as at September 30, 2023, the carrying value of the Group’s borrowings amounts to €312,160 thousand (December 31, 2022: €269,033 thousand). Additionally, the Group had €69,491 thousand in lease liabilities (December 31, 2022: €51,324 thousand) and €53,755 thousand in trade and other payables (December 31, 2022: €56,390 thousand). Impact of increasing energy prices The Group provides electricity directly through its own chargers and needs to procure this energy from the power markets in Europe. As a result of the war in Ukraine the price of gas has increased sharply, thereby increasing the demand on the European power markets with corresponding constraints in supply. This supply and demand imbalance has caused record increases in the price of electricity in Europe. Allego obtains electricity through contracts with power suppliers or through direct sourcing on the power market. Allego utilizes an external, technology-enabled energy management platform to diversify its supply of power. Allego has entered into medium- and long-term power purchase agreements with renewable power to mitigate the future negative impact of increased energy costs. This has allowed the Group to fix the price of a portion of energy purchased, with plans to grow this percentage substantially over the next 6-18 months. Additionally, the Group expects to be able to pass these costs onto EV customers. The Group increased prices several times during 2022, particularly in the second half of the year in response to rises in the price of electricity, whereas prices decreased during the first nine months of 2023 as a result of a reduction in the price of electricity. Despite the shifts in prices, the Group experienced improved utilization rates, indicating a relatively high degree of demand inelasticity by customers. If energy prices were to decline below the fixed price obtained through power purchase agreements, the Group would still expect to keep prices charged to customers constant, enabling predictable margins on charging revenues. Financing On December 19, 2022, the Group entered into the renewed facility with a group of lenders led by Société Générale and Banco Santander, increasing the total available facility by €230,000 thousand to €400,000 thousand, to further support its growth. The renewed facility expires in December 2027 and bears interest at Euribor plus a margin. Under the terms of the renewed facility, the Group is required to comply with financial covenants relating to interest and EBITDA at the consolidated level of Allego N.V. as detailed in Note 13. Historically the Group met its covenants as per the old facility agreement. A covenant breach would negatively affect the Group’s financial position and cash flows, in a way that could reasonably be expected to influence the decisions of the primary users of these interim condensed consolidated financial statements. The Group considers the likelihood of a breach occurring as higher than remote as the Group incurred losses during the first years of its operations, even though the Group has complied with the covenants of the old facility throughout all reporting periods presented and expects to continue to meet financial covenants performance criteria of the renewed facility. In parallel to the renewed facility, the Group entered into two interest rate caps derivatives to help offset the interest rate risk on between 65% and 74% (2022: between 65% and 85%) of the outstanding loan amounts under the renewed facility, with a notional of €237,458 thousand, which mature in December 2027. Interest rate risks on the remaining portion of the outstanding loan amounts, including the impact that higher interest rates would have on the Company’s going concern analysis, was included in the cash flow forecasts described below. Additional information on interest rate risk is described in Note 17. As at September 30, 2023 the Group has not drawn on €77,390 thousand (December 31, 2022: €120,790 thousand) of this facility. Liquidity forecasts Management prepares detailed liquidity forecasts and monitors cash and liquidity forecasts on a continuous basis. In assessing the going concern basis of preparation of the interim condensed consolidated financial statements, management estimated the expected cash flows for the next 12 months, incorporating current cash levels, revenue projections and detailed capital expenditures, operating expenses budget, interest payment obligations, and working capital projections, as well as compliance with covenants, the potential exercise of warrants, potential future equity raises, and availability of other financial funding from banks, like those obtained in 2022. The Group invests in new stations, chargers and grid connections and potential business acquisitions only if the Group has secured financing for such investments. These forecasts reflect potential scenarios and management plans and are dependent on securing significant contracts and related revenues. The Group has applied different scenarios ranging from a scenario that assumes regular capital expenditure levels based on the current available capex facility and a scenario that assumes a service-light model including revenues based only on existing contracts. All scenarios result in the Group having sufficient available cash and liquidity. Based on these estimations, management has concluded that Allego will be able to fund the expected cash outflows in the next 12 months. Although the expectation for the coming year is that the Company will continue to make additional investments, its cash flows from operations and renewed credit facility is sufficient for at least the next 12 months from the issuance of these interim condensed consolidated financial statements. Therefore, the interim condensed consolidated financial statements have been prepared under the assumption that the Group operates on a going concern basis. As described above, long-term investments, development activities, and operations more than 12 months out may require additional financing to be obtained. Currently, no commitments exist for further growth investments. The Group will be required to seek additional financing to continue to execute its growth strategy and business plan in the long-term. The realization of such financing is inherently uncertain. Securing additional funding — by raising additional equity or debt financing — is important for the Group’s ability to continue as a going concern in the long-term. However, there is no assurance that the Group will be able to raise additional equity or debt financing on acceptable terms, or at all. 2.3. Significant accounting policies The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s consolidated annual financial statements for the year ended December 31, 2022 as well as the Group's interim condensed consolidated financial statements for the six months ended June 30, 2023, except for the adoption of new standards effective as of January 1, 2023 (refer to Note 2.4), and the adoption of new accounting policies as indicated in this note. 2.3.1 Share-based payments 2.3.1.1 Other share-based payment plans The share-based payment arrangements in place related to the Long-Term Incentive Plan ("LTIP") qualify as equity settled share-based payments in accordance with IFRS 2. As mentioned in Note 7.3, as part of Allego´s incentive plans, certain eligible members of the board of directors and employees were granted Restricted Stock Units ("RSUs"), performance based share options ("LTIP Performance Options") and Company ordinary shares ("IPO Grant Shares"), based on the Company's internal performance evaluation framework. The grant date fair value is recognized as an operating expense with a corresponding increase in retained earnings. The fair value is determined at the grant date and the total expense is recognized over the vesting period. At the end of each reporting period, the Group revises the expense for the services received based on the vesting conditions. The impact is recognized in the (interim condensed) consolidated statement of profit or loss with the corresponding increase in retained earnings. The IPO Grant Shares, LTIP Performance Options and RSUs do not include any market conditions or non-vesting conditions that should be included in their fair value. The grant date fair value remains the same over time. 2.4. New accounting standards, interpretations and amendments adopted by the group A number of amended standards became applicable for the current reporting period as disclosed in the Group’s consolidated annual financial statements for the year ended December 31, 2022. The Group did not have to change its accounting policies or make retrospective adjustments as these amended standards do not have a material effect on the Group's interim condensed consolidated financial statements: Furthermore, the following amendments to standards have been published by the IASB. The amendments to IAS 12 are effective as of January 1, 2023. All other amendments will become effective on or after January 1, 2024. These have no material effect on the Group's interim condensed consolidated financial statements: •Amendments to IAS 21 - Lack of Exchangeability •Amendments to IAS 7 and IFRS 7 - Supplier Finance Arrangements •Amendments to IAS 12 - International Tax Reform — Pillar Two Model Rules •Amendment to IFRS 16 – Leases on sale and leaseback •Amendments to IAS 1 – Presentation of Financial Statements

v3.23.3

Significant accounting estimates, assumptions and judgments	9 Months Ended
	Sep. 30, 2023
Significant Accounting Estimates, Assumption, and Adjustments [Abstract]
Significant accounting estimates, assumptions and judgments	Significant accounting estimates, assumptions and judgments The preparation of the Group’s interim condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent assets and liabilities. The reported amounts that result from making estimates and assumptions, by definition, will seldom equal the actual results. Management also needs to exercise judgment in applying the Group’s accounting policies. The significant accounting estimates, assumptions and judgments applied in preparing these interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s consolidated annual financial statements for the year ended December 31, 2022, as well as the Group's interim condensed consolidated financial statements for the six months ended June 30, 2023. 3.1. Judgments In the process of applying the Group’s accounting policies, no significant changes have occurred compared to the judgements disclosed in the Group’s consolidated annual financial statements for the year ended December 31, 2022, as well as the Group's interim condensed consolidated financial statements for the six months ended June 30, 2023. 3.2. Estimates and assumptions In the process of applying the Group’s accounting policies, no significant changes have occurred compared to the estimates and assumptions disclosed in Group’s consolidated annual financial statements for the year ended December 31, 2022, as well as the Group's interim condensed consolidated financial statements for the six months ended June 30, 2023.

v3.23.3

Segmentation	9 Months Ended
	Sep. 30, 2023
Segmentation [Abstract]
Segmentation	SegmentationThe Executive Board of the Group is the chief operating decision maker (“CODM”) which monitors the operating results of the business for the purpose of making decisions about resource allocation and performance assessment. The management information provided to the CODM includes financial information related to revenue, cost of sales and gross result disaggregated by charging revenue and combined service revenue streams and by region. These performance measures are measured consistently with the same measures as disclosed in the (interim condensed) consolidated financial statements. Further financial information, including net income (loss), employee expenses and operating expenses are only provided on a consolidated basis. The CODM assesses the financial information of the business on a consolidated level. As the operating results of the business for the purpose of making decisions about resource allocation and performance assessment are monitored on a consolidated level, the Group has one operating segment which is also its only reporting segment. As the Group only has one reporting segment, all relevant financial information is disclosed in the interim condensed consolidated financial statements. Revenue from external customers The Company is domiciled in the Netherlands. The amount of revenue from external customers, based on the locations of the customers, can be broken down by country as follows: For the three months ended September 30, For the nine months ended September 30, (in €‘000) 2023 2022 2023 2022 The Netherlands 12,492  9,925  46,475  29,901  Belgium 4,546  2,217  14,201  6,016  Germany 5,071  3,434  15,264  10,041  France 5,394  6,188  18,076  25,327  Other 1,104  556  2,801  1,727  Total 28,607  22,320  96,817  73,012

v3.23.3

Revenue from contracts with customers	9 Months Ended
	Sep. 30, 2023
Revenue [abstract]
Revenue from contracts with customers	Revenue from contracts with customers Disaggregation and timing of revenue from contracts with customers Set out below is the disaggregation of the Group’s revenue from contracts with customers. For the three months ended September 30, For the nine months ended September 30, (in €‘000) 2023 2022 2023 2022 Type of goods or service Charging sessions 22,036  14,405  73,174  38,399  Service revenue from the sale of charging equipment 523  889  2,009  19,331  Service revenue from installation services 3,451  5,181  13,734  11,145  Service revenue from operation and maintenance of charging equipment 1,073  556  3,329  2,378  Service revenue from consulting services 1,524  1,289  4,571  1,759  Total revenue from external customers 28,607  22,320  96,817  73,012  Timing of revenue recognition Services transferred over time 6,048  7,026  21,634  15,282  Goods and services transferred at a point in time 22,559  15,294  75,183  57,730  Total revenue from external customers 28,607  22,320  96,817  73,012

v3.23.3

Other income/(expenses)	9 Months Ended
	Sep. 30, 2023
Disclosure of Other Income expenses [Abstract]
Other income/(expenses)	Other income/(expenses) For the three months ended September 30, For the nine months ended September 30, (in €‘000) 2023 2022 2023 2022 Government grants 92  320  277  320  Income from sale of CO2 tickets 1,728  4,106  5,851  8,979  Net gain/(loss) on disposal of property, plant and equipment (4,784) 1  (5,365) 1  Sublease rental income 50  46  150  150  Fair value gains/(losses) on derivatives (purchase options) —  —  —  3,856  Fair value gains/(losses) on pref. shares derivatives —  34  —  34  Other items 1,406  36  1,732  190  Total (1,508) 4,543  2,645  13,530  Other items Other items primarily consist of reimbursements that the Group has received from one of its suppliers for chargers. During the year ended December 31, 2022, the Group purchased a number of chargers that malfunctioned and the Group has disposed of these chargers. As disclosed in the table above, the Group recognized a loss on disposal during the three and nine months ended September 30, 2023. In July 2023, a settlement has been reached with a supplier for damages caused. As a result, the Group has recognized a gain of €1,400 thousand for reimbursement received from suppliers (nine months ended September 30, 2022 and three months ended September 30, 2022: € nil).

v3.23.3

Share-based payments	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangements [Abstract]
Share-based payments	Share-based payments 7.1. Second Special Fees Agreement On February 25, 2022, the then immediate parent entity of Allego Holding — Madeleine — entered into a second Special Fees Agreement (the “Second Agreement”) with the same external consulting firm as for the First Agreement described in Note 11.1 of the consolidated financial statements for the year ended December 31, 2022. The purpose of this Second Special Fees Agreement is to compensate the external consulting firm for their continuous strategic and operational advice, as well as support with regards to Allego’s fundraising efforts in the near future. The Agreement ultimately expires on the earlier of June 30, 2025, and the date on which Madeleine would no longer hold any equity security in Allego. As consideration for the Second Special Fees Agreement, the external consulting firm is entitled to receive cash compensation based on the value of the Group in connection with any new injection of equity, whether in cash or in kind, in any entity of the Group subsequent to the Business Combination (each an “Equity Injection”). On March 10, 2022, the Second Special Fees Agreement was amended to modify the formula of the relevant percentage used in the determination of the fees payable (the “Relevant Percentage”) for equity injections subsequent to the first Equity Injection. The Group accounts for the Second Special Fees Agreement as a share-based payment since the Group obtained services from the consulting firm in exchange for cash amounts based on the equity value of the Company. Madeleine, instead of the Group, had the obligation to settle the share-based payment arrangement with the consulting firm. The Second Agreement was therefore classified as an equity-settled share-based payment arrangement. On April 20, 2022, the Second Special Fees Agreement was novated from Madeleine to Allego (the “Novation”), with all the other terms of the Second Special Fees Agreement remaining the same. As a result of the Novation, Allego has now the obligation, instead of Madeleine, to settle the share-based payment arrangement with the consulting firm. The Second Special Fees Agreement’s classification therefore changed to a cash-settled share-based payment arrangement from the Novation date. Certain directors of the Company are entitled to compensation from the external consulting firm in the form of a fixed percentage of the total benefits that the external consulting firm will generate under the Second Special Fees Agreement, including any amendments. The share-based payment expenses for the Second Special Fees Agreement therefore reflect both compensation for external consulting services and key management remuneration. Measurement of fair value as an equity-settled plan In accordance with IFRS 2 Share-based Payment, the fair value of key management remuneration under an equity-settled share-based payment arrangement is measured by reference to the fair value of the equity instruments granted, measured at the grant date. The fair value determined at the grant date is not subsequently adjusted. As the value of the services provided by the consulting firm is not directly related to the time incurred by the consultants, management considers that the fair value of the services cannot be measured reliably. Therefore, the fair value of the services received under the Second Special Fees Agreement are measured by reference to the fair value of the share-based payment arrangement offered as consideration, as the Group obtains these services. The Group applies an approach where the average fair value over the reporting period is used to determine the fair value of the services received. Since the Second Special Fees Agreement includes an implicit service condition, the services received under the Second Special Fees Agreement are recognized as expenses over the period in which the Company expects to have the Equity Injections, therefore between February 25, 2022 (the “grant date”) and the dates of the Equity Injections by reference to the fair value of the share-based payment arrangement measured at the grant date (for key management remuneration) or the average fair value over the reporting period (for external consulting services). Measurement of fair value as a cash-settled plan Following the Novation, the Second Special Fees Agreement was classified as a cash-settled plan as opposed to an equity-settled plan. Therefore, in accordance with IFRS 2 Share-based Payment, the fair value of both the key management remuneration and the services provided by the consulting firm under a cash-settled share-based payment arrangement is measured by reference to the fair value of the share-based payment arrangement offered as consideration, as the Group obtains these services. The fair value of the liability is recognized over the service period. In effect, IFRS 2 Share-based Payment provides that the cumulative amount recognized as the expense over the life of the Second Special Fees Agreement is the grant-date fair value plus or minus any subsequent changes in fair value after the change in classification. Therefore, the cumulative amount may be less than the original grant-date fair value. Fair value of equity instruments granted The fees payable under the Second Special Fees Agreement will depend on the future value of the Allego Group following each future Equity Injection. Since there is no market price for the services, to measure the fair value of this instrument under IFRS 2 Share-based Payment, the future value of the Allego Group for the Equity Injections has been derived from a weighted average valuation model in which that value can be simulated based on various amounts and expected dates of Equity Injection events, and taking into account the likelihood of Equity Injections to happen, as well as the expected price per share upon Equity Injection. The total fair value of the share-based payment arrangement as at September 30, 2023 is estimated at €49,958 thousand (grant date: €32,250 thousand). The increase in fair value of the share-based payment arrangement is mainly driven by an increase in the probability and expected amount of the Equity Injection events. The Group assessed the impact to the fair value of the share-based payment arrangement as a result of the amendment to the Second Special Fees Agreement which was entered into in March 2022. The amendment modifies the formula of the Relevant Percentage applied to the future value of the Group for equity injections subsequent to the first Equity Injection, which is a component of the calculation of the fees payable. However, the Relevant Percentage used to calculate the fees remained the same following the amendment and therefore did not impact the fair value of the Second Special Fees Agreement as of the amendment date. Additionally, the Group assessed the accounting impact of the Novation. The Group measured the liability using the Novation date fair value of the equity-settled shared-based payment arrangement based on the elapsed portion of the vesting period (period from Grant Date to each Equity Injection date). Therefore, as of the Novation, an amount of €4,440 thousand was recognized as a current liability, and an amount of €1,353 thousand was recognized as a non-current liability, with a corresponding decrease to equity of €5,793 thousand. The Group recognized a share-based payment provision related to the Second Special Fees Agreement of €38,357 thousand as of September 30, 2023 (December 31, 2022: €16,806 thousand), included in the current liabilities in the interim condensed consolidated statement of financial position. Share-based payment expenses During the three months ended September 30, 2023, the Group recognized total share-based payment expenses with respect to the Second Special Fees Agreement of €15,028 thousand (three months ended September 30, 2022: gain of €421 thousand). As the share-based payment expenses for the Second Special Fees Agreement reflect both compensation for external consulting services and key management remuneration, the Group has recognized share-based payment expenses for an amount of €9,843 thousand (three months ended September 30, 2022: gain of €276 thousand) as legal, accounting and consulting fees and share-based payments expenses for an amount of €5,185 thousand (three months ended September 30, 2022: gain of €145 thousand) has been recognized as employee benefits expenses, both within general and administrative expenses. During the nine months ended September 30, 2023, the Group recognized total share-based payment expenses with respect to the Second Special Fees Agreement of €21,551 thousand (nine months ended September 30, 2022: €2,187 thousand). As the share-based payment expenses for the Second Special Fees Agreement reflect both compensation for external consulting services and key management remuneration, the Group has recognized share-based payment expenses for an amount of €14,116 thousand (nine months ended September 30, 2022; €1,752 thousand) as legal, accounting and consulting fees and share-based payments expenses for an amount of €7,435 thousand (nine months ended September 30, 2022: €435 thousand) has been recognized as employee benefits expenses, both within general and administrative expenses. During the nine months ended September 30, 2022, the Second Special Fees Agreement was modified from equity-settled plan to cash-settled plan as a result of the Novation. The Group recognized share-based payments expenses of €6,380 thousand for the period before the Novation, with a corresponding increase in retained earnings. This amount was split into legal, accounting and consulting fees of €4,498 thousand and employee benefits expenses of €1,882 thousand. For the period after the Novation, the Group recognized a gain on the share-based payments of €4,193 thousand with a corresponding decrease in liability. This amount consisted of a gain of €2,747 thousand recognized in legal, accounting and consulting fees and a gain of €1,446 thousand recognized in employee benefits expenses. 7.2. Management incentive plan The establishment of the Company’s MIP was approved by the board of directors on April 20, 2022. The MIP is designed to provide long-term incentives for key management employees to deliver long-term shareholder returns, and includes two types of granted options: the right to acquire a percentage of the Company's issued share capital immediately following the listing, subject to the expiry of a blocking period of 18 months (the “MIP Grant Options”), and the right to acquire a percentage of the Company's issued share capital immediately following the listing, subject to predefined performance conditions and the expiry of the blocking period (the “MIP Performance Options”). The granted options carry no dividend or voting rights. The options do not include any market conditions or non-vesting conditions that should be included in the fair value at recognition. Under the plan, the MIP Grant Options vest immediately, and the MIP Performance Options only vest if certain performance standards are met. Participation in the plan is at the board of directors’ discretion, and no individual has a contractual right to participate in the plan or to receive any guaranteed benefits. The amount of MIP Performance Options that will vest depends on the group’s performance, including operational EBITDA, financing targets, compliance and reporting, engagement with investors, and the minimum service period of the employees. Once vested, the granted options remain exercisable for a period of ten years following the end of the blocking period, which ended on September 18, 2023 for the MIP Grant Options and ten years from the grant date (May 14, 2022) for the MIP Performance Options. In April 2023, one non-market performance condition included in the original MIP agreement was modified, together with their respective service periods, to be applied to the group's performance over financial year 2023 instead of 2022. For the MIP performance options the blocking period was extended to April 30, 2024. The exercise period is ten years following the end of the blocking period. The exercise period and blocking period end date remain unchanged for the other MIP Performance Options. These changes result in an increased number of awards being expected to vest but do not have an impact on the fair value of the options. The exercise price of the granted options under the plan is €0.12 per option. When exercisable, each option is convertible into one ordinary share of the Company. Set out below are summaries of MIP Grant Options and MIP Performance Options granted under the plan: 2023 2022 Average exercise price per share option (in €) Number of MIP Grant Options Number of MIP performance options Average exercise price per share option (in €) Number of MIP Grant Options Number of MIP Performance Options As at January 1 0.12  1,329,213  1,329,213  —  —  —  Granted during the period —  —  —  0.12  1,329,213  1,329,213  Exercised during the period —  —  —  —  —  —  Forfeited during the period —  —  —  —  —  —  As at September 30 0.12  1,329,213  1,329,213  0.12  1,329,213  1,329,213  Vested and exercisable at September 30 0.12  1,329,213  996,910  —  —  —  As of September 30, 2023, 1,329,213 MIP Grant Options and 996,910 MIP Performance Options vested and became exercisable after the end of the blocking period, which ended on September 18, 2023. No options expired and no options were exercised during the period ended September 30, 2023. Share options outstanding at the end of the reporting period have the following expiry dates and exercise prices: Options Grant date Expiry date Exercise price (in €) Share options September  30, 2023 MIP Grant Options May 14, 2022 September 17, 2033 0.12  1,329,213  MIP Performance Options May 14, 2022 May 13, 2032 0.12  996,910  MIP Performance Options (modified) May 14, 2022 April 29, 2034 0.12 332,303  Total 2,658,426  The weighted average remaining contractual life of options outstanding at the end of period is 9.54 years. For the three months ended September 30, 2023, the total expenses arising from the MIP transactions recognized during the period as part of employee benefit expense was €1,612 thousand (three months ended September 30, 2022: €1,200 thousand). This includes an amount of €489 thousand (three months ended September 30, 2022: € nil) related to the additional expense recognized as a result of the modification of the MIP agreement. For the nine months ended September 30, 2023 the total expenses arising from the MIP transactions recognized during the period as part of employee benefit expense was €5,110,682 (nine months ended September 30, 2022: €12,976,086). This includes an amount of €1,444 thousand (nine months ended September 30, 2022: € nil ) related to the additional expense recognized as a result of the modification of the MIP agreement. Fair value of options granted The assessed fair value of options was €7.75 per option (September 30, 2022: €7.75) for both the MIP Grant Options and MIP Performance Options. The fair value was determined as the share price of the Company’s ordinary shares on grant date of $8.17 (€7.871), determined as the closing price on May 13, 2022 (the last working day preceding the grant date), less the exercise price of €0.12. No specific option-pricing model (e.g., Black-Scholes) was applied for the valuation, as in the situation when the exercise price applicable to the options is negligible, the calculated fair value of an option is close (or equal) to the value of an ordinary share less the exercise price, regardless of the other input parameters applied in the option valuation. As the options do not include any market conditions or non-vesting conditions that has an impact on the fair value and there is no adjustment for dividends, the grant date fair value of both MIP Grant Options and MIP Performance Options was determined using the same approach. 7.3. Long-term Incentive Plan The Allego board of directors and the compensation committee approved the general framework for the LTIP on 16 March 2022. The purpose of the LTIP is to provide eligible directors and employees the opportunity to receive stock-based incentive awards for employee motivation and retention and to align the economic interests of such persons with those of Allego’s shareholders. The delivery of certain shares or other instruments under the LTIP to directors and key management are agreed and approved in certain Allego board of directors meetings. On December 20, 2022, the Allego board of directors approved a detailed plan for the LTIP for future years. Performance Based Share Options As it relates to the LTIP for Allego executive officers, performance based share options may be granted annually and would be exercisable after a contractual vesting period of two to three years. The number of LTIP Performance Options issued under the LTIP in 2023 is based on four equally-weighted performance criteria: revenue, operational EBITDA, renewable GWh delivered, and appreciation at the discretion of the board of directors. The targets for the performance criteria are set annually. During the nine months ended September 30, 2023, LTIP Performance Options were granted to executive officers based on 2022 and (expected) 2023 year-end company performance. The LTIP Performance Options related to performance in financial year 2022 have a contractual vesting period of two years, and the number of options awarded was determined in line with the level of completion of the performance criteria for that financial year. In addition, Allego granted LTIP Performance Options with a contractual vesting period of three years and subject to company performance in financial year 2023. This estimated number may be adjusted in the next reporting period depending on the completion of the performance criteria. The exercise price of the LTIP Performance Options granted under the LTIP is €0.12 per option. When exercised, each LTIP Performance Option is convertible into one ordinary share of the Company. Set out below is a summary of LTIP Performance Options granted under the plan: 2023 Average exercise price per LTIP Performance Option (in €) Number of LTIP Performance Options As at January 1 —  —  Granted during the period 0.12  3,059,955  Exercised during the period —  —  Forfeited during the period —  —  As at September 30 0.12  3,059,955  Vested and exercisable at September 30 —  —  During the nine months ended September 30, 2023, the Company granted two types of LTIP Performance Options: 1,039,222 options based on actual 2022 company performance and 2,020,733 options with vesting based on 2023 company performance. The number of options based on 2022 company performance is final, subject to meeting the service condition of two years. The number of options based on 2023 company performance is estimated and will be adjusted, if necessary, based on the actual performance. LTIP Performance Options outstanding at the end of the reporting period have the following expiry dates and exercise prices: Options Grant date Vesting date Expiry date Exercise price (in €) Number of options September  30, 2023 LTIP Performance Options (2022) April 12, 2023 April 12, 2025 April 12, 2032 0.12  1,039,222  LTIP Performance Options (2023) January 1, 2023 April 12, 2026 April 12, 2033 0.12  2,020,733  The weighted average remaining contractual life of LTIP Performance Options outstanding at the end of period is 9.65 years. The total expense arising from the LTIP Performance Options recognized during the three months ended September 30, 2023 as part of employee benefit expense was €1,644 thousand (three months ended September 30, 2022: € nil). For the nine months ended September 30, 2023, the total expense arising from the LTIP Performance Options recognized as part of employee benefit expense was €1,742 thousand (nine months ended September 30, 2022: €nil). Fair value of LTIP Performance Options granted The assessed fair value of LTIP Performance Options 2022 was €1.83 per option (September 30, 2022: no options granted). This fair value was determined as the share price of the Company’s ordinary shares on grant date of $2.13 (€1.952), determined as the closing price on April 12, 2023 (the grant date), less the exercise price of €0.12. The assessed fair value of LTIP Performance Options 2023 was €2.82 per option (September 30, 2022: no options granted). This fair value was determined as the share price of the Company’s ordinary shares on grant date of $3.14 (€2.943), determined as the closing price on December 30, 2022 (the last working day preceding the grant date), less the exercise price of €0.12. As the LTIP Performance Options do not include any market conditions or non-vesting conditions that have an impact on the fair value and there is no adjustment for dividends, the grant date fair value of LTIP Performance Options was determined using the same approach as used for the options granted under the MIP. Restricted Stock Units As it relates to the LTIP for other Allego employees, individuals may elect to receive up to 50% of their annual performance bonus to be paid in RSUs, which would vest on an annual basis. Additionally, certain Allego employees are eligible to receive additional RSUs based on the Company's existing internal performance evaluation framework. These RSUs would be granted annually and vest after three years. In May 2023, the Group awarded RSUs to eligible and selected employees based on the Company's internal performance evaluation framework. The RSUs have a vesting period of three years and are subject to the participant's continued employment until the vesting date. Under the terms of the same plan, RSUs were awarded to eligible members of the board of directors in May 2023. These RSUs were not subject to any vesting conditions and vested fully on the grant date. The Company's ordinary shares were issued to the eligible members of the board of directors on August 10, 2023. Set out below are summaries of the number of RSUs granted under the plan: 2023 Employees Eligible directors As at January 1 —  —  Granted during the period 189,201  666,968  Forfeited during the period —  —  Vested and issued during the period —  (666,968) As at September 30 189,201  —  Vested and exercisable at September 30 —  —  Fair value of RSUs granted The grant date fair value of the RSUs granted to the employees in 2023 is recognized as an expense on a straight-line basis over the three-year vesting period, with a corresponding entry in equity. Since the RSUs granted to certain members of the board of directors are not subject to any vesting conditions, the grant date fair value of these awards is recognized immediately, on the grant date, as an expense with a corresponding entry in equity. The assessed fair value of RSUs granted during the period ended September 30, 2023, was €1.97 per option (September 30, 2022: no RSUs granted). The fair value of the RSUs has been determined with reference to the share price of the Company’s ordinary shares at the grant date. Since the Company does not expect to pay dividends during the vesting period, the weighted average fair value of the RSUs granted in the nine months ended September 30, 2023 of $2.13 (€1.974) is equal to share price at the grant date, May 24, 2023. The share-based payment expense recognized for the three months ended September 30, 2023 for the equity-settled RSUs amounted to €31 thousand (three months ended September 30, 2022: € nil), and only represented the expense in relation to the RSUs issued to employees. The share-based payment expense recognized for the nine months ended September 30, 2023 for the equity-settled RSUs amounted to €1,361 thousand (nine months ended September 30, 2022: € nil), consisting of €1,317 thousand related to the fully vested board of directors' RSUs recognized on grant date and €44 thousand representing the expense for the current period in relation to the RSUs issued to employees. IPO Grant Shares In May 2023, the Group awarded 100 ordinary shares per employee to a select group of individuals who were instrumental in the success of the IPO. The Company granted this one-off share award as of the IPO date to employees of the Company, who were still employed by the Company a year later. This award granted in 2023 was not subject to any vesting conditions. The Company awarded a total number of 9,600 ordinary shares in May 2023. The ordinary shares were issued to the employees on June 9, 2023. The fair value of the share awards of $2.13 (€1.972) is equal to the share price of the Company's ordinary shares at the date of grant. The share-based payment expenses for the three months ended September 30, 2023 is € nil (three months ended September 30, 2022: € nil) and for the nine months ended September 30, 2023 is €19 thousand (nine months ended September 30, 2022: € nil). 7.4. SPAC TransactionDuring the nine months ended September 30, 2022, the Group incurred share-based payment expenses of €158,714 thousand recognized within general and administrative expenses related to the SPAC Transaction, representing the difference between Spartan's net asses at the closing date and the fair value of the Company's shares exchanged in the transaction to Spartan. This difference is considered as an expense representing the costs of service in respect of the stock exchange listing for Spartan's shares.

v3.23.3

Finance income/(costs)	9 Months Ended
	Sep. 30, 2023
Finance Costs Disclosure [Abstract]
Finance income/(costs)	Finance income/(costs) For the three months ended September 30, For the nine months ended September 30, (in €‘000) 2023 2022 2023 2022 Interest expenses on shareholder loans —  —  —  (1,755) Interest expenses on old facility —  (3,392) —  (8,048) Loss on modification of old facility —  (1,730) —  (1,730) Interest expenses on renewed facility (6,471) —  (17,284) —  Finance costs on borrowings (6,471) (5,122) (17,284) (11,533) Interest expenses on lease liabilities (1,017) (689) (2,473) (1,155) Fair value gains/(losses) on derivatives (122) 2,847  (529) 4,907  Fair value gains/(losses) on public warrant liabilities (1,762) 343  (4,175) 14,889  Fair value gains/(losses) on private placement warrant liabilities —  —  —  7,139  Exchange differences – net (535) (1,817) (195) (3,512) Finance income/(costs) (9,907) (4,438) (24,656) 10,735

v3.23.3

Loss per share	9 Months Ended
	Sep. 30, 2023
Earnings per share [abstract]
Loss per share	Loss per share Basic loss per share is calculated by dividing the loss for the period attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding during the period. The following table reflects the loss and share data used in the basic and diluted loss per share calculations for the three months ended September 30, 2023 and 2022, and the nine months ended September 30, 2023 and 2022: For the three months ended September 30, For the nine months ended September 30, 2023 2022 2023 2022 Loss attributable to ordinary equity holders of the Company (in €‘000) (43,015) (21,356) (81,829) (268,269) Weighted average number of ordinary shares for basic and diluted loss per share 267,564,249 267,177,592 267,308,676 246,129,260 Basic and diluted loss per share (in €'000) (0.16) (0.08) (0.31) (1.09) The Company only has ordinary shares. Refer to Note 12 for details about the Company’s share capital. There is no difference between basic and diluted loss per share as the effect of the potential ordinary shares that would be issued by the Company under the Management Incentive Plan, the Long Term Incentive Plan, or the Public Warrants is anti-dilutive for all periods presented. Refer to Note 7.2 and 7.3 for details on the Management Incentive Plan and the Long Term Incentive Plan, and refer to Note 27 of the consolidated financial statements for the year ended December 31, 2022 for details on the Public Warrants. Ordinary shares were issued after the reporting date in relation to the exchange of Public Warrants as disclosed in Note 20. There have been no other transactions involving ordinary shares or potential ordinary shares between the reporting date and the date of authorization of these interim condensed consolidated financial statements.

v3.23.3

Cash generated from operations	9 Months Ended
	Sep. 30, 2023
Statement of cash flows [abstract]
Cash generated from operations	Cash generated from operations For the nine months ended September 30, (in €‘000) Notes 2023 2022 Loss before income tax (81,671) (267,610) Adjustments to reconcile loss before income tax to net cash flows: Loss on modification of old facility —  1,730  Fair value (gains)/losses on derivatives —  (3,890) Fair value (gains)/losses on Public and Private warrant liabilities 4,175  (22,028) Other finance (income)/costs 20,545  9,563  Share-based payment expenses 7 29,784  241,497  Depreciation, impairments and reversal of impairments of property, plant and equipment 15,216  11,383  Depreciation and impairments of right-of-use of assets 6,061  4,860  Amortization and impairments of intangible assets 3,244  3,589  Net (gain)/loss on disposal of property, plant and equipment 5,064  183  Movements in working capital: Decrease/(increase) in inventories (15,108) (19,903) Decrease/(increase) in other financial assets (6,336) 12,257  Decrease/(increase) in trade and other receivables, contract assets and prepayments and other assets (3,429) (29,139) Increase/(decrease) in trade and other payables and contract liabilities (11,097) (32,039) Increase/(decrease) in provisions and other liabilities 638  (93) Cash generated from/(used in) operations (32,914) (89,640)

v3.23.3

Property, plant and equipment, intangible assets and goodwill	9 Months Ended
	Sep. 30, 2023
Disclosure of detailed information about property, plant and equipment [abstract]
Property, plant and equipment, intangible assets and goodwill	Property, plant and equipment, intangible assets and goodwill (in €‘000) Property, plant and equipment Intangible assets (excl. goodwill)     Goodwill     Carrying amount at December 31, 2022 134,718  13,924  10,724  Movements in the nine months ended September 30, 2023 Additions 43,070  —  —  Disposals (9,691) —  —  Depreciation and amortization (15,444) (3,244) —  Accumulated depreciation and amortization of disposals 4,628  —  —  Impairments (321) —  —  Reversal of impairments 549  —  —  Carrying amount at September 30, 2023 157,509  10,680  10,724  Investments and disposals of property, plant and equipment During the nine months ended September 30, 2023, investments in property, plant and equipment amounted to €43,070 thousand (September 30, 2022: €116,590 thousand) and disposals of property, plant and equipment amounted to €5,063 thousand (September 30, 2022: €196 thousand). The disposals during the nine months ended September 30, 2023 mainly relate to chargers purchased by the Group during the year ended December 31, 2022, that malfunctioned and were disposed, refer to Note 6 for further details. Impairments and reversals of impairments of chargers During the three months ended September 30, 2023, the Group recorded an impairment loss of €85 thousand (three months ended September 30, 2022: €133 thousand) and a reversal of impairment of €218 thousand (three months ended September 30, 2022: €270 thousand). During the nine months ended September 30, 2023, the Group recorded an impairment loss of €321 thousand (nine months ended September 30, 2022: €678 thousand) and a reversal of impairment of €549 thousand (nine months ended September 30, 2022: €392 thousand). Purchase commitments The Group’s purchase commitments for chargers and charging infrastructure are disclosed in Note 18. At the end of each reporting period presented, the Group did not have purchase commitments for other asset classes of property, plant and equipment.

v3.23.3

Share capital, share premium and transaction costs on new equity instruments	9 Months Ended
	Sep. 30, 2023
Share Capital and Share Premium [Abstract]
Share capital, share premium and transaction costs on new equity instruments	Share capital, share premium and transaction costs on new equity instruments Share capital As at September 30, 2023, the issued share capital of the Company amounts to €32,142 thousand (December 31, 2022: 32,061 thousand), divided into 267,854,160 ordinary shares of €0.12 per share (December 31, 2022: 267,177,592 ordinary shares of €0.12 per share). They entitle the holders to participate in dividends, and to share in the proceeds of winding up the Company in proportion to the number of shares held. The authorized share capital of the Company as at September 30, 2023 amounted to €108,000 thousand (December 31, 2022: €108,000 thousand), divided into 900,000,000 ordinary shares of € 0.12 per share (December 31, 2022: 900,000,000 ordinary shares of € 0.12 per share). Issuance of ordinary shares related to the IPO Grant Shares award under the LTIP On June 9, 2023, 9,600 ordinary shares, with a nominal value of €0.12 per share, were issued for no consideration to employees of the Company. These shares relate to the IPO Grant Shares award under LTIP as described in note 7.3. Issuance of ordinary shares related to the RSUs award under the LTIP On August 10, 2023, 666,968 ordinary shares, with a nominal value of €0.12 per share, were issued for no consideration to eligible members of the board of directors. These shares relate to the RSUs award under the LTIP as described in note 7.3. Transaction costs for the future issuance of ordinary shares in exchange of Public Warrants During the nine months ended September 30, 2023, the Group incurred transaction costs of €972 thousand (nine months ended September 30, 2022: € nil) that are directly attributable to the future issuance of ordinary shares in relation to the exchange of Public Warrants. These transaction costs have been recorded as a deduction to share premium. For further details on the exchange of Public Warrants, refer to Note 20. Share capital and share premium movements Movement of share capital and share premium are as follows: Notes Shares Price per share (in €) Share Capital (in €'000) Share Premium (in €'000) As at January 1, 2022 100  1.00  —  61,888  Immediately prior to the Allego Holding and Spartan Acquisition Corp. III merger (“the SPAC Transaction”) Shareholder loan equity conversion March 16, 2022 2  1.00  —  101,931  E8 Special Fee Arrangement March 16, 2022 22  1.00  —  —  As at March 16, 2022 immediately prior to the closing of the SPAC Transaction 124  1.00  —  163,819  Resulting from the Allego Holding and Spartan Acquisition Corp. III merger (“the SPAC Transaction”) Elimination old shares March 16, 2022 (124) 1.00  —  —  Share Capital increase on conversion March 16, 2022 235,935,061  0.12  28,312  (28,311) Share Capital Spartan March 16, 2022 14,907,582  0.12  1,789  85,808  Share Capital for PIPE March 16, 2022 12,500,000  0.12  1,500  108,515  Share Capital for PIPE March 22, 2022 2,500,000  0.12  300  22,375  Other equity movements in the nine months ended September 30, 2022 Private warrants exercise April 15, 2022 1,334,949  0.12 160  13,694  As at September 30, 2022 267,177,592  0.12 32,061  365,900  As at January 1, 2023 267,177,592  0.12 32,061  365,900  Issuance of shares under the LTIP from IPO Grant Shares June 9, 2023 9,600  0.12 1  —  Issuance of shares under the LTIP from RSUs August 10, 2023 666,968  0.12 80  —  Transaction costs related to issuance of ordinary shares in exchange of Public Warrants —  —  —  (972) As at September 30, 2023 267,854,160  0.12 32,142  364,928  All the shares issued have been fully paid at the date of the capital issuance.

v3.23.3

Borrowings	9 Months Ended
	Sep. 30, 2023
Disclosure of detailed information about borrowings [abstract]
Borrowings	Borrowings This note provides a breakdown of borrowings in place as at September 30, 2023 and December 31, 2022. (in €‘000) Interest rate Maturity September 30, 2023 December 31, 2022 Renewed facility Euribor* + 3.9%** December 19, 2027 312,160  269,033  Total 312,160  269,033  *The Euribor rate (6M) is floored at 0%. This floor is closely related to the contract of the loan and is therefore not presented separately in the interim condensed consolidated statement of financial position. **The margin of 3.9% will increase by 0.2% per year, for the first time in December 2025. Refinancing of the old facility with the renewed facility On December 19, 2022, the Group has entered into a new facility agreement (“the renewed facility”) with a group of lenders led by Société Générale and Banco Santander, increasing the total existing available facility ("the old facility") by €230,000 thousand to €400,000 thousand, to further support its growth. The renewed facility consists of: i.€170,000 thousand used to settle the old facility; ii.up to €200,000 thousand to be used for financing and refinancing certain capital expenditures and permitted acquisitions (and for other permitted debt servicing uses); and iii.up to €30,000 thousand to be used for issuance of guarantees and letters of credit (and when utilized by way of letters of credit, for general corporate purposes). The renewed facility expires in December 2027 and bears interest at EURIBOR plus a margin. The principal terms and conditions of the renewed facility are as follows: •drawdown stop when conditions precedent are not met; •repayment in full at maturity date; •commitment fee per year equals to 35% of the applicable margin and is payable for each undrawn facility in the period from the agreement signing date to the date being 42 months following the signing date. For the nine months ended September 30, 2023, the commitment fee was 1.365% per year (equal to 35% of the margin of 3.9%). In December 2022, the Group completed two drawdowns on the renewed facility for a total amount of €279,210 thousand, of which €170,000 thousand was used to repay the Group’s old facility by a way of netting with the drawdown on the renewed facility. In June 2023, the Group completed an additional drawdown on the renewed facility of €43,400 thousand bringing the total drawdowns of the facility to €322,610 thousand. In parallel to the renewed facility, the Group entered into two interest rate caps to hedge the interest rate risk on between 65% and 74% (2022: between 65% and 85%) of the outstanding loan amounts under the renewed facility. Details about the Group’s interest rate caps are included Note 16. The refinancing of the old facility was accounted for as extinguishment of the former financial liability and recognition of the new debt instrument. Details about the accounting treatment are included in Note 25 of the consolidated financial statements for the year ended December 31, 2022. Assets pledged as security The renewed facility is secured by pledges on the bank accounts (presented as part of cash and cash equivalents and non-current other financial assets), trade and other receivables and pledges on the shares in the capital of Allego Holding B.V., Allego B.V., Allego GmbH and Allego France SAS held by the Company. During the nine months ended September 30, 2023, the Group has pledged additional assets in relation to the renewed facility as detailed in the table below. The carrying amount of assets pledged as security for the renewed facility is as follows: (in €‘000) September 30, 2023 December 31, 2022 Current assets Floating charge Cash and cash equivalents 6,543  56,317  Trade receivables 8,480  —  Total current assets pledged as security 15,023  56,317  Non-current assets Floating charge Non-current other financial assets 10,500  10,500  Total non-current assets pledged as security 10,500  10,500  Total assets pledged as security 25,523  66,817  Transaction costs During the period ended September 30, 2023, the Group incurred €1,689 thousand (September 30, 2022: €nil) of transaction costs that are directly attributable to the renewed facility. These costs are included in the measurement of the respective drawdowns and are amortized over the term of these drawdowns using the effective interest method. Interest expense on the Group’s renewed facility is recognized as part of finance income/(costs) in the interim condensed consolidated statement of profit or loss. The Group expects that it will draw on the funds available under the renewed facility. Therefore, commitment fees paid on the unused portion of the renewed facility are deferred and treated as an adjustment to the loan’s effective interest rate and recognized as interest expense over the term of the facility. Loan covenants Under the terms of the renewed facility, the Group is required to comply with the following financial covenants related to interest and earnings before interest, taxes, depreciation and amortization (“EBITDA”) at the consolidated level of the Group: 1.Leverage ratio: calculated on a consolidated level as (total net debt / Group EBITDA). 2.Interest cover ratio: calculated on a consolidated basis as (Group EBITDA / interest paid). The covenants shall be determined based on the IFRS financial statements of the Group, as required by the terms and conditions of the renewed facility. The compliance with these covenants shall be tested every six months, with the testing period being twelve months ending December 31 and June 30, with the first testing date being June 30, 2023. The target covenant ratios are determined based on a twelve-month running basis and are as follows: Testing period ending on Leverage ratio Interest cover ratio June 30, 2023 Unconditional -0.8x December 31, 2023 Unconditional -0.9x June 30, 2024 33.9x 0.4x December 31, 2024 5.4x 2.3x June 30, 2025 3.2x 3.8x December 31, 2025 2.2x 5.5x June 30, 2026 2.2x 5.5x December 31, 2026 2.2x 5.5x June 30, 2027 2.2x 5.5x The Group may within ten business days from the occurrence of a breach or the anticipated breach of the loan covenants remedy such default by providing evidence of receipt of new funding, sufficient to cure such breach (“equity cure right”). Such remediation is available for not more than two consecutive testing dates and four times over the duration of the renewed facility. In case if the covenants breach is not cured, such a breach is considered a default and could lead to the cancellation of the total undrawn commitments and the loan to become immediately due and payable. Additionally, the following ratios are set as drawstop event conditions for the part of the renewed facility aimed at financing and refinancing certain capital expenditures and permitted acquisitions, which if breached prior to the anticipated utilization of the capex portion of the renewed facility – will result in the drawdown stop: •Group EBITDA margin ratio: calculated on a consolidated level as (Group EBITDA / Real Period Revenue). •Group EBITDA amount: calculated on a consolidated level •Fast/ultra-fast charging equipment utilization rate: calculated on a consolidated level as (average number of sessions over the relevant Group charger base, divided by 50). The target drawdown stop conditions are determined based on a twelve-month running basis and are as follows: Testing period ending on EBITDA margin (drawstop) EBITDA (drawstop) Fast/ultrafast charging equipment utilization rate (drawstop) June 30, 2023 -4.3  % € (8.5)  million 10.4  % December 31, 2023 -5.8  % € (11.6)  million 11.5  % June 30, 2024 8.1  % € 19.8   million 12.7  % December 31, 2024 19.4  % € 68.2   million 12.9  % June 30, 2025 24.1  % € 111.2   million 14.2  % December 31, 2025 27.3  % € 157.5   million 15.5  % June 30, 2026 28.9  % € 200.0   million 16.6  % December 31, 2026 Unconditional Unconditional Unconditional June 30, 2027 Unconditional Unconditional Unconditional Breaching the requirements would cause a drawdown stop. Continuing breaches in the drawstop conditions would permit the bank to cancel the total undrawn commitments. The Group may within twenty business days from the occurrence of a drawstop event provide a remedial plan setting out the actions, steps and/or measures (which may include a proposal for adjustments of the financial covenants' or utilization rate's levels) which are proposed to be implemented in order to remedy such drawstop event. In the preparation of its interim condensed consolidated financial statements, the Group assessed whether information about the existence of the covenant and its terms is material information, considering both the consequences and the likelihood of a breach occurring. The consequences of a covenant breach have been described in this note. A covenant breach would affect the Group’s financial position and cash flows in a way that could reasonably be expected to influence the decisions of the primary users of these interim condensed consolidated financial statements. Refer to Note 2.2 for additional information. The Group has complied with these covenants in the reporting period ended September 30, 2023.

v3.23.3

Income tax	9 Months Ended
	Sep. 30, 2023
Major components of tax expense (income) [abstract]
Income tax	Income tax The income tax expense for the nine months ended September 30, 2023 is recognized based on the Group’s estimate of the weighted average effective annual income tax rate expected for the full financial year. The estimated average annual tax rate used for the nine months ended September 30, 2023 is 0.38% (nine months ended September 30, 2022: 0.36%).

v3.23.3

Financial instruments	9 Months Ended
	Sep. 30, 2023
Disclosure of detailed information about financial instruments [abstract]
Financial instruments	Financial instruments This note provides information about the Group’s financial instruments, including: •an overview of all financial instruments held by the Group; •the classification of the financial instruments; •the line item on the interim condensed consolidated statement of financial position in which the financial instrument is included; •the financial instrument’s book and fair value. The Group holds the following financial instruments: Financial assets (in €‘000) Notes At amortized cost Fair value through PL Fair value through OCI Total book value Total fair value As at December 31, 2022 Non-current other financial assets 21,900  9,198  31,389  62,487  62,487  Current other financial assets 601  —  —  601  601  Trade and other receivables 44,776  —  —  44,776  44,776  Cash and cash equivalents 83,022  —  —  83,022  83,022  Total 150,299  9,198  31,389  190,886  190,886  As at September 30, 2023 Non-current other financial assets 22,439  8,603  29,463  60,505  60,505  Current other financial assets 6,469  —  —  6,469  6,469  Trade and other receivables 36,639  —  —  36,639  36,639  Cash and cash equivalents 28,829  —  —  28,829  28,829  Total 94,376  8,603  29,463  132,442  132,442  Due to the highly liquid nature of cash and cash equivalents and the pledged bank balances classified within non-current other financial assets, their carrying amount is considered to be the same as their fair value. Due to the short-term nature of trade and other receivables as well as current other financial assets, their carrying amount is considered to be the same as their fair value. Financial liabilities (in €‘000) Notes At amortized cost Fair value through PL Total book value Total fair value As at December 31, 2022 Borrowings 13 269,033  —  269,033  272,641  Non-current lease liabilities 44,044  —  44,044  N/A Current lease liabilities 7,280  —  7,280  N/A Trade and other payables 51,263  —  51,263  51,263  Warrant Liabilities —  1,296  1,296  1,296  Total 371,620  1,296  372,916  325,200  As at September 30, 2023 Borrowings 13 312,160  —  312,160  325,409  Non-current lease liabilities 60,212  —  60,212  N/A Current lease liabilities 9,279  —  9,279  N/A Trade and other payables 51,640  —  51,640  51,640  Warrant liabilities —  5,471  5,471  5,471  Total 433,291  5,471  438,762  382,520  Due to the short-term nature of the trade and other payables, their carrying amount is considered to be the same as their fair value.

v3.23.3

Fair value measurement	9 Months Ended
	Sep. 30, 2023
Fair Value Measurement [Abstract]
Fair value measurement	Fair value measurement This note explains the judgments and estimates made in determining the fair values of the financial instruments that are recognized and measured at fair value and the financial instruments for which the fair value is disclosed in the interim condensed consolidated financial statements. To provide an indication about the reliability of the inputs used in determining fair value, the Group has classified its financial instruments into the three levels prescribed under the accounting standards. An explanation of each level is included in Note 2.7.18 of the consolidated financial statements for the year ended December 31, 2022. Assets and liabilities measured at fair value As at September 30, 2023, the Group has recorded the following financial instruments at fair value in the interim condensed consolidated statement of financial position: •interest rate cap derivatives; •warrant liabilities; •investment in equity securities. Interest rate cap derivatives and the investment in equity securities are presented within non-current other financial assets. Warrant liabilities are presented as a separate line in the interim condensed consolidated statement of financial position as at September 30, 2023. The interest rate caps qualify for the level 2 category in the fair value hierarchy due to the fact that they are not traded in an active market and the fair value is determined using valuation techniques which maximize the use of observable market data. Since all significant inputs required to fair value the instruments are observable, the instruments are included in level 2. The investment in equity securities qualifies for the level 3 category in the fair value hierarchy due to the fact that the securities are not traded in an active market and there is no observable market data. Therefore, the fair value of these securities is determined using valuation techniques which use unobservable inputs that are significant to fair value. The warrants qualify for the level 1 category in the fair value hierarchy due to the fact that their fair value is determined based on quoted market inputs. For assets and liabilities that are recognized in the interim condensed consolidated financial statements at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period. During the nine months ended September 30, 2023, there were no transfers that occurred between levels. The fair values of the Group’s assets and liabilities measured at fair value are disclosed in the table in Note 15. Fair value of assets and liabilities not measured at fair value The Group has determined the fair value of assets and liabilities not measured at fair value, but for which the fair value is required to be disclosed. Borrowings: For the renewed facility, the fair value differs from its carrying amount because the interest payable on the facility is (partially) fixed. The borrowings qualify for the level 3 category in the fair value category due to the use of unobservable inputs, including own credit risk. The fair values of the Group’s assets and liabilities not measured at fair value are disclosed in the table in Note 15. Specific valuation techniques to determine fair values Specific valuation techniques used to value financial instruments include: •interest rate cap derivatives: option pricing model; •investment in equity securities: discounted cash flow analysis; •borrowings: discounted cash flow analysis using a market interest rate; Financial instruments measured at fair value (level 3) The changes in level 3 items for the nine months ended September 30, 2023 have been as follows: (in €‘000) Investment in equity securities Carrying amount at January 1, 2023 31,389  Movements in the nine months ended September 30, 2023 Fair value loss on investment in equity securities recognized in other comprehensive income (1,926) Carrying amount at September 30, 2023 29,463  The Group’s engages with third party valuation specialists to perform its fair value measurements for financial reporting purposes on a periodic basis. Involvement of external valuers is determined annually by the Group’s finance team after discussion with and approval by the Group’s Executive Board. Selection criteria for valuation specialist include market knowledge, reputation, independence and whether professional standards are maintained. The Group works closely with the qualified external valuers to establish the appropriate valuation techniques and inputs to the model. At each reporting date, the Group analyses the movements in the values of assets and liabilities which are required to be remeasured or re-assessed as per the Group’s accounting policies. Valuation inputs to the fair value of investments in equity securities The Group updated the third party valuation report to determine the fair value of investments in equity securities. Inputs to the fair value of the investments in equity securities are the earnings growth factor and risk-adjusted discount rate. The following table summarizes the quantitative information about the significant unobservable input parameters used in the level 3 fair value measurement of the investments in equity securities, using the DCF (“Discounted Cash Flows”) methodology. In % September 30, 2023 Growth factor 3.0  % Discount rate 11.9  % An increase or decrease of 100 basis point in the growth factor would change the fair value of the investment in equity by an increase of €3,741 thousand or a decrease of €2,984 thousand, respectively. An increase or decrease of 100 basis point in the discount rate would change the fair value of the investment in equity by a decrease of €4,187 thousand or an increase of €5,255 thousand

v3.23.3

Financial risk management	9 Months Ended
	Sep. 30, 2023
Disclosure of nature and extent of risks arising from financial instruments [abstract]
Financial risk management	Financial risk management This note explains the Group’s exposure to financial risks and how these risks could affect the Group’s future financial performance. Risk Exposure arising from Measurement Management Market risk – interest rate risk Long-term borrowings at variable rates Sensitivity analysis Economic hedge with an interest rate caps Market risk – price risk Investments in equity securities Sensitivity analysis Monitoring quarterly valuation updates and forecasts of future cash flows Liquidity risk Borrowings and other liabilities Cash flow forecasts Availability of borrowing facilities. The Group’s management oversees the management of these risks. The Group’s management is supported by the Finance department that advises on financial risks and the appropriate financial risk governance framework for the Group. The Group’s risk management is predominantly controlled by the Finance department under policies approved by the Executive Board. The Executive Board provides principles for overall risk management, as well as policies covering specific areas, such as foreign exchange risk, interest rate risk, credit risk, use of derivative financial instruments and non-derivative financial instruments. Since the largest part of the Group’s assets, liabilities, and transactions are denominated in euro, the market risk of foreign exchange is considered not to be significant. There are no changes compared to the previous period. Market risk Cash flow and fair value interest rate risk The Group’s main interest rate risk arises from a long-term borrowing with a variable rate, which exposes the Group to cash flow interest rate risk. The cash flow risk is mitigated through the usage of interest rate caps. During the nine months ended September 30, 2023 and 2022, the Group’s borrowings at a variable rate were denominated in euro. The Group’s borrowings are carried at amortized cost. Instruments used by the Group The Group has two interest rate caps in place with a notional of €237,458 thousand (December 31, 2022: two interest rate caps with a notional of €181,487 thousand) which mature in December 2027 (December 31, 2022: in December 2027). As at September 30, 2023, the interest rate caps cover approximately 74% (December 31, 2022: 65%) of the variable loan principal outstanding. The strike price changes over time and ranges between 1.50% and 3.43%. The interest rate caps mitigate between 65% and 74% (December 31, 2022: between 65% and 85%) of the variable debt outstanding, as the notional of the derivative instruments and the renewed facility changes over time. The remaining cash flow risk is accepted. The interest rate caps require settlement of any interest receivable, if applicable, semiannually. The settlement dates coincide with the dates on which interest is payable on the renewed facility. Sensitivity The interim condensed consolidated statement of profit or loss is sensitive to higher/lower interest expenses from borrowings as a result of changes in interest rates as both the Group’s old and renewed facilities have a variable interest rate. Equity is not impacted as no hedge accounting is applied. Additionally, an increase or decrease of the Euribor has an impact on the fair value of the Group’s interest rate caps. The impact on loss for the three and nine months ended September 30, 2023 and 2022 as a result of a change in interest rates is as follows: (in €‘000) Impact on pre-tax loss For the three months ended September 30, For the nine months ended September 30, 2023 2022 2023 2022 Interest rates – increase by 10 basis points* 5  31  463  258  Interest rates – decrease by 10 basis points* (4) (38) (439) (253) *Keeping all other variables constant. Global regulators and central banks have been driving international efforts to reform key benchmark interest rates. The market is therefore in transition to alternative risk-free reference rates. Although limited impact is expected on the Euribor, the Group is in the process of evaluating the implications of such a phase out. The Group has no interest rate hedging relationships which are affected by the reform and does not expect any significant impact on existing contracts due to a change in the interest rates. The Group will continue to monitor market developments. Price risk Exposure The Group’s exposure to equity securities price risk arises from investments held by the group and classified in the interim condensed consolidated statement of financial position as at fair value through other comprehensive income ("FVOCI") as detailed in Note 19 of the consolidated financial statements for the year ended December 31, 2022. The price risk is mitigated by monitoring quarterly valuation updates and forecasts of future cash flows and aligning the business strategy accordingly. Sensitivity The table below summarizes the impact of increases/decreases of the price of equity securities on the group’s equity through OCI reserve for the period. The analysis is based on the assumption that the fair value of the equity securities held by the group has increased or decreased by 40%, with all other variables held constant. (in €‘000) Impact on Group's Equity For the nine months ended September 30, Fair Value – increase by 4,000 basis points 11,785  Fair Value – decrease by 4,000 basis points (11,785) Liquidity risk Prudent liquidity risk management implies maintaining sufficient cash and the availability of funding through an adequate amount of committed credit facilities to meet obligations when due and to close out market positions. Due to the dynamic nature of the underlying businesses, the Group maintains flexibility in funding by maintaining availability under committed credit lines. The Group has been predominantly contracting customers of sound commercial standing and their payment behavior was generally good. Refer to Note 2.2 for details about the Group’s financial position and the going concern assumption applied in preparing the interim condensed consolidated financial statements. As disclosed in Note 13, the Group has pledged bank balances to secure the payment of interest and commitment fees to the Group’s external lenders and pledged bank balances in relation to bank guarantees issued to suppliers of the Group. The main risk for the Group is not meeting the debt covenants or drawdown requirements described in Note 13. In this case, funding via the renewed facility would not be available. The Group monitors the liquidity risk on a weekly basis. Management monitors rolling forecasts of the Group’s cash and cash equivalents on the basis of expected cash flows. This is generally carried out at Group level, in accordance with practice and limits set by the Group. In addition, the Group’s liquidity management policy involves projecting cash flows and considering the level of liquid assets necessary to meet these, monitoring balance sheet liquidity ratios against internal and external regulatory requirements and maintaining debt financing plans. The Group assessed the concentration of risk with respect to refinancing its debt and concluded it to be low. Financing arrangements The Group had access to the following undrawn borrowing facilities for each reporting period presented: (in €‘000) September 30, 2023 December 31, 2022 Expiring beyond one year—renewed facility 77,390  120,790  The renewed facility is available to be drawn if the drawdown covenants are met, in euros and has an average maturity of approximately 4 years (December 31, 2022: 5 years).

v3.23.3

Commitments and contingencies	9 Months Ended
	Sep. 30, 2023
Statement of Commitments and Contingencies [Abstract]
Commitments and contingencies	Commitments and contingencies Purchase commitments for chargers and charging infrastructure Significant expenditures for chargers and charging infrastructure contracted for, but not recognized as liabilities, as at September 30, 2023 were €18,974 thousand (December 31, 2022: €2,452 thousand). The Group uses these assets either as own chargers (property, plant and equipment) or as charging equipment to fulfill its obligations under development contracts entered into with its customers (inventory). As a result of the additional liquidity obtained from the renewed facility in December 2022, and in line with the growth strategy and business plan of the Group, the company has been increasing its level of commitment towards capital expenditures and inventory purchases during the nine months ended September 30, 2023. Purchase commitments for renewable electricity As disclosed in Note 2.2, Allego has entered into medium- and long-term power purchase agreements with renewable power producers. Significant expenditures for renewable electricity and corresponding CO2 tickets contracted for, but not recognized as liabilities, as at September 30, 2023 were €233,149 thousand (December 31, 2022: €69,701 thousand).

v3.23.3

Related-party transactions	9 Months Ended
	Sep. 30, 2023
Disclosure of transactions between related parties [abstract]
Related-party transactions	Related-party transactions Balances and transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note. Details of transactions between the Group and other related parties are disclosed below. Terms and conditions of transactions with related parties Management services were bought from the immediate parent entity for a fixed fee. All other transactions were made on normal commercial terms and conditions and at market rates. Outstanding balances are unsecured. Asset and liability positions can either be offset or can be settled in cash. No loss allowance is recognized on these balances. 19.1. Transactions with related parties For the three months ended September 30, For the nine months ended September 30, (in €‘000) Relationship 2023 2022 2023 2022 Madeleine Charging B.V. Immediate parent entity Interest expenses on shareholder loans —  —  —  1,755  Management fee —  —  —  12  Reimbursement of advisory fees —  —  —  280  Share-based payment expenses —  —  —  74,001  Mega-E Group (Mega-E Charging B.V. and its subsidiaries) Other related party Revenue from contracts with related party —  —  —  1,474  EV Cars Other related party Revenue from contracts with related party 3,205  4,482  12,311  22,826  Voltalis Other related party Revenue from contracts with related party 1,364  989  4,091  1,279  Madeleine Charging B.V For the three months ended September 30, 2023, transactions with Madeleine amounted to € nil (three months ended September 30, 2022 : € nil). For the nine months ended September 30, 2023, transactions with Madeleine amounted to € nil (nine months ended September 30, 2022: €76,048 thousand). The change is largely driven by the SPAC Transaction, which occurred on March 16, 2022. On March 16, 2022, immediately prior to the closing of the SPAC Transaction, the outstanding principal of the shareholder loans together with the accrued interest on these loans with Madeleine was converted into equity. As a result no further interest expenses related to these shareholder loans were incurred by the Group (Refer to Note 25 of the consolidated financial statements for the year ended December 31, 2022). Prior to the SPAC Transaction, Allego was required to pay Madeleine management fees and reimburse advisory fees, which are no longer applicable From March 16, 2022 as a result of the SPAC Transaction. Share-based payment expenses with Madeleine related to the First Special Fees Agreement and the Second Special Fees Agreement. The First Special Fees Agreement was terminated prior and in connection with the SPAC Transaction and no further share-based payment expenses with Madeleine were incurred in relation to it after March 16, 2022 (Refer to Note 11.1 of the consolidated financial statements for the year ended December 31, 2022). The Second Special Fees Agreement was novated from Madeleine to Allego on April 20, 2022 and no further share-based payment expenses were incurred from that date in relation to Madeleine (refer to note 7.1 for details on the Second Special Fees Agreement). Mega-E Group The transactions with Mega-E until March 16, 2022, are considered related-party transactions. The Group obtained control of Mega-E as of that date. All subsequent transactions are therefore considered to be intra-group transactions and have been eliminated in these interim condensed consolidated financial statements.

v3.23.3

Subsequent events	9 Months Ended
	Sep. 30, 2023
Disclosure of non-adjusting events after reporting period [abstract]
Subsequent events	Subsequent events The following subsequent events occurred after September 30, 2023: Public warrants exchange As at September 30, 2023, the Group had 13,799,948 public warrants outstanding and no private placement warrants. On October 3, 2023, the Group announced the completion of its previously announced exchange offer (dated August 25, 2023) and consent solicitation relating to its outstanding public warrants. On October 3, 2023, the Company issued 2,996,918 ordinary shares in exchange for the 13,029,838 public warrants tendered in the exchange offer. The remaining 770,110 public warrants were exchanged for 159,712 ordinary shares, effective October 18, 2023. No consideration was received from the Company as part of the exchange. As a result of these transactions, no public warrants remain outstanding. Guarantee facility On December 19, 2022, the Group has entered into a renewed facility agreement with a group of lenders led by Société Générale and Banco Santander, which included up to €30,000 thousand to be used for issuance of guarantees and letters of credit. The first letters of credit were issued on October 19, 2023 to Solarpark Lindenhof GmbH, as follows: one letter of credit from Banco Santander for the maximum original amount of €6,250 thousand and one letter of credit from Société Générale for the maximum original amount of €6,250 thousand.

v3.23.3

Basis of preparation and changes to the Group's accounting policies (Policies)	9 Months Ended
	Sep. 30, 2023
Significant Accounting Policies [Abstract]
Basis of preparation	2.1. Basis of preparation The interim condensed consolidated financial statements for the three months ended September 30, 2023 and the nine months ended September 30, 2023 have been prepared in accordance with IAS 34 Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”) and are unaudited. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended December 31, 2022 as well as the Group's interim condensed consolidated financial statements for the six months ended June 30, 2023. The interim condensed consolidated financial statements have been prepared on a historical cost basis, unless otherwise stated. All amounts disclosed in the interim condensed consolidated financial statements are presented in thousands of euros (€), unless otherwise indicated. The interim condensed consolidated financial statements were prepared by the Executive Board and were authorized for issue in accordance with a resolution of the Executive Board on November 28, 2023.
Going concern assumption and financial position, Impact of increasing energy prices, Liquidity forecasts	2.2. Going concern assumption and financial position The accompanying interim condensed consolidated financial statements of the Group have been prepared assuming the Group will continue as a going concern. The going concern basis of presentation assumes that the Group will continue in operation for a period of at least one year after the date these interim condensed consolidated financial statements are issued and contemplates the realization of assets and the settlement of liabilities in the normal course of business. See further discussion below. The Group’s scale of operations The Group’s strategy requires significant capital expenditures, as well as investments in building the Group’s organization aimed at increasing the scale of its operations. The Group incurred losses during the first years of its operations including the three months ended September 30, 2023 and the nine months ended September 30, 2023 and expects to continue to incur losses in the next twelve months from the issuance date of these interim condensed consolidated financial statements. This is typical in the industry, as builders and operators of EV charging sites often incur losses in the early years of operation as the network grows and consumers begin adopting EVs. Therefore, the Group relies heavily on funding from bank financing and equity issuance. Impact of increasing energy prices The Group provides electricity directly through its own chargers and needs to procure this energy from the power markets in Europe. As a result of the war in Ukraine the price of gas has increased sharply, thereby increasing the demand on the European power markets with corresponding constraints in supply. This supply and demand imbalance has caused record increases in the price of electricity in Europe. Allego obtains electricity through contracts with power suppliers or through direct sourcing on the power market. Allego utilizes an external, technology-enabled energy management platform to diversify its supply of power. Allego has entered into medium- and long-term power purchase agreements with renewable power to mitigate the future negative impact of increased energy costs. This has allowed the Group to fix the price of a portion of energy purchased, with plans to grow this percentage substantially over the next 6-18 months. Additionally, the Group expects to be able to pass these costs onto EV customers. The Group increased prices several times during 2022, particularly in the second half of the year in response to rises in the price of electricity, whereas prices decreased during the first nine months of 2023 as a result of a reduction in the price of electricity. Despite the shifts in prices, the Group experienced improved utilization rates, indicating a relatively high degree of demand inelasticity by customers. If energy prices were to decline below the fixed price obtained through power purchase agreements, the Group would still expect to keep prices charged to customers constant, enabling predictable margins on charging revenues. Liquidity forecasts Management prepares detailed liquidity forecasts and monitors cash and liquidity forecasts on a continuous basis. In assessing the going concern basis of preparation of the interim condensed consolidated financial statements, management estimated the expected cash flows for the next 12 months, incorporating current cash levels, revenue projections and detailed capital expenditures, operating expenses budget, interest payment obligations, and working capital projections, as well as compliance with covenants, the potential exercise of warrants, potential future equity raises, and availability of other financial funding from banks, like those obtained in 2022. The Group invests in new stations, chargers and grid connections and potential business acquisitions only if the Group has secured financing for such investments. These forecasts reflect potential scenarios and management plans and are dependent on securing significant contracts and related revenues. The Group has applied different scenarios ranging from a scenario that assumes regular capital expenditure levels based on the current available capex facility and a scenario that assumes a service-light model including revenues based only on existing contracts. All scenarios result in the Group having sufficient available cash and liquidity. Based on these estimations, management has concluded that Allego will be able to fund the expected cash outflows in the next 12 months. Although the expectation for the coming year is that the Company will continue to make additional investments, its cash flows from operations and renewed credit facility is sufficient for at least the next 12 months from the issuance of these interim condensed consolidated financial statements. Therefore, the interim condensed consolidated financial statements have been prepared under the assumption that the Group operates on a going concern basis. As described above, long-term investments, development activities, and operations more than 12 months out may require additional financing to be obtained. Currently, no commitments exist for further growth investments. The Group will be required to seek additional financing to continue to execute its growth strategy and business plan in the long-term. The realization of such financing is inherently uncertain. Securing additional funding — by raising additional equity or debt financing — is important for the Group’s ability to continue as a going concern in the long-term. However, there is no assurance that the Group will be able to raise additional equity or debt financing on acceptable terms, or at all.
Share-based payments	2.3.1 Share-based payments 2.3.1.1 Other share-based payment plans The share-based payment arrangements in place related to the Long-Term Incentive Plan ("LTIP") qualify as equity settled share-based payments in accordance with IFRS 2. As mentioned in Note 7.3, as part of Allego´s incentive plans, certain eligible members of the board of directors and employees were granted Restricted Stock Units ("RSUs"), performance based share options ("LTIP Performance Options") and Company ordinary shares ("IPO Grant Shares"), based on the Company's internal performance evaluation framework. The grant date fair value is recognized as an operating expense with a corresponding increase in retained earnings. The fair value is determined at the grant date and the total expense is recognized over the vesting period. At the end of each reporting period, the Group revises the expense for the services received based on the vesting conditions. The impact is recognized in the (interim condensed) consolidated statement of profit or loss with the corresponding increase in retained earnings. The IPO Grant Shares, LTIP Performance Options and RSUs do not include any market conditions or non-vesting conditions that should be included in their fair value. The grant date fair value remains the same over time.
New accounting standards, interpretations and amendments adopted by the group	2.4. New accounting standards, interpretations and amendments adopted by the group A number of amended standards became applicable for the current reporting period as disclosed in the Group’s consolidated annual financial statements for the year ended December 31, 2022. The Group did not have to change its accounting policies or make retrospective adjustments as these amended standards do not have a material effect on the Group's interim condensed consolidated financial statements: Furthermore, the following amendments to standards have been published by the IASB. The amendments to IAS 12 are effective as of January 1, 2023. All other amendments will become effective on or after January 1, 2024. These have no material effect on the Group's interim condensed consolidated financial statements: •Amendments to IAS 21 - Lack of Exchangeability •Amendments to IAS 7 and IFRS 7 - Supplier Finance Arrangements •Amendments to IAS 12 - International Tax Reform — Pillar Two Model Rules •Amendment to IFRS 16 – Leases on sale and leaseback •Amendments to IAS 1 – Presentation of Financial Statements

v3.23.3

Segmentation (Tables)	9 Months Ended
	Sep. 30, 2023
Segmentation [Abstract]
Summary of the Amount of Revenue from External Customers	The Company is domiciled in the Netherlands. The amount of revenue from external customers, based on the locations of the customers, can be broken down by country as follows: For the three months ended September 30, For the nine months ended September 30, (in €‘000) 2023 2022 2023 2022 The Netherlands 12,492  9,925  46,475  29,901  Belgium 4,546  2,217  14,201  6,016  Germany 5,071  3,434  15,264  10,041  France 5,394  6,188  18,076  25,327  Other 1,104  556  2,801  1,727  Total 28,607  22,320  96,817  73,012

v3.23.3

Revenue from contracts with customers (Tables)	9 Months Ended
	Sep. 30, 2023
Revenue [abstract]
Summary of the Disaggregation of the Group's Revenue from Contracts with Customers	Set out below is the disaggregation of the Group’s revenue from contracts with customers. For the three months ended September 30, For the nine months ended September 30, (in €‘000) 2023 2022 2023 2022 Type of goods or service Charging sessions 22,036  14,405  73,174  38,399  Service revenue from the sale of charging equipment 523  889  2,009  19,331  Service revenue from installation services 3,451  5,181  13,734  11,145  Service revenue from operation and maintenance of charging equipment 1,073  556  3,329  2,378  Service revenue from consulting services 1,524  1,289  4,571  1,759  Total revenue from external customers 28,607  22,320  96,817  73,012  Timing of revenue recognition Services transferred over time 6,048  7,026  21,634  15,282  Goods and services transferred at a point in time 22,559  15,294  75,183  57,730  Total revenue from external customers 28,607  22,320  96,817  73,012

v3.23.3

Other income/(expenses) (Tables)	9 Months Ended
	Sep. 30, 2023
Disclosure of Other Income expenses [Abstract]
Summary of Other Income	For the three months ended September 30, For the nine months ended September 30, (in €‘000) 2023 2022 2023 2022 Government grants 92  320  277  320  Income from sale of CO2 tickets 1,728  4,106  5,851  8,979  Net gain/(loss) on disposal of property, plant and equipment (4,784) 1  (5,365) 1  Sublease rental income 50  46  150  150  Fair value gains/(losses) on derivatives (purchase options) —  —  —  3,856  Fair value gains/(losses) on pref. shares derivatives —  34  —  34  Other items 1,406  36  1,732  190  Total (1,508) 4,543  2,645  13,530

v3.23.3

Share-based payments (Tables)	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangements [Abstract]
Summary of Number and Weighted Average Exercise Prices of Share Options	Set out below are summaries of MIP Grant Options and MIP Performance Options granted under the plan: 2023 2022 Average exercise price per share option (in €) Number of MIP Grant Options Number of MIP performance options Average exercise price per share option (in €) Number of MIP Grant Options Number of MIP Performance Options As at January 1 0.12  1,329,213  1,329,213  —  —  —  Granted during the period —  —  —  0.12  1,329,213  1,329,213  Exercised during the period —  —  —  —  —  —  Forfeited during the period —  —  —  —  —  —  As at September 30 0.12  1,329,213  1,329,213  0.12  1,329,213  1,329,213  Vested and exercisable at September 30 0.12  1,329,213  996,910  —  —  —  Set out below is a summary of LTIP Performance Options granted under the plan: 2023 Average exercise price per LTIP Performance Option (in €) Number of LTIP Performance Options As at January 1 —  —  Granted during the period 0.12  3,059,955  Exercised during the period —  —  Forfeited during the period —  —  As at September 30 0.12  3,059,955  Vested and exercisable at September 30 —  —
Summary of Range of Exercise Prices of Outstanding Share Options	Share options outstanding at the end of the reporting period have the following expiry dates and exercise prices: Options Grant date Expiry date Exercise price (in €) Share options September  30, 2023 MIP Grant Options May 14, 2022 September 17, 2033 0.12  1,329,213  MIP Performance Options May 14, 2022 May 13, 2032 0.12  996,910  MIP Performance Options (modified) May 14, 2022 April 29, 2034 0.12 332,303  Total 2,658,426  LTIP Performance Options outstanding at the end of the reporting period have the following expiry dates and exercise prices: Options Grant date Vesting date Expiry date Exercise price (in €) Number of options September  30, 2023 LTIP Performance Options (2022) April 12, 2023 April 12, 2025 April 12, 2032 0.12  1,039,222  LTIP Performance Options (2023) January 1, 2023 April 12, 2026 April 12, 2033 0.12  2,020,733
Disclosure of number and weighted average exercise prices of other equity instruments	Set out below are summaries of the number of RSUs granted under the plan: 2023 Employees Eligible directors As at January 1 —  —  Granted during the period 189,201  666,968  Forfeited during the period —  —  Vested and issued during the period —  (666,968) As at September 30 189,201  —  Vested and exercisable at September 30 —  —

v3.23.3

Finance income/(costs) (Tables)	9 Months Ended
	Sep. 30, 2023
Finance Costs Disclosure [Abstract]
Schedule of Finance cost	For the three months ended September 30, For the nine months ended September 30, (in €‘000) 2023 2022 2023 2022 Interest expenses on shareholder loans —  —  —  (1,755) Interest expenses on old facility —  (3,392) —  (8,048) Loss on modification of old facility —  (1,730) —  (1,730) Interest expenses on renewed facility (6,471) —  (17,284) —  Finance costs on borrowings (6,471) (5,122) (17,284) (11,533) Interest expenses on lease liabilities (1,017) (689) (2,473) (1,155) Fair value gains/(losses) on derivatives (122) 2,847  (529) 4,907  Fair value gains/(losses) on public warrant liabilities (1,762) 343  (4,175) 14,889  Fair value gains/(losses) on private placement warrant liabilities —  —  —  7,139  Exchange differences – net (535) (1,817) (195) (3,512) Finance income/(costs) (9,907) (4,438) (24,656) 10,735

v3.23.3

Loss per share (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings per share [abstract]
Summary of Loss per share	The following table reflects the loss and share data used in the basic and diluted loss per share calculations for the three months ended September 30, 2023 and 2022, and the nine months ended September 30, 2023 and 2022: For the three months ended September 30, For the nine months ended September 30, 2023 2022 2023 2022 Loss attributable to ordinary equity holders of the Company (in €‘000) (43,015) (21,356) (81,829) (268,269) Weighted average number of ordinary shares for basic and diluted loss per share 267,564,249 267,177,592 267,308,676 246,129,260 Basic and diluted loss per share (in €'000) (0.16) (0.08) (0.31) (1.09)

v3.23.3

Cash generated from operations (Tables)	9 Months Ended
	Sep. 30, 2023
Statement of cash flows [abstract]
Summary Of Cash Generated From Operations	For the nine months ended September 30, (in €‘000) Notes 2023 2022 Loss before income tax (81,671) (267,610) Adjustments to reconcile loss before income tax to net cash flows: Loss on modification of old facility —  1,730  Fair value (gains)/losses on derivatives —  (3,890) Fair value (gains)/losses on Public and Private warrant liabilities 4,175  (22,028) Other finance (income)/costs 20,545  9,563  Share-based payment expenses 7 29,784  241,497  Depreciation, impairments and reversal of impairments of property, plant and equipment 15,216  11,383  Depreciation and impairments of right-of-use of assets 6,061  4,860  Amortization and impairments of intangible assets 3,244  3,589  Net (gain)/loss on disposal of property, plant and equipment 5,064  183  Movements in working capital: Decrease/(increase) in inventories (15,108) (19,903) Decrease/(increase) in other financial assets (6,336) 12,257  Decrease/(increase) in trade and other receivables, contract assets and prepayments and other assets (3,429) (29,139) Increase/(decrease) in trade and other payables and contract liabilities (11,097) (32,039) Increase/(decrease) in provisions and other liabilities 638  (93) Cash generated from/(used in) operations (32,914) (89,640)

v3.23.3

Property, plant and equipment, intangible assets and goodwill (Tables)	9 Months Ended
	Sep. 30, 2023
Disclosure of detailed information about property, plant and equipment [abstract]
Summary of Movements in Property, Plant and Equipment	(in €‘000) Property, plant and equipment Intangible assets (excl. goodwill)     Goodwill     Carrying amount at December 31, 2022 134,718  13,924  10,724  Movements in the nine months ended September 30, 2023 Additions 43,070  —  —  Disposals (9,691) —  —  Depreciation and amortization (15,444) (3,244) —  Accumulated depreciation and amortization of disposals 4,628  —  —  Impairments (321) —  —  Reversal of impairments 549  —  —  Carrying amount at September 30, 2023 157,509  10,680  10,724

v3.23.3

Share capital, share premium and transaction costs on new equity instruments (Tables)	9 Months Ended
	Sep. 30, 2023
Share Capital and Share Premium [Abstract]
Schedule of Movement of Share Capital and Share Premium	Movement of share capital and share premium are as follows: Notes Shares Price per share (in €) Share Capital (in €'000) Share Premium (in €'000) As at January 1, 2022 100  1.00  —  61,888  Immediately prior to the Allego Holding and Spartan Acquisition Corp. III merger (“the SPAC Transaction”) Shareholder loan equity conversion March 16, 2022 2  1.00  —  101,931  E8 Special Fee Arrangement March 16, 2022 22  1.00  —  —  As at March 16, 2022 immediately prior to the closing of the SPAC Transaction 124  1.00  —  163,819  Resulting from the Allego Holding and Spartan Acquisition Corp. III merger (“the SPAC Transaction”) Elimination old shares March 16, 2022 (124) 1.00  —  —  Share Capital increase on conversion March 16, 2022 235,935,061  0.12  28,312  (28,311) Share Capital Spartan March 16, 2022 14,907,582  0.12  1,789  85,808  Share Capital for PIPE March 16, 2022 12,500,000  0.12  1,500  108,515  Share Capital for PIPE March 22, 2022 2,500,000  0.12  300  22,375  Other equity movements in the nine months ended September 30, 2022 Private warrants exercise April 15, 2022 1,334,949  0.12 160  13,694  As at September 30, 2022 267,177,592  0.12 32,061  365,900  As at January 1, 2023 267,177,592  0.12 32,061  365,900  Issuance of shares under the LTIP from IPO Grant Shares June 9, 2023 9,600  0.12 1  —  Issuance of shares under the LTIP from RSUs August 10, 2023 666,968  0.12 80  —  Transaction costs related to issuance of ordinary shares in exchange of Public Warrants —  —  —  (972) As at September 30, 2023 267,854,160  0.12 32,142  364,928

v3.23.3

Borrowings (Tables)	9 Months Ended
	Sep. 30, 2023
Disclosure of detailed information about borrowings [abstract]
Summary of Breakdown of Borrowings	This note provides a breakdown of borrowings in place as at September 30, 2023 and December 31, 2022. (in €‘000) Interest rate Maturity September 30, 2023 December 31, 2022 Renewed facility Euribor* + 3.9%** December 19, 2027 312,160  269,033  Total 312,160  269,033  *The Euribor rate (6M) is floored at 0%. This floor is closely related to the contract of the loan and is therefore not presented separately in the interim condensed consolidated statement of financial position. **The margin of 3.9% will increase by 0.2% per year, for the first time in December 2025.
Summary of Carrying Amount of Assets Pledged	The carrying amount of assets pledged as security for the renewed facility is as follows: (in €‘000) September 30, 2023 December 31, 2022 Current assets Floating charge Cash and cash equivalents 6,543  56,317  Trade receivables 8,480  —  Total current assets pledged as security 15,023  56,317  Non-current assets Floating charge Non-current other financial assets 10,500  10,500  Total non-current assets pledged as security 10,500  10,500  Total assets pledged as security 25,523  66,817
Disclosure Of Covenant Ratios	The target covenant ratios are determined based on a twelve-month running basis and are as follows: Testing period ending on Leverage ratio Interest cover ratio June 30, 2023 Unconditional -0.8x December 31, 2023 Unconditional -0.9x June 30, 2024 33.9x 0.4x December 31, 2024 5.4x 2.3x June 30, 2025 3.2x 3.8x December 31, 2025 2.2x 5.5x June 30, 2026 2.2x 5.5x December 31, 2026 2.2x 5.5x June 30, 2027 2.2x 5.5x The target drawdown stop conditions are determined based on a twelve-month running basis and are as follows: Testing period ending on EBITDA margin (drawstop) EBITDA (drawstop) Fast/ultrafast charging equipment utilization rate (drawstop) June 30, 2023 -4.3  % € (8.5)  million 10.4  % December 31, 2023 -5.8  % € (11.6)  million 11.5  % June 30, 2024 8.1  % € 19.8   million 12.7  % December 31, 2024 19.4  % € 68.2   million 12.9  % June 30, 2025 24.1  % € 111.2   million 14.2  % December 31, 2025 27.3  % € 157.5   million 15.5  % June 30, 2026 28.9  % € 200.0   million 16.6  % December 31, 2026 Unconditional Unconditional Unconditional June 30, 2027 Unconditional Unconditional Unconditional

v3.23.3

Financial instruments (Tables)	9 Months Ended
	Sep. 30, 2023
Disclosure of detailed information about financial instruments [abstract]
Summary of Financial Assets	Financial assets (in €‘000) Notes At amortized cost Fair value through PL Fair value through OCI Total book value Total fair value As at December 31, 2022 Non-current other financial assets 21,900  9,198  31,389  62,487  62,487  Current other financial assets 601  —  —  601  601  Trade and other receivables 44,776  —  —  44,776  44,776  Cash and cash equivalents 83,022  —  —  83,022  83,022  Total 150,299  9,198  31,389  190,886  190,886  As at September 30, 2023 Non-current other financial assets 22,439  8,603  29,463  60,505  60,505  Current other financial assets 6,469  —  —  6,469  6,469  Trade and other receivables 36,639  —  —  36,639  36,639  Cash and cash equivalents 28,829  —  —  28,829  28,829  Total 94,376  8,603  29,463  132,442  132,442
Summary of Financial Liabilities	Financial liabilities (in €‘000) Notes At amortized cost Fair value through PL Total book value Total fair value As at December 31, 2022 Borrowings 13 269,033  —  269,033  272,641  Non-current lease liabilities 44,044  —  44,044  N/A Current lease liabilities 7,280  —  7,280  N/A Trade and other payables 51,263  —  51,263  51,263  Warrant Liabilities —  1,296  1,296  1,296  Total 371,620  1,296  372,916  325,200  As at September 30, 2023 Borrowings 13 312,160  —  312,160  325,409  Non-current lease liabilities 60,212  —  60,212  N/A Current lease liabilities 9,279  —  9,279  N/A Trade and other payables 51,640  —  51,640  51,640  Warrant liabilities —  5,471  5,471  5,471  Total 433,291  5,471  438,762  382,520

v3.23.3

Fair value measurement (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Measurement [Abstract]
Summary of Financial Instruments Measured At Fair Value (Level 3)	The changes in level 3 items for the nine months ended September 30, 2023 have been as follows: (in €‘000) Investment in equity securities Carrying amount at January 1, 2023 31,389  Movements in the nine months ended September 30, 2023 Fair value loss on investment in equity securities recognized in other comprehensive income (1,926) Carrying amount at September 30, 2023 29,463
Summary of Valuation Inputs To The Fair Value of Purchase Options	The Group updated the third party valuation report to determine the fair value of investments in equity securities. Inputs to the fair value of the investments in equity securities are the earnings growth factor and risk-adjusted discount rate. The following table summarizes the quantitative information about the significant unobservable input parameters used in the level 3 fair value measurement of the investments in equity securities, using the DCF (“Discounted Cash Flows”) methodology. In % September 30, 2023 Growth factor 3.0  % Discount rate 11.9  %

v3.23.3

Financial risk management (Tables)	9 Months Ended
	Sep. 30, 2023
Disclosure of nature and extent of risks arising from financial instruments [abstract]
Summary of Nature and Extent of Risks Arising From Financial Instruments	This note explains the Group’s exposure to financial risks and how these risks could affect the Group’s future financial performance. Risk Exposure arising from Measurement Management Market risk – interest rate risk Long-term borrowings at variable rates Sensitivity analysis Economic hedge with an interest rate caps Market risk – price risk Investments in equity securities Sensitivity analysis Monitoring quarterly valuation updates and forecasts of future cash flows Liquidity risk Borrowings and other liabilities Cash flow forecasts Availability of borrowing facilities.
Summary of Sensitivity Analysis of Fair Value Measurement to Changes in Unobservable Inputs, Liabilities	The impact on loss for the three and nine months ended September 30, 2023 and 2022 as a result of a change in interest rates is as follows: (in €‘000) Impact on pre-tax loss For the three months ended September 30, For the nine months ended September 30, 2023 2022 2023 2022 Interest rates – increase by 10 basis points* 5  31  463  258  Interest rates – decrease by 10 basis points* (4) (38) (439) (253)
Summary of Unobservable Input Parameters Used in The Valuation Model	The table below summarizes the impact of increases/decreases of the price of equity securities on the group’s equity through OCI reserve for the period. The analysis is based on the assumption that the fair value of the equity securities held by the group has increased or decreased by 40%, with all other variables held constant. (in €‘000) Impact on Group's Equity For the nine months ended September 30, Fair Value – increase by 4,000 basis points 11,785  Fair Value – decrease by 4,000 basis points (11,785)
Summary of Undrawn Borrowing Facilities	The Group had access to the following undrawn borrowing facilities for each reporting period presented: (in €‘000) September 30, 2023 December 31, 2022 Expiring beyond one year—renewed facility 77,390  120,790

v3.23.3

Related-party transactions (Tables)	9 Months Ended
	Sep. 30, 2023
Disclosure of transactions between related parties [abstract]
Summary of Transactions Between Related Parties	For the three months ended September 30, For the nine months ended September 30, (in €‘000) Relationship 2023 2022 2023 2022 Madeleine Charging B.V. Immediate parent entity Interest expenses on shareholder loans —  —  —  1,755  Management fee —  —  —  12  Reimbursement of advisory fees —  —  —  280  Share-based payment expenses —  —  —  74,001  Mega-E Group (Mega-E Charging B.V. and its subsidiaries) Other related party Revenue from contracts with related party —  —  —  1,474  EV Cars Other related party Revenue from contracts with related party 3,205  4,482  12,311  22,826  Voltalis Other related party Revenue from contracts with related party 1,364  989  4,091  1,279

v3.23.3

Basis of preparation and changes to the Group's accounting policies - Additional Information (Detail)	Sep. 30, 2023 EUR (€)	Jun. 30, 2023 EUR (€)	Dec. 31, 2022 EUR (€)	Dec. 19, 2022 EUR (€) instrument	Sep. 30, 2022 EUR (€)	Dec. 31, 2021 EUR (€)
Disclosure Of Significant Accounting Policies [Line Items]
Equity	€ (48,826,000)		€ 27,758,000		€ 70,430,000	€ (76,651,000)
Cash and cash equivalents	28,829,000		83,022,000		€ 16,398,000	€ 24,652,000
Non-current portion of non-current borrowings	312,160,000		269,033,000
Lease liabilities	69,491,000		51,324,000
Trade and other current payables	53,755,000		56,390,000
Borrowings	€ 312,160,000		€ 269,033,000
Interest Rate Cap
Disclosure Of Significant Accounting Policies [Line Items]
Notional amount				€ 237,458,000
Interest Rate Cap
Disclosure Of Significant Accounting Policies [Line Items]
Number of interest rates caps | instrument				2
Bottom of range | Interest rate risk | Interest Rate Cap
Disclosure Of Significant Accounting Policies [Line Items]
Derivative instrument mitigation risk percentage	0.65%		0.65%
Top of range | Interest rate risk | Interest Rate Cap
Disclosure Of Significant Accounting Policies [Line Items]
Derivative instrument mitigation risk percentage	0.74%		0.85%
Senior debt
Disclosure Of Significant Accounting Policies [Line Items]
Increasing total existing available facility			€ 50,000,000
Undrawn borrowing facilities	€ 77,390,000		120,790,000
Borrowings	0		0
Renewed facility
Disclosure Of Significant Accounting Policies [Line Items]
Increasing total existing available facility			230,000,000	€ 230,000,000
Notional amount			400,000,000	€ 400,000,000
Borrowings	€ 312,160,000	€ 322,610,000	€ 269,033,000

v3.23.3

Segmentation - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2023 segment
Segmentation [Abstract]
Number of operating segment	1
Number of reporting segment	1

v3.23.3

Segmentation - Summary of the Amount of Revenue from External Customers (Detail) - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disclosure of Revenue From External Customers [Line Items]
Revenue from contracts with customers	€ 28,607	€ 22,320	€ 96,817	€ 73,012
The Netherlands
Disclosure of Revenue From External Customers [Line Items]
Revenue from contracts with customers	12,492	9,925	46,475	29,901
Belgium
Disclosure of Revenue From External Customers [Line Items]
Revenue from contracts with customers	4,546	2,217	14,201	6,016
Germany
Disclosure of Revenue From External Customers [Line Items]
Revenue from contracts with customers	5,071	3,434	15,264	10,041
France
Disclosure of Revenue From External Customers [Line Items]
Revenue from contracts with customers	5,394	6,188	18,076	25,327
Other
Disclosure of Revenue From External Customers [Line Items]
Revenue from contracts with customers	€ 1,104	€ 556	€ 2,801	€ 1,727

v3.23.3

Revenue from contracts with customers - Summary of the Disaggregation of the Group's Revenue from Contracts with Customers (Detail) - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	€ 28,607	€ 22,320	€ 96,817	€ 73,012
Services transferred over time
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	6,048	7,026	21,634	15,282
Goods and services transferred at a point in time
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	22,559	15,294	75,183	57,730
Charging sessions
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	22,036	14,405	73,174	38,399
Service revenue from the sale of charging equipment
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	523	889	2,009	19,331
Service revenue from installation services
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	3,451	5,181	13,734	11,145
Service revenue from operation and maintenance of charging equipment
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	1,073	556	3,329	2,378
Service revenue from consulting services
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	€ 1,524	€ 1,289	€ 4,571	€ 1,759

v3.23.3

Other income/(expenses) - Summary of Other Income (Detail) - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disclosure of detailed information about financial instruments [line items]
Government grants	€ 92	€ 320	€ 277	€ 320
Income from sale of CO2 tickets	1,728	4,106	5,851	8,979
Net gain/(loss) on disposal of property, plant and equipment	(4,784)	1	(5,365)	1
Sublease rental income	50	46	150	150
Other items	1,406	36	1,732	190
Total	(1,508)	4,543	2,645	13,530
Purchased call options
Disclosure of detailed information about financial instruments [line items]
Fair value gains/(losses) on derivatives	0	0	0	3,856
Preferred shares derivatives
Disclosure of detailed information about financial instruments [line items]
Fair value gains/(losses) on derivatives	€ 0	€ 34	€ 0	€ 34

v3.23.3

Other income/(expenses) - Additional Information (Detail) - EUR (€) € in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2022
Disclosure of Other Income expenses [Abstract]
Gain (loss) on reimbursement from suppliers	€ 0	€ 0	€ 1,400

v3.23.3

Share-based payments - Second Special Fees Agreement (Details) - EUR (€)		3 Months Ended		4 Months Ended	5 Months Ended	9 Months Ended
	Apr. 20, 2022	Sep. 30, 2023	Sep. 30, 2022	Apr. 20, 2022	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Feb. 25, 2022
Second Special Fees Agreement
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share based compensation by share based award equity instruments other than options aggregate fair value		€ 49,958,000				€ 49,958,000			€ 32,250,000
Recognized as a current liability	€ 4,440,000	38,357,000		€ 4,440,000		38,357,000		€ 16,806,000
Recognized as a non-current liability	1,353,000			1,353,000
Decrease in equity	€ 5,793,000
Share-based payment expenses		15,028,000	€ (421,000)			21,551,000	€ 2,187,000
Legal fees		9,843,000				14,116,000	1,752,000
Employee benefits expenses		€ 5,185,000				€ 7,435,000	€ 435,000
Second Special Fees Agreement | Professional Fees Expense
Disclosure of terms and conditions of share-based payment arrangement [line items]
Incremental fair value granted modified share based payment arrangements			276,000		€ 2,747,000
Second Special Fees Agreement | Employee Benefit Expense
Disclosure of terms and conditions of share-based payment arrangement [line items]
Incremental fair value granted modified share based payment arrangements			€ 145,000		1,446,000
Second Special Fees Agreement, Award Modification
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based payment expenses				6,380,000
Legal fees				4,498,000
Employee benefits expenses				€ 1,882,000
Incremental fair value granted modified share based payment arrangements					€ 4,193,000

v3.23.3

Share-based payments - Management Incentive Plan (Details)			1 Months Ended	3 Months Ended		9 Months Ended
	May 13, 2022 € / shares	May 13, 2022 $ / shares	Apr. 30, 2023 € / shares	Sep. 30, 2023 EUR (€) shares	Sep. 30, 2022 EUR (€) shares	Sep. 30, 2023 EUR (€) shares € / shares	Sep. 30, 2022 EUR (€) shares € / shares	Dec. 31, 2022 shares	Dec. 31, 2021 shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of shares reserved for issuance, per option (in shares)				1		1
Weighted average remaining contractual life of outstanding share options						9 years 6 months 14 days
Performance Options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Granted during the period (in EUR per share) | € / shares						€ 0.12
Number of shares reserved for issuance, per option (in shares)				1		1
Management Incentive Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Blocking period						18 months
Granted during the period (in EUR per share) | € / shares			€ 0.12			€ 0	€ 0.12
Number of options exercisable (in shares)				2,658,426		2,658,426
Number of share options expired in share-based payment arrangement				0		0
Share-based payment expenses | €				€ 1,612,000	€ 1,200,000	€ 5,110,682	€ 12,976,086
Fair value of options granted (in EUR per share) | € / shares						€ 7.75	€ 7.75
Weighted average share price, share options granted (in EUR per share) | (per share)	€ 7.87	$ 8.17
Exercise price, share options granted (in EUR per share) | € / shares	€ 0.12
Management Incentive Plan | May 13, 2032
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options exercisable (in shares)				996,910		996,910
Management Incentive Plan | Grant Options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expiration period						10 years
Number of options exercisable (in shares)				1,329,213	1,329,213	1,329,213	1,329,213	1,329,213	0
Number of options exercisable (in shares)				1,329,213	0	1,329,213	0
Management Incentive Plan | Performance Options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expiration period						10 years
Number of options exercisable (in shares)				1,329,213	1,329,213	1,329,213	1,329,213	1,329,213	0
Number of options exercisable (in shares)				996,910	0	996,910	0
Management Incentive Plan Modification
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based payment expenses | €				€ 489,000	€ 0	€ 1,444,000	€ 0

v3.23.3

Share-based payments - Summary of Grant Options and Performance Options granted (Details)	1 Months Ended	3 Months Ended	9 Months Ended
	Apr. 30, 2023 € / shares	Sep. 30, 2023 shares € / shares	Sep. 30, 2023 shares € / shares	Sep. 30, 2022 shares € / shares
Management Incentive Plan
Average Exercise Price Per Share Option [Abstract]
Beginning of year (in EUR per share) | € / shares			€ 0.12	€ 0
Granted during the period (in EUR per share) | € / shares	€ 0.12		0	0.12
Exercised during the period (in EUR per share) | € / shares			0	0
Forfeited during the period (in EUR per share) | € / shares			0	0
Ended of year (in EUR per share) | € / shares		€ 0.12	0.12	0.12
Average exercise price per share options, Vested and exercisable (in EUR per share) | € / shares		€ 0.12	€ 0.12	€ 0
Number Of Grant Options [Abstract]
Exercised during the period (in shares)		0	0
End of year (in shares)		2,658,426	2,658,426
Grant Options | Management Incentive Plan
Number Of Grant Options [Abstract]
Beginning of year (in shares)			1,329,213	0
Granted during the period (in shares)			0	1,329,213
Exercised during the period (in shares)			0	0
Forfeited during the period (in shares)			0	0
End of year (in shares)		1,329,213	1,329,213	1,329,213
Number of options exercisable (in shares)		1,329,213	1,329,213	0
Performance Options
Average Exercise Price Per Share Option [Abstract]
Granted during the period (in EUR per share) | € / shares			€ 0.12
Performance Options | Management Incentive Plan
Number Of Grant Options [Abstract]
Beginning of year (in shares)			1,329,213	0
Granted during the period (in shares)			0	1,329,213
Exercised during the period (in shares)			0	0
Forfeited during the period (in shares)			0	0
End of year (in shares)		1,329,213	1,329,213	1,329,213
Number of options exercisable (in shares)		996,910	996,910	0
Performance Options | Long-term Incentive Plan
Average Exercise Price Per Share Option [Abstract]
Beginning of year (in EUR per share) | € / shares			€ 0
Granted during the period (in EUR per share) | € / shares			0.12
Exercised during the period (in EUR per share) | € / shares			0
Forfeited during the period (in EUR per share) | € / shares			0
Ended of year (in EUR per share) | € / shares		€ 0.12	0.12
Average exercise price per share options, Vested and exercisable (in EUR per share) | € / shares		€ 0	€ 0
Number Of Grant Options [Abstract]
Beginning of year (in shares)				0
Granted during the period (in shares)				3,059,955
Exercised during the period (in shares)				0
Forfeited during the period (in shares)				0
End of year (in shares)				3,059,955
Number of options exercisable (in shares)				0

v3.23.3

Share-based payments - Summary of Range of Exercise Prices of Outstanding Share Options (Details)	Sep. 30, 2023 shares € / shares	Dec. 31, 2022 shares	Sep. 30, 2022 shares	Dec. 31, 2021 shares
Management Incentive Plan
Disclosure of range of exercise prices of outstanding share options [line items]
Number of options exercisable (in shares)	2,658,426
Management Incentive Plan | Performance Options
Disclosure of range of exercise prices of outstanding share options [line items]
Number of options exercisable (in shares)	1,329,213	1,329,213	1,329,213	0
Management Incentive Plan | September 17, 2033
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price (in EUR per share) | € / shares	€ 0.12
Management Incentive Plan | May 13, 2032
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price (in EUR per share) | € / shares	€ 0.12
Number of options exercisable (in shares)	996,910
Management Incentive Plan | April 29, 2034
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price (in EUR per share) | € / shares	€ 0.12
Number of options exercisable (in shares)	332,303
Long-term Incentive Plan | Performance Options
Disclosure of range of exercise prices of outstanding share options [line items]
Number of options exercisable (in shares)			3,059,955	0
Long-term Incentive Plan | April 12, 2032 | Performance Options
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price (in EUR per share) | € / shares	€ 0.12
Number of options exercisable (in shares)	1,039,222
Long-term Incentive Plan | April 12, 2033 | Performance Options
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price (in EUR per share) | € / shares	€ 0.12
Number of options exercisable (in shares)	2,020,733

v3.23.3

Share-based payments - Long-term Incentive Plan (Details) € / shares in Units, € in Thousands			3 Months Ended		9 Months Ended		12 Months Ended
	May 24, 2023 € / shares	May 24, 2023 $ / shares	Sep. 30, 2023 EUR (€) shares associate	Sep. 30, 2022 EUR (€) shares	Sep. 30, 2023 EUR (€) shares associate € / shares	Sep. 30, 2022 EUR (€) shares € / shares	Dec. 31, 2022 € / shares	Dec. 31, 2022 $ / shares	Dec. 31, 2021 shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of shares reserved for issuance, per option (in shares) | shares			1		1
Weighted average remaining contractual life of outstanding share options					9 years 6 months 14 days
Performance Options
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSU vesting period					3 years		2 years	2 years
Granted during the period (in EUR per share)					€ 0.12
Number of shares reserved for issuance, per option (in shares) | shares			1		1
Performance Options | Long-term Incentive Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSU vesting period							2 years	2 years
Granted during the period (in EUR per share)					€ 0.12
Number of options exercisable (in shares) | shares				3,059,955		3,059,955			0
Number of plans | associate			2		2
Weighted average remaining contractual life of outstanding share options					9 years 7 months 24 days
Share-based payment expenses | €			€ 1,644	€ 0	€ 1,742	€ 0
Performance Options | April 12, 2032 | Long-term Incentive Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options exercisable (in shares) | shares			1,039,222		1,039,222
Performance Options | April 12, 2033 | Long-term Incentive Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options exercisable (in shares) | shares			2,020,733		2,020,733
Performance Options 2022 | Long-term Incentive Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Fair value of options granted (in EUR per share)					€ 1.83	€ 0
Weighted average share price, share options granted (in EUR per share) | (per share)	€ 1.95	$ 2.13
Exercise price, share options granted (in EUR per share)	€ 0.12
Performance Options 2023 | Long-term Incentive Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Fair value of options granted (in EUR per share)					€ 2.82	€ 0
Weighted average share price, share options granted (in EUR per share) | (per share)							€ 2.94	$ 3.14
Exercise price, share options granted (in EUR per share)							€ 0.12
Bottom of range | Performance Options
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSU vesting period					2 years
Top of range | Performance Options
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSU vesting period					3 years

v3.23.3

Share-based payments - Restricted Stock Units (Details) - Restricted Stock Units (RSU)			1 Months Ended	3 Months Ended		9 Months Ended
	May 24, 2023 € / shares	May 24, 2023 $ / shares	May 31, 2023	Sep. 30, 2023 EUR (€)	Sep. 30, 2022 EUR (€)	Sep. 30, 2023 EUR (€) € / shares	Sep. 30, 2022 EUR (€) € / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percent of bonus receivable in award				50.00%		50.00%
RSU vesting period			3 years			3 years
Long-term Incentive Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSU vesting period						3 years
Fair value of options granted (in EUR per share) | (per share)	€ 1.97	$ 2.13				€ 1.97	€ 0
Share-based payment expenses				€ 31,000	€ 0	€ 1,361,000	€ 0
Long-term Incentive Plan | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based payment expenses							€ 44,000
Long-term Incentive Plan | Eligible directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based payment expenses						€ 1,317,000

v3.23.3

Share-based payments - Summary of RSUs Granted (Details) - Long-term Incentive Plan - Restricted Stock Units (RSU)	9 Months Ended
	Sep. 30, 2023 shares
Employees
Disclosure of range of exercise prices of outstanding share options [line items]
Beginning of year (in shares)	0
Granted during the period (in shares)	189,201
Forfeited during the period (in shares)	0
Vested during the period (in shares)	0
End of year (in shares)	189,201
Vested and exercisable (in shares)	0
Eligible directors
Disclosure of range of exercise prices of outstanding share options [line items]
Beginning of year (in shares)	0
Granted during the period (in shares)	666,968
Forfeited during the period (in shares)	0
Vested during the period (in shares)	(666,968)
End of year (in shares)	0
Vested and exercisable (in shares)	0

v3.23.3

Share-based payments - IPO Grant Shares (Details) - Equity Settled Awards € / shares in Units, € in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	May 31, 2023 shares $ / shares	May 31, 2023 shares € / shares	Sep. 30, 2023 EUR (€)	Sep. 30, 2022 EUR (€)	Sep. 30, 2023 EUR (€)	Sep. 30, 2022 EUR (€)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average grant date fair value (in Eur per share) | (per share)	$ 2.13	€ 1.97
Share-based payment expenses | €			€ 0	€ 0	€ 19	€ 0
Employees Instrumental In IPO
Disclosure of terms and conditions of share-based payment arrangement [line items]
Granted during the period (in shares)	100	100
Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Granted during the period (in shares)	9,600	9,600

v3.23.3

Share-based payments - SPAC Transaction (Details) € in Thousands	9 Months Ended
	Sep. 30, 2022 EUR (€)
Statistical Disclosure for Banks [Abstract]
Expense from share-based payment transactions with parties other than employees	€ 158,714

v3.23.3

Finance income/(costs) - Schedule of Finance Cost (Details) - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disclosure of detailed information about borrowings [line items]
Interest expenses on shareholder loans	€ 0	€ 0	€ 0	€ (1,755)
Loss on modification of old facility	0	(1,730)	0	(1,730)
Finance costs on borrowings	(6,471)	(5,122)	(17,284)	(11,533)
Interest expenses on lease liabilities	(1,017)	(689)	(2,473)	(1,155)
Fair value gains/(losses) on derivatives	(122)	2,847	(529)	4,907
Fair value gains/(losses) on public warrant liabilities	(1,762)	343	(4,175)	14,889
Fair value gains/(losses) on private placement warrant liabilities	0	0	0	7,139
Exchange differences – net	(535)	(1,817)	(195)	(3,512)
Finance income/(costs)	(9,907)	(4,438)	(24,656)	10,735
Old facility
Disclosure of detailed information about borrowings [line items]
Interest expense on debt instruments issued	0	(3,392)	0	(8,048)
Renewed facility
Disclosure of detailed information about borrowings [line items]
Interest expense on debt instruments issued	€ (6,471)	€ 0	€ (17,284)	€ 0

v3.23.3

Loss per share - Summary of Loss Per Share (Detail) - EUR (€) € / shares in Units, € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Earnings per share [abstract]
Loss attributable to ordinary equity holders of the Company	€ (43,015)	€ (21,356)	€ (81,829)	€ (268,269)
Weighted average number of ordinary shares for basic loss per share (in shares)	267,564,249	267,177,592	267,308,676	246,129,260
Weighted average number of ordinary shares for diluted loss per share (in shares)	267,564,249	267,177,592	267,308,676	246,129,260
Basic loss per share (in EUR per share)	€ (0.16)	€ (0.08)	€ (0.31)	€ (1.09)
Diluted loss per share (in EUR per share)	€ (0.16)	€ (0.08)	€ (0.31)	€ (1.09)

v3.23.3

Cash generated from operations (Details) - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of cash flows [abstract]
Loss before income tax	€ (43,230)	€ (20,696)	€ (81,671)	€ (267,610)
Adjustments to reconcile loss before income tax to net cash flows:
Loss on modification of old facility	€ 0	€ 1,730	0	1,730
Fair value (gains)/losses on derivatives			0	(3,890)
Fair value (gains)/losses on Public and Private warrant liabilities			4,175	(22,028)
Other finance (income)/costs			20,545	9,563
Share-based payment expenses			29,784	241,497
Depreciation, impairments and reversal of impairments of property, plant and equipment			15,216	11,383
Depreciation and impairments of right-of-use of assets			6,061	4,860
Amortization and impairments of intangible assets			3,244	3,589
Net (gain)/loss on disposal of property, plant and equipment			5,064	183
Movements in working capital:
Decrease/(increase) in inventories			(15,108)	(19,903)
Decrease/(increase) in other financial assets			(6,336)	12,257
Decrease/(increase) in trade and other receivables, contract assets and prepayments and other assets			(3,429)	(29,139)
Increase/(decrease) in trade and other payables and contract liabilities			(11,097)	(32,039)
Increase/(decrease) in provisions and other liabilities			638	(93)
Cash generated from/(used in) operations			€ (32,914)	€ (89,640)

v3.23.3

Property, plant and equipment, intangible assets and goodwill - Summary of Movements in Property, Plant and Equipment (Details) - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Reconciliation of changes in property, plant and equipment [abstract]
Carrying amount at December 31, 2022			€ 134,718
Reversal of impairments		€ 270		€ 392
Carrying amount at September 30, 2023	€ 157,509		157,509
Property, plant and equipment
Reconciliation of changes in property, plant and equipment [abstract]
Additions			43,070	116,590
Disposals			(9,691)
Depreciation and amortization			(15,444)
Accumulated depreciation and amortization of disposals			4,628
Impairments	(85)	€ (133)	(321)	€ (678)
Reversal of impairments	218		549
Carrying amount at September 30, 2023	157,509		157,509
Intangible assets (excl. goodwill)
Reconciliation of changes in property, plant and equipment [abstract]
Additions			0
Disposals			0
Depreciation and amortization			(3,244)
Accumulated depreciation and amortization of disposals			0
Impairments			0
Reversal of impairments			0
Carrying amount at September 30, 2023	10,680		10,680
Goodwill
Reconciliation of changes in property, plant and equipment [abstract]
Additions			0
Disposals			0
Depreciation and amortization			0
Accumulated depreciation and amortization of disposals			0
Impairments			0
Reversal of impairments			0
Carrying amount at September 30, 2023	€ 10,724		10,724
Carrying amount at December 31, 2022 | Property, plant and equipment
Reconciliation of changes in property, plant and equipment [abstract]
Carrying amount at December 31, 2022			134,718
Carrying amount at December 31, 2022 | Intangible assets (excl. goodwill)
Reconciliation of changes in property, plant and equipment [abstract]
Carrying amount at December 31, 2022			13,924
Carrying amount at December 31, 2022 | Goodwill
Reconciliation of changes in property, plant and equipment [abstract]
Carrying amount at December 31, 2022			€ 10,724

v3.23.3

Property, plant and equipment, intangible assets and goodwill - Additional Information (Details) - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disclosure of detailed information about property, plant and equipment [line items]
Reversal of impairments loss		€ 270		€ 392
Property, plant and equipment
Disclosure of detailed information about property, plant and equipment [line items]
Additions			€ 43,070	116,590
Disposal of property, plant and equipment, net			5,063	196
Impairments	€ 85	€ 133	321	€ 678
Reversal of impairments loss	€ 218		€ 549

v3.23.3

Share capital, share premium and transaction costs on new equity instruments - Additional Information (Details) - EUR (€)			9 Months Ended
	Aug. 10, 2023	Jun. 09, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Apr. 15, 2022	Mar. 22, 2022	Mar. 16, 2022
Share Capital, Share Premium and Transaction Costs On New Equity Instruments [Line Items]
Issued capital			€ 32,142,000		€ 32,061,000
Par value per share (in EUR per share)			€ 0.12	€ 0.12	€ 0.12	€ 0.12	€ 0.12	€ 0.12
Number of shares issued (in shares)			267,854,160	267,177,592	267,177,592
Transaction costs related to issuance of ordinary shares in exchange of Public Warrants			€ (972,000)
Long-term Incentive Plan
Share Capital, Share Premium and Transaction Costs On New Equity Instruments [Line Items]
Number of shares issued (in shares)	666,968	9,600
Proceeds from issuing shares	€ 0	€ 0
Ordinary Shares
Share Capital, Share Premium and Transaction Costs On New Equity Instruments [Line Items]
Issued capital			€ 32,142,000		€ 32,061,000
Number of shares outstanding (in shares)			267,854,160		267,177,592
Par value per share (in EUR per share)			€ 0.12		€ 0.12
Authorized share capital			€ 108,000,000		€ 108,000,000
Number of shares authorised			900,000,000		900,000,000
Transaction costs related to issuance of ordinary shares in exchange of Public Warrants			€ (972,000)	€ 0
Ordinary Shares | Long-term Incentive Plan
Share Capital, Share Premium and Transaction Costs On New Equity Instruments [Line Items]
Par value per share (in EUR per share)	€ 0.12	€ 0.12

v3.23.3

Share capital, share premium and transaction costs on new equity instruments - Schedule of Movement of Share Capital and Share Premium (Details) - EUR (€) € / shares in Units, € in Thousands						9 Months Ended
	Aug. 10, 2023	Jun. 09, 2023	Apr. 15, 2022	Mar. 22, 2022	Mar. 16, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Share Capital, Share Premium and Transaction Costs On New Equity Instruments [Line Items]
Number of shares issued (in shares)						267,177,592
Par value per share (in EUR per share)			€ 0.12	€ 0.12	€ 0.12	€ 0.12	€ 0.12	€ 0.12
Beginning balance						€ 27,758	€ (76,651)
Share Capital increase on conversion (in shares)					235,935,061
Increase (decrease) through exchange of ordinary shares (in shares)					14,907,582
Equity contribution (Spartan shareholders)							87,597
Increase (decrease) in number of ordinary shares issued (in shares)				2,500,000	12,500,000
Private Placement Warrants exercise (in shares)			1,334,949
Equity contribution (Private warrants exercise)							13,854
Increase (decrease) through share-based payment transactions, equity						8,233	€ 81,184
Transaction costs related to issuance of ordinary shares in exchange of Public Warrants						€ (972)
Number of shares issued (in shares)						267,854,160	267,177,592
Ending balance						€ (48,826)	€ 70,430
IPO
Share Capital, Share Premium and Transaction Costs On New Equity Instruments [Line Items]
Par value per share (in EUR per share)		€ 0.12
Increase (decrease) in number of ordinary shares issued (in shares)		9,600
Increase (decrease) through share-based payment transactions, equity						1
Restricted Stock Units (RSU)
Share Capital, Share Premium and Transaction Costs On New Equity Instruments [Line Items]
Par value per share (in EUR per share)	€ 0.12
Increase (decrease) in number of ordinary shares issued (in shares)	666,968
Increase (decrease) through share-based payment transactions, equity						0
Allego Holding
Share Capital, Share Premium and Transaction Costs On New Equity Instruments [Line Items]
Number of shares issued (in shares)							100
Par value per share (in EUR per share)					€ 1.00				€ 1.00
Shareholder loan to equity conversion (in shares)					2
Number of shares issued in the fee agreement (in shares)					22
Number of shares exchanged for shares in new company (in share)					(124)
Number of shares issued (in shares)					124
Issued capital
Share Capital, Share Premium and Transaction Costs On New Equity Instruments [Line Items]
Beginning balance						32,061	€ 1
Equity contribution (Allego Holding shareholders)					€ 28,312
Equity contribution (Spartan shareholders)					1,789		1,789
Equity contribution (PIPE financing)				€ 300	1,500
Equity contribution (Private warrants exercise)			€ 160				160
Ending balance						32,142	32,061
Issued capital | IPO
Share Capital, Share Premium and Transaction Costs On New Equity Instruments [Line Items]
Increase (decrease) through share-based payment transactions, equity		€ 1				1
Issued capital | Restricted Stock Units (RSU)
Share Capital, Share Premium and Transaction Costs On New Equity Instruments [Line Items]
Increase (decrease) through share-based payment transactions, equity	€ 80					80
Issued capital | Allego Holding
Share Capital, Share Premium and Transaction Costs On New Equity Instruments [Line Items]
Beginning balance							0
Ending balance					0
Share premium
Share Capital, Share Premium and Transaction Costs On New Equity Instruments [Line Items]
Beginning balance						365,900	61,888
Equity contribution (Allego Holding shareholders)					(28,311)
Equity contribution (Spartan shareholders)					85,808		85,808
Equity contribution (PIPE financing)				€ 22,375	108,515
Equity contribution (Private warrants exercise)			€ 13,694				13,694
Transaction costs related to issuance of ordinary shares in exchange of Public Warrants						(972)
Ending balance						€ 364,928	365,900
Share premium | Allego Holding
Share Capital, Share Premium and Transaction Costs On New Equity Instruments [Line Items]
Beginning balance							€ 61,888
Equity contribution (Allego Holding shareholders)					101,931
Ending balance					€ 163,819

v3.23.3

Borrowings - Summary of Breakdown of Borrowings (Detail) - EUR (€) € in Thousands		9 Months Ended
	Dec. 19, 2022	Sep. 30, 2023	Dec. 31, 2025	Jun. 30, 2023	Dec. 31, 2022
Disclosure of detailed information about borrowings [line items]
Borrowings		€ 312,160			€ 269,033
Euribor floored rate		0.00%
Renewed facility
Disclosure of detailed information about borrowings [line items]
Borrowings, adjustment to interest rate basis		3.90%
Borrowings		€ 312,160		€ 322,610	€ 269,033
Interest rate		3.90%
Renewed facility | Issuance of guarantees and letters of credit
Disclosure of detailed information about borrowings [line items]
Draw down condition breach remediation period	20 days
Renewed facility | Top of range | Forecast
Disclosure of detailed information about borrowings [line items]
Borrowings, adjustment to interest rate basis			0.20%

v3.23.3

Borrowings - Additional Information (Detail)		1 Months Ended		9 Months Ended
	Dec. 19, 2022 EUR (€) test	Jun. 30, 2023 EUR (€)	Dec. 31, 2022 EUR (€) associate	Sep. 30, 2023 EUR (€)	Sep. 30, 2022 EUR (€)
Disclosure of detailed information about borrowings [line items]
Repayments of borrowings				€ 0	€ 11,936,000
Proceeds from borrowings				43,400,000	50,000,000
Borrowings			€ 269,033,000	€ 312,160,000
Interest Rate Cap | Bottom of range | Interest rate risk
Disclosure of detailed information about borrowings [line items]
Derivative instrument mitigation risk percentage			0.65%	0.65%
Interest Rate Cap | Top of range | Interest rate risk
Disclosure of detailed information about borrowings [line items]
Derivative instrument mitigation risk percentage			0.85%	0.74%
Renewed facility
Disclosure of detailed information about borrowings [line items]
Increasing total existing available facility	€ 230,000,000		€ 230,000,000
Notional amount	400,000,000		€ 400,000,000
Percentage of commitment fee per year equal to the applicable margin (percent)				35.00%
Commitment fee payment period				42 months
Commitment fee rate (percent)				1.365%
Interest rate				3.90%
Number of drawdowns | associate			2
Proceeds from borrowings		€ 43,400,000	€ 279,210,000
Borrowings		€ 322,610,000	€ 269,033,000	€ 312,160,000
Renewed facility | Financing And Refinancing Capital Expenditures
Disclosure of detailed information about borrowings [line items]
Notional amount	200,000,000
Renewed facility | Issuance of guarantees and letters of credit
Disclosure of detailed information about borrowings [line items]
Notional amount	€ 30,000,000
Remedy period	10 days
Remedy consecutive testing dates, maximum | test	2
Remedy total testing dates, maximum | test	4
Draw down condition breach remediation period	20 days
Senior Debt Bank Facility
Disclosure of detailed information about borrowings [line items]
Repayments of borrowings	€ 170,000,000
Renewed facility
Disclosure of detailed information about borrowings [line items]
Borrowing costs incurred				€ 1,689,000	€ 0
Renewed facility | Issuance of guarantees and letters of credit
Disclosure of detailed information about borrowings [line items]
Notional amount	€ 30,000,000

v3.23.3

Borrowings - Summary of Carrying Amount of Assets Pledged (Detail) - EUR (€) € in Thousands	Sep. 30, 2023	Dec. 31, 2022
Disclosure of detailed information about borrowings [abstract]
Cash and cash equivalents	€ 6,543	€ 56,317
Trade receivables	8,480	0
Total current assets pledged as security	15,023	56,317
Non-current other financial assets	10,500	10,500
Total non-current assets pledged as security	10,500	10,500
Total assets pledged as security	€ 25,523	€ 66,817

v3.23.3

Borrowings - Summary of Covenant Ratios Are Determined Based on a Twelvemonth Running Basis (Detail) € in Millions	9 Months Ended
	Sep. 30, 2023 EUR (€) shares
June 30, 2023
Capital Management [Line Items]
Interest cover ratio	(0.8)
EBITDA margin	(4.30%)
EBITDA (drawstop) | €	€ (8.5)
Fast/ultrafast charging equipment utilization rate (drawstop)	0.104
December 31, 2023
Capital Management [Line Items]
Interest cover ratio	(0.9)
EBITDA margin	(5.80%)
EBITDA (drawstop) | €	€ (11.6)
Fast/ultrafast charging equipment utilization rate (drawstop)	0.115
June 30, 2024
Capital Management [Line Items]
Leverage ratio	33.9
Interest cover ratio	0.4
EBITDA margin	8.10%
EBITDA (drawstop) | €	€ 19.8
Fast/ultrafast charging equipment utilization rate (drawstop)	0.127
December 31, 2024
Capital Management [Line Items]
Leverage ratio	5.4
Interest cover ratio	2.3
EBITDA margin	19.40%
EBITDA (drawstop) | €	€ 68.2
Fast/ultrafast charging equipment utilization rate (drawstop)	0.129
June 30, 2025
Capital Management [Line Items]
Leverage ratio	3.2
Interest cover ratio	3.8
EBITDA margin	24.10%
EBITDA (drawstop) | €	€ 111.2
Fast/ultrafast charging equipment utilization rate (drawstop)	0.142
December 31, 2025
Capital Management [Line Items]
Leverage ratio	2.2
Interest cover ratio	5.5
EBITDA margin	27.30%
EBITDA (drawstop) | €	€ 157.5
Fast/ultrafast charging equipment utilization rate (drawstop)	0.155
June 30, 2026
Capital Management [Line Items]
Leverage ratio	2.2
Interest cover ratio	5.5
EBITDA margin	28.90%
EBITDA (drawstop) | €	€ 200.0
Fast/ultrafast charging equipment utilization rate (drawstop)	0.166
December 31, 2026
Capital Management [Line Items]
Leverage ratio	2.2
Interest cover ratio	5.5
June 30, 2027
Capital Management [Line Items]
Leverage ratio	2.2
Interest cover ratio	5.5

v3.23.3

Income tax (Details)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Major components of tax expense (income) [abstract]
Average annual tax rate	0.38%	0.36%

v3.23.3

Financial instruments - Summary of Financial Assets (Detail) - EUR (€) € in Thousands	Sep. 30, 2023	Dec. 31, 2022
Disclosure of financial assets [line items]
At amortized cost	€ 94,376	€ 150,299
Fair value through PL	8,603	9,198
Fair value through OCI	29,463	31,389
Total book value	132,442	190,886
Total fair value	132,442	190,886
Non-current other financial assets
Disclosure of financial assets [line items]
At amortized cost	22,439	21,900
Fair value through PL	8,603	9,198
Fair value through OCI	29,463	31,389
Total book value	60,505	62,487
Total fair value	60,505	62,487
Current other financial assets
Disclosure of financial assets [line items]
At amortized cost	6,469	601
Fair value through PL	0	0
Fair value through OCI	0	0
Total book value	6,469	601
Total fair value	6,469	601
Trade and other receivables
Disclosure of financial assets [line items]
At amortized cost	36,639	44,776
Fair value through PL	0	0
Fair value through OCI	0	0
Total book value	36,639	44,776
Total fair value	36,639	44,776
Cash and cash equivalents
Disclosure of financial assets [line items]
At amortized cost	28,829	83,022
Fair value through PL	0	0
Fair value through OCI	0	0
Total book value	28,829	83,022
Total fair value	€ 28,829	€ 83,022

v3.23.3

Financial instruments - Summary of Financial Liabilities (Detail) - EUR (€) € in Thousands	Sep. 30, 2023	Dec. 31, 2022
Disclosure of financial liabilities [line items]
At amortized cost	€ 433,291	€ 371,620
Fair value through PL	5,471	1,296
Total book value	438,762	372,916
Total fair value	382,520	325,200
Borrowings
Disclosure of financial liabilities [line items]
At amortized cost	312,160	269,033
Fair value through PL	0	0
Total book value	312,160	269,033
Total fair value	325,409	272,641
Non-current lease liabilities
Disclosure of financial liabilities [line items]
At amortized cost	60,212	44,044
Fair value through PL	0	0
Total book value	60,212	44,044
Current lease liabilities
Disclosure of financial liabilities [line items]
At amortized cost	9,279	7,280
Fair value through PL	0	0
Total book value	9,279	7,280
Trade and other payables
Disclosure of financial liabilities [line items]
At amortized cost	51,640	51,263
Fair value through PL	0	0
Total book value	51,640	51,263
Total fair value	51,640	51,263
Warrant Liabilities
Disclosure of financial liabilities [line items]
At amortized cost	0	0
Fair value through PL	5,471	1,296
Total book value	5,471	1,296
Total fair value	€ 5,471	€ 1,296

v3.23.3

Fair value measurement - Summary of Financial Instruments Measured At Fair Value (Level 3) (Detail) € in Thousands	9 Months Ended
	Sep. 30, 2023 EUR (€)
Disclosure Of Movement In Financial Assets Measured At Fair Value Using Significant Unboservable Input [Line Items]
Carrying amount at January 1, 2023	€ 437,659
Carrying amount at September 30, 2023	440,369
Level 3 of fair value hierarchy | Investment in equity securities
Disclosure Of Movement In Financial Assets Measured At Fair Value Using Significant Unboservable Input [Line Items]
Carrying amount at January 1, 2023	31,389
Fair value loss on investment in equity securities recognized in other comprehensive income	(1,926)
Carrying amount at September 30, 2023	€ 29,463

v3.23.3

Fair value measurement - Summary of Valuation Inputs To The Fair Value of Purchase Options (Detail) - Investments in equity securities	Sep. 30, 2023
Growth factor
Disclosure of significant unobservable inputs used in fair value measurement of assets [line items]
Unobservable input, assets	0.030
Discount rate
Disclosure of significant unobservable inputs used in fair value measurement of assets [line items]
Unobservable input, assets	0.119

v3.23.3

Fair value measurement - Additional Information (Details) - Investments accounted for using equity method - EUR (€) € in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Growth factor
Disclosure of significant unobservable inputs used in fair value measurement of assets [line items]
Changes to parameters increase percentage	1.00%
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in profit or loss, after tax, assets	€ 3,741	€ (2,984)
Pre-tax discount rate
Disclosure of significant unobservable inputs used in fair value measurement of assets [line items]
Changes to parameters increase percentage	1.00%
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, recognised in profit or loss, after tax, assets	€ (4,187)	€ 5,255

v3.23.3

Financial risk management - Additional Information (Detail) € in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023 EUR (€) interest_cap	Dec. 31, 2022 EUR (€) interest_cap	Dec. 19, 2022 EUR (€)
Fair Value Measurement Input
Disclosure of Financial Risk Management [Line Items]
Percentage of reasonably possible decrease in unobservable input, entity's own equity instruments	40.00%
Percentage of reasonably possible increase in unobservable input, entity's own equity instruments	40.00%
Interest Rate Cap | Interest rate risk
Disclosure of Financial Risk Management [Line Items]
Derivative instrument coverage of variable loan principal outstanding (percent)	0.74%	0.65%
Interest Rate Cap | Interest rate risk | Bottom of range
Disclosure of Financial Risk Management [Line Items]
Derivative instrument strike price percentage	0.015%
Derivative instrument mitigation risk percentage	0.65%	0.65%
Interest Rate Cap | Interest rate risk | Top of range
Disclosure of Financial Risk Management [Line Items]
Derivative instrument strike price percentage	0.0343%
Derivative instrument mitigation risk percentage	0.74%	0.85%
Later than one year | Renewed facility
Disclosure of Financial Risk Management [Line Items]
Debt instrument, term	4 years	5 years
Interest Rate Cap
Disclosure of Financial Risk Management [Line Items]
Number of derivative instruments | interest_cap	2	2
Notional amount			€ 237,458
Interest Rate Cap | 2027
Disclosure of Financial Risk Management [Line Items]
Notional amount	€ 237,458
Interest Rate Cap | 2026
Disclosure of Financial Risk Management [Line Items]
Notional amount		€ 181,487

v3.23.3

Financial risk management - Summary of Sensitivity Analysis of Fair Value Measurement to Changes in Unobservable Inputs, Liabilities (Detail) - Interest rate, measurement input - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [line items]
Percentage of reasonably possible increase in unobservable input, entity's own equity instruments	0.10%		0.10%
Percentage of reasonably possible decrease in unobservable input, entity's own equity instruments	0.10%		0.10%
Interest rate risk
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [line items]
Interest rates – increase by 10 basis points	€ 5	€ 31	€ 463	€ 258
Interest rates – decrease by 10 basis points	€ (4)	€ (38)	€ (439)	€ (253)

v3.23.3

Financial risk management - Increases/Decreases of the Price of Equity Securities (Details) - Fair Value Measurement Input € in Thousands	9 Months Ended
	Sep. 30, 2023 EUR (€)
Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, liabilities [line items]
Fair Value – increase by 4,000 basis points	€ 11,785
Fair Value – decrease by 4,000 basis points	€ (11,785)
Percentage of reasonably possible increase in unobservable input, entity's own equity instruments	40.00%
Percentage of reasonably possible decrease in unobservable input, entity's own equity instruments	40.00%

v3.23.3

Financial risk management - Summary of Undrawn Borrowing Facilities (Detail) - EUR (€) € in Thousands	Sep. 30, 2023	Dec. 31, 2022
Later than one year | Renewed facility
Disclosure of Detailed Information About Undrawn Borrowing Facilities [Line Items]
Expiring beyond one year	€ 77,390	€ 120,790

v3.23.3

Commitments and contingencies - Additional Information (Detail) - EUR (€) € in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Statement of Commitments and Contingencies [Abstract]
Purchase commitments for chargers and charging infrastructure	€ 18,974	€ 2,452
Purchase commitments for renewable electricity	€ 233,149	€ 69,701

v3.23.3

Related-party transactions - Summary of Transactions Between Related Parties (Detail) - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disclosure of transactions between related parties [line items]
Interest expenses on shareholder loans	€ 0	€ 0	€ 0	€ 1,755
Madeleine Charging B.V.
Disclosure of transactions between related parties [line items]
Interest expenses on shareholder loans	0	0	0	1,755
Management fee	0	0	0	12
Reimbursement of advisory fees	0	0	0	280
Share-based payment expenses	0	0	0	74,001
Current receivables (payable) from related party	0	0	0	76,048
Mega-E Group
Disclosure of transactions between related parties [line items]
Revenue from contracts with related party	0	0	0	1,474
EV Cars
Disclosure of transactions between related parties [line items]
Revenue from contracts with related party	3,205	4,482	12,311	22,826
Voltalis
Disclosure of transactions between related parties [line items]
Revenue from contracts with related party	€ 1,364	€ 989	€ 4,091	€ 1,279

v3.23.3

Subsequent events - Additional Information (Detail)	Oct. 08, 2023 shares	Oct. 03, 2023 shares	Oct. 19, 2023 EUR (€) letter_of_credit	Sep. 30, 2023 shares	Dec. 19, 2022 EUR (€)
Issuance of guarantees and letters of credit | Renewed facility
Disclosure of non-adjusting events after reporting period [line items]
Notional amount | €					€ 30,000,000
Entering into significant commitments or contingent liabilities | Issuance of guarantees and letters of credit | Renewed facility | Solarpark Lindenhof GmbH
Disclosure of non-adjusting events after reporting period [line items]
Notional amount | €			€ 6,250,000
Number of borrowing instruments | letter_of_credit			1
Entering into significant commitments or contingent liabilities | Issuance of guarantees and letters of credit | Renewed facility | Société Générale
Disclosure of non-adjusting events after reporting period [line items]
Notional amount | €			€ 6,250,000
Number of borrowing instruments | letter_of_credit			1
Public warrants
Disclosure of non-adjusting events after reporting period [line items]
Warrants outstanding (in shares)				13,799,948
Public warrants | Major ordinary share transactions
Disclosure of non-adjusting events after reporting period [line items]
Issuance of shares due to conversion of warrants (in shares)	770,110	2,996,918
Conversion of warrants (in shares)	(159,712)	13,029,838
Private warrants
Disclosure of non-adjusting events after reporting period [line items]
Warrants outstanding (in shares)				0

---